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Abstract 
Existing, dermal, regenerative scaffolds facilitate dermal repair and wound healing of 
severe burn injuries; however, new tissue is often functionally, mechanically and 
aesthetically abnormal due to irregular deposition of new extracellular matrix. In the 
present study two novel, elastin-containing scaffolds were developed, characterised 
and examined both in vitro and in vivo aiming to minimise wound contraction, improve 
scar appearance and increase skin elasticity post-healing. 
The first types of scaffolds were electrospun from a triple polymer solution of collagen, 
elastin and poly(ϵ-caprolactone) (CEP). Two scaffolds were chosen for 
characterisation: CEP 1 was fabricated using a 1.5 % (w/v) collagen, 12 % (w/v) elastin 
and 1.5 % (w/v) poly(ϵ-caprolactone) (PCL) solution, a flow rate of 3 mL/h, an air gap 
of 15 cm and an applied electric potential of 25 kV; and CEP 2 was electrospun using 
a 2 % (w/v) collagen, 12 % (w/v) elastin and 1 % (w/v) PCL solution at 1 mL/h, 20 cm 
and 20 kV. In vitro cell studies using human, dermal fibroblasts (HDFs) and 
immortalised, human keratinocytes (HaCaTs) revealed CEP 1 and CEP 2 supported 
cell-seeding and cell proliferation with significantly higher proliferation of both cell 
types on CEP 1. Additionally, subcutaneous implant studies in mice revealed minimal 
inflammation in response to both scaffolds with CEP 1 vascularised by week 2 post-
surgery. However, CEP 1 was rapidly biodegraded after 2 weeks. Collagen deposition 
was observed in encapsulating tissue and new tissue with consistent collagen 
expression over 24 weeks. 
The second type of scaffold investigated was an elastin-modified version of the 
commercial, dermal substitute Integra Dermal Regeneration Template (IDRT). Elastin-
IDRT (EDRT) was developed by inclusion of 10% human tropoelastin and then 
ix 
investigated in comparison with IDRT. Morphological analysis by scanning electron 
microscope and mechanical characterisation revealed EDRT had significantly 
enlarged pores, higher porosity and increased deformability. Higher cell seeding 
efficiency of HaCaTs on EDRT was observed compared to IDRT but cell proliferation 
rate was found to be similar over 28 days. HDFs displayed increased cell growth rate 
on EDRT over 28 days compared to IDRT. Enhanced and accelerated HDF infiltration 
of EDRT was also visualised with complete infiltration by day 14 post-seeding. An in 
vivo, mouse, subcutaneous implant model showed that EDRT induced minimal 
inflammation. Gene expression of mouse collagen was consistent over 24 weeks with 
non-significant increases in elastin expression from weeks 2 and 4. One-step grafting 
demonstrated similar contraction between EDRT-, IDRT- and autografted wounds with 
final contraction around 40 % compared to 100 % in open wounds. EDRT displayed 
significantly accelerated, early-stage angiogenesis with higher vascularisation than 
IDRT-grafted, autografted or open wounds 2 weeks post grafting. By week 4 EDRT- 
and IDRT-grafted wounds had similar levels of vascularisation which were higher than 
autografted and open wounds. EDRT showed improved mechanical performance, 
supported enhanced cell interactions in vitro and accelerated angiogenesis in vivo.  
In summary, investigated scaffolds demonstrated properties that could potentially 
improve burn wound healing. The inclusion of elastin in scaffolds produced by either 
electrospinning or lyophilisation improved HDF infiltration and supported formation of 
a confluent layer of HaCaTs which could result in increased pliability of new skin and 
accelerated wound healing. In EDRT elastin improved scaffold porosity, pore size and 
accelerated angiogenesis in vivo indicating EDRT can facilitate and improve wound 
remodelling. Further investigation of both scaffolds is warranted especially due to the 
x 
vascular inductive effects of EDRT and the synchronous spatial and temporal 
biodegradation of CEP 2 observed in vivo.  
xi 
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Chapter 1  General Introduction 
1.1 Human skin structure and function 
Skin is the largest organ of the human body housing appendages such as hair, 
capillaries and sweat glands which provide sensory, thermoregulatory and protective 
functions (1) (Figure 1.1A). The skin is composed of two main layers, the outermost 
layer is the epidermis which is interlocked to the inner layer, the dermis (Figure 1.1B). 
The dermis is also connected to the subcutaneous tissue (hypodermis) which is mainly 
composed of adipose tissue (1) (Figure 1.1B). 
1.1.1 Epidermis 
The epidermis is the thinnest skin layer protecting the body from friction and 
microorganisms (1). There are up to five layers mainly comprised of keratinocytes with 
other cell types also present, namely, melanocytes which produce melanin, Merkel 
cells which detect the sensation of touch, Langerhans cells which participate in 
immune responses and Odland’s bodies which produce a lipid to tightly bind 
keratinocytes together (1, 2). 
Keratinocytes originate from the deepest layer, called the stratum basale (1) (Figure 
1.2). Until recently the stratum basale was thought to consist of a pool of stem cells 
called transit-amplifying cells located in specific locations which underwent several 
rounds of division to amplify the keratinocyte population (3, 4). These keratinocytes 
would be differentiated and keratinised as they migrated upwards (5). Keratinisation 
is the deposition of keratin, a tough, pliable protein, in keratinocytes (6). 
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However, recent findings in xenografted human foreskin have shown that where the 
human epidermis has an undulating basal layer and varying number of strata, 
epidermal proliferation units are organised into narrow compartments with cross-
sections ranging from one to ten and cells would migrate perpendicular to the skin 
surface. There was no preferred site of origin of the epidermal proliferation units with 
sites located on the relatively flat regions of the basement membrane, the side of the 
rete ridges, the base of the rete ridges and the tip of the dermal papillae with no 
specialised structure or niche for stem cells (7). 
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Figure 1.1: (A) Schematic representation of skin layers and appendages, adapted from (8); 
and (B) image of haematoxylin and eosin (H&E) stained skin (9). 
Epidermis 
Dermis 
Hypodermis 
A 
B 
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Figure 1.2: Image of H&E stained human skin showing epidermal layers in thin skin (A) and 
thick skin (B). Adapted from (9). 
1.1.2 Basement membrane 
The basement membrane acts as a physical barrier between the epidermis and dermis 
while also serving to connect the two layers with proteins such as anchoring fibril type 
VII collagen (10). It is a complex assembly of proteins such as type IV collagen, laminin 
and heparin sulphate proteoglycans (11). It also regulates the movement of cells and 
molecules between the two layers binding a range of cytokines and growth factors to 
control release during wound remodelling and repair (12, 13). Research also suggests 
the basement membrane affects the regenerative ability of skin by keeping stem cells 
in their niche through very strong interaction and adherence between the two (14, 15). 
A B 
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1.1.3 Dermis 
The dermis houses most of the skin appendages and is responsible for providing 
nutrients and physical support to the epidermis via rete ridges (16, 17). The dermis 
encompasses vascular networks which provide nutrient and waste exchange for cells, 
nerve networks permitting interaction with the environment and keratinised appendage 
structures such as nails which provide protection (18, 19). The dermis is structurally 
subdivided into two layers; the upper, papillary layer and lower, reticular layer (2) 
(Figure 1.3A). The papillary layer of the dermis has a network of fine collagen and 
elastin fibres which compose the loosely connected tissue which surround a large 
amount of nerves, capillaries, water and cells (2). The finger-like projections, called 
dermal papillae, originate from this layer and connect the dermis to the epidermis 
forming unique fingerprints in humans (20). The reticular dermis is more dense and 
irregular than the papillary layer with thick bundles of interlacing collagen and elastin 
fibres which are mostly orientated parallel to the skin exterior (20). There are also 
fewer nerves and capillaries compared to the papillary dermis (2) (Figure 1.3B). This 
combination of collagen and elastin fibres in the reticular layer gives skin its strength 
and elasticity (21). 
The dermis is much thicker than the epidermis and mostly consists of collagen and 
elastin fibres (1, 2). Collagen accounts for approximately 70 % of the dry weight of 
dermis and is responsible for the tensile strength of skin preventing skin from tearing 
when stretched. There are several types of collagen present in the dermis including 
types I, III, V, VI, XII, XIV and XVI (22, 23). Elastin accounts for 2-4 % of the dry weight 
of skin (24) and has thinner fibres than collagen. These fibres are interwoven among 
the collagen bundles returning skin to its normal position after stretching (1). Collagen 
and elastin are synthesised by fibroblasts, the main cell in the dermis.  
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Figure 1.3: (A) Image of H&E stained skin showing dermal layers in thin skin and (B) image of 
van Gieson stained skin showing collagen (pink) and elastin (black) fibres in thick skin. 
Adapted from (9). 
1.2 Burn injuries 
Damage to skin can be incurred numerous ways ranging from surgically removing skin 
defects, such as nevi, to involvement in a vehicular accident or fire. At times, surgical 
intervention is required when tissue has been extensively damaged and is beyond its 
ability to repair itself. Specifically focussing on burn injuries, such damage or 
destruction of skin can be inflicted by heat, cold, electricity, chemicals, radiation or 
friction. Severe burns are one of the most debilitating injuries requiring prolonged 
hospital stays and often resulting in not only physical scarring but emotional trauma. 
Globally, there were nearly 11 million incidences of burns requiring medical attention 
(25). 
A B 
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Burn injuries are classified according to the depth of the burn (Figure 1.4) and, in 
conjunction with the affected total body surface area (TBSA), treated accordingly. Burn 
depth is related to the amount of epidermis and dermis damaged and this determines 
the skin’s ability to achieve wound healing autonomously or whether surgical treatment 
of the wound is required (26, 27). 
 
Figure 1.4: Schematic of burn depth classification demonstrating the layers of skin damaged. 
Adapted from (28). 
According to Evers et al. (2010) (29) a superficial burn can be caused by excessive 
sun exposure or by short exposure to hot liquids and only affects the epidermis. The 
burn does not blister but is moist with a pink to red appearance and can be moderately 
to severely painful. The burn heals spontaneously within a week usually with no 
scarring due to regenerative, epidermal, stem cells present at the base of hair follicles 
in the undamaged dermis. 
Partial-thickness burns can be further subdivided into superficial dermal and deep 
dermal burns. Superficial dermal burns are caused by hot liquids, weak acids and also 
flash burns (29). This type of burn affects the epidermis and papillary dermis resulting 
in blistering and redness but nerves are intact so the pain is severe. Superficial, dermal 
Epidermis 
Dermis 
Subcutaneous 
Tissue 
Superficial 
burn 
Partial-thickness 
burn 
Full-thickness 
burn 
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burns can regenerate from the viable stratum basale of surrounding undamaged tissue 
in conjunction with stem cells from surviving hair follicles in the wound area (18, 26, 
30). Wound healing can take up to 3 weeks with pigment changes possibly occurring. 
Deep dermal burns could be caused by flame, chemical, electrical or hot liquid burns 
(29). The epidermis, papillary dermis and reticular dermis are affected with injured skin 
appearing dry and white. There is minimal pain due to loss of epidermal appendages. 
Deep, dermal burns heal through formation of granulation tissue over 3-6 weeks. 
Fibroblasts in this tissue produce collagen and differentiate into contractile 
myofibroblasts which rapidly close the wound along with migration of basal 
keratinocytes from edges of the wound (26, 30). This form of healing results in varying 
degrees of scarring and contraction depending on the extent of damage to the dermis. 
Full-thickness burns are the most severe form and they affect the full thickness of skin 
extending to the subcutaneous tissue or deeper. These burns are caused by flame, 
electrical, chemical, blast or self-immolation and damaged tissue appears leathery, 
dry and white or red. There is no pain associated with deep burns due to the complete 
destruction of nerves and other appendages in the affected area. Treatment of such 
injuries requires removal of necrotic tissue and assisted wound closure with the use 
of skin grafts or substitutes to minimise infection and sepsis; however, there is usually 
significant scarring and contraction. 
1.3 Wound healing 
Wound healing is a rapid process which has evolved to allow humans to recover tissue 
integrity using scarring to join the edges of wounds or to fill voids of tissue resulting 
from dermal loss (31). This repair process is sequential with four overlapping stages: 
haemostasis, inflammation, proliferation and remodelling and is an event-driven 
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cascade triggered by one cell type propelling the wound through the phases of wound 
healing (32). 
Adult wound healing begins immediately with haemostasis in which blood flow to the 
injured area is limited by vasoconstriction and platelets released from the damaged 
blood vessels adhere to collagen at the edge of damaged vessels forming a plug and 
activating the clotting cascade (33, 34). The platelet plug is secured by a fibrin clot at 
the site of injury which holds the damaged tissue together and provides a provisional 
matrix to support cell migration (34, 35). Platelets also release cytokines and growth 
factors which recruit neutrophils and macrophages advancing the process of wound 
healing to the inflammatory stage (36, 37). 
The inflammatory response begins with vasodilation of blood vessels and increasing 
vascular permeability to allow fluids to pass through the vessel walls (38) giving the 
classical signs of inflammation with the area surrounding the wound appearing red, 
hot and swollen (39, 40). The neutrophils attracted to the area squeeze through the 
porous walls and migrate to the wound area (41) reaching a maximum concentration 
24-48 hours after injury and declining thereafter. The neutrophils phagocytose foreign 
particles, bacteria and devitalised tissue by secreting proteases and free radicals 
which also have a bactericidal effect (42). The dead neutrophils are removed from the 
area by macrophages which are derived from monocytes. This prevents disintegrating 
neutrophils from continuing to release proteases and cytokines, which would prolong 
the inflammatory phase thereby allow the wound to progress to the proliferative phase 
(43). 
The proliferative phase is when granulation tissue begins to fill the wound and consists 
of angiogenesis and the deposition of collagen by fibroblasts to form a new matrix. 
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Fibroblasts are attracted to the wound by the growth factors released from platelets 
and macrophages (44) and migrate over the provisional fibrin matrix proliferating and 
depositing new ECM (34). As fibroblasts have a limited replicative ability they 
eventually senesce (45) and removal of accumulated senescent fibroblasts helps to 
stimulate wound healing (46). Concurrently, endothelial cells lining the blood vessels 
in the wound are activated and begin to divide sprouting or budding through the vessel 
basement membrane in the new matrix (47). New blood vessels form where the tips 
of new capillary buds meet (35, 47). 
Re-epithelialisation occurs around the same time with basal keratinocytes migrating 
across the granulation tissue. Stem cells also migrate from within the dermis and 
keratinocytes migrate from the wound edge to establish a new skin barrier. Once this 
has been achieved keratinocytes resume a basal cell phenotype differentiating into a 
stratified, squamous, keratinising epidermis (48). The source of stem cells from within 
the dermis reside at the base of hair follicle bulges (49) and it is thought that these 
cells migrate to the surface to aid re-epithelialisation (50) and contribute to the 
regeneration of sebaceous glands and hair follicles (49). The final phases of the 
inflammatory response and epithelialisation coincide with the formation of granulation 
tissue and migration of fibroblasts and endothelial cells (51).  
The final phase of wound healing is remodelling of scar tissue which is partly 
performed by matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs 
produced by fibroblasts and macrophages and can last several months. In adults, scar 
formation is characteristic (52) with the balance of newly formed collagen and 
destruction of old collagen determining the final physical characteristics of the scar 
(51). There are three types of scars: atrophic scars are depressions in the skin; 
hypertrophic scars are elevated and can subside with time; and keloid scars are 
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elevated, expansive and continue to grow beyond the margin of the original wound 
(51). 
Scarring of wounds is thought to be caused by high expressions of two isoforms of the 
TGF-β family, TGF-β1 and TGF-β2. During wound remodelling, inflammatory cells, 
such as monocytes and macrophages, and the degranulation of platelets, release 
TGF-β1 and TGF-β2. These two isoforms are heavily implicated as a cause of scarring 
in adults. Application of neutralising antibodies to TGF-β1 and/or TGF-β2 markedly 
reduced scarring in rodent wounds (53-55) with no delays in wound healing (56). 
Comparatively fetal wounds, which heal by regeneration rather than repair, have very 
low levels of TGF-β1 and TGF-β2 and very high levels of TGF-β3 (51). Additionally, 
adult wounds treated exogenously to attain TGF-β3 levels similar to those in scar-free 
embryonic healing resulted in improved or absent scarring (55). 
More extensive injuries in which large areas of tissue are damaged or lost pose even 
more serious issues. If left untreated these wounds result in severe contraction which 
occurs when surrounding skin pulls together to more quickly close a wound and this 
can result in a loss of mobility while also having a detrimental, psychological impact. 
These wounds may also be unable to achieve autonomous wound closure as they are 
likely to have no blood supply to initiate clotting and begin the wound healing cascade. 
The extensive tissue damage or loss would also result in the absence of regenerative 
elements such as stem cells. In such situations, surgical intervention is required using 
treatments which can provide wound closure as well as provide guidance for wound 
healing. 
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1.4 Skin grafts and substitutes used for the treatment of burn 
injuries 
1.4.1  Skin grafts 
The gold-standard treatment of partial- and full-thickness burn injuries is the early 
excision of necrotic tissue followed by autografting. Autografts are autologous skin 
consisting of the epidermis and dermis excised from healthy, undamaged sites of the 
patient which are grafted onto a clean wound bed (57) (Figure 1.5). They can be full-
thickness grafts, consisting of the epidermis and whole dermis, or split-thickness, 
consisting of epidermis and the upper part of the dermis (51). A disadvantage of full-
thickness autografts compared to split-thickness autografts is that full-thickness 
autografts they are less likely to vascularise and, therefore, likelihood of graft rejection 
is higher (51). Autografts provide wound coverage while reducing wound contraction 
by reintroducing regenerative elements. 
Unfortunately, a shortage of skin donor sites can occur with burn survivors who have 
more than 50 % TBSA (58, 59). This can be overcome by repeated harvesting of donor 
sites over a period; however, healing of harvest sites can be slow with additional 
scarring and possible pigmentation changes occurring. Therefore, autografts 
themselves are not an ideal solution as additional injury is inflicted on the patient. 
 14 
 
Figure 1.5: Schematic of autograft harvest and application. Adapted from (60). 
Two biologically sourced alternatives investigated as substitutes for autografts were 
allografts and xenografts. Allografting is transplantation between individuals of the 
same species with skin tissue sourced from cadavers. Xenografting is transplantation 
between individuals of different species. Both alternatives have proved useful as 
temporary dressings which improve the quality of the wound for further treatment but 
they are not permanent replacements as graft rejection occurs due to the immune 
system rejecting the foreign objects (61). Additionally, allografts and xenografts have 
limited supply and inconsistent quality with the risk of pathogen transfer between the 
donor and recipient (27). 
1.4.2 Skin substitutes 
In response to the need for reliable, skin substitutes the field of skin tissue engineering 
evolved. It is an interdisciplinary field focussing on the generation of new tissue for 
replacement, repair or regeneration of damaged skin. Skin tissue engineering aims to 
create a low-cost, reproducible substitute capable of promoting and accelerating the 
regeneration of new, skin tissue possessing normal structural and functional 
properties. Current, manufactured substitutes have been developed which are able to 
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replace damaged epidermal and/or dermal layers of skin (62) (Table 1.1) and are able 
to improve wound healing to an extent. 
 Acellular wound dressings 
Biobrane is a biosynthetic dressing available for treatment of superficial and partial-
thickness injuries. It is a temporary skin dressing composed of a silicone membrane 
bonded to a nylon mesh with porcine, dermal, collagen peptides. Studies found 
Biobrane remained attached to a range of skin injuries, including donor sites and 
meshed autografts, until re-epithelialisation occurred (63). Its use was also observed 
to reduce pain, permit range of motion when applied over joints, usually had no fluid 
accumulation underneath the dressing and its translucency allowed direct observation 
of healing process (63-66). 
 Cultured epidermal substitutes 
One of the greatest developments in skin tissue engineering was the cultivation of 
human keratinocytes in the late 1970s (67, 68). This achievement permitted the 
expansion of a patient’s own keratinocytes to form cell sheets which could be grafted 
back onto the patient as an epidermal substitute. These sheets of keratinocytes were 
termed cultured epithelial autografts (CEAs) and have been shown to aid dermal 
regeneration with smoother graft appearance and more even pigmentation than 
autografts (69, 70). 
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Table 1.1: Examples of skin substitutes used in the treatment of skin injuries (51, 62, 71-75). 
 Product Epidermal component Dermal component Advantages Disadvantages 
Epidermal 
substitutes 
Cultured 
epithelial 
autografts 
sheet of autologous 
keratinocytes grown from 
skin biopsy 
none cover large area with little rejection 
risk; aid dermal regeneration; 
smoother graft appearance 
3 weeks required to produce 
fragile sheets; susceptible to 
blistering 
Epicel 
(Genzyme Tissue 
repair Corp.) 
cultured epithelial 
autografts grown on 
petrolatum gauze backing 
none large area of permanent wound 
coverage with little risk of rejection 
3 weeks required to produce 
fragile, confluent sheets; 
susceptible to blistering 
Dermal 
substitutes 
Alloderm 
(Life Cell 
Corporation) 
none processed cadaver 
allograft skin 
processing reduces antigenic 
components; successful resurfacing 
of full-thickness burns 
graft rejection and risk of 
disease transfer 
Permacol 
(Tissue Sciences 
Laboratories) 
none porcine-derived 
acellular dermal matrix 
non-immunogenic due to removal 
of non-collagenous and cellular 
materials; supports fibroblast 
infiltration and revascularisation 
revascularisation sometimes 
inefficient to support 
epidermal graft 
MatriDerm 
(Skin and Health 
Care AG) 
none Bovine collagens type 
I, II and V and bovine 
α-elastin from 
ligamentum nuchae 
improves skin pliability; reduces 
contraction; stimulates dermal 
regeneration 
mixed results with pliability; 
risk of disease transfer 
Integra 
(Integra Life 
Sciences Corp.) 
silicone layer bovine, collagen type I 
and chondroitin-6-
sulphate 
promotes fibroblasts and epithelial 
cell ingrowth; silicone replaced with 
an autograft after vascularisation 
bovine collagen is antigenic 
and a disease risk; 3 weeks 
required to expand dermal 
autograft 
TransCyte 
(Advance 
BioHealing, Inc.) 
thin silicone layer 
(Biobrane) 
collagen-coated nylon 
mesh seeded with 
neonatal, allogeneic 
fibroblasts 
dermal fibroblasts secrete collagen, 
glycosaminoglycan and growth 
factors to aid wound healing 
nylon mesh not 
biodegradable; rejection and 
disease risk from fibroblasts 
Bilayered 
substitutes 
Autografts epidermis harvested from 
healthy site of patient 
dermis harvested from 
healthy site of patient 
gold-standard treatment; replaces 
regenerative elements; good 
cosmetic results 
revascularisation sometimes 
inefficient leading to graft 
rejection; additional scarring 
Apligraf 
(Organogenesis) 
allogeneic, neonatal 
keratinocytes 
neonatal, allogeneic, 
foreskin fibroblasts on 
bovine, collagen type I 
comparable graft take to autografts; 
good cosmetic results; no signs of 
rejection observed 
risk of chronic graft rejection 
and disease from allogeneic 
cells; requires repeated 
applications 
OrCel 
(Ortec 
International) 
allogeneic, neonatal 
keratinocytes 
neonatal, allogeneic, 
foreskin fibroblasts in 
bovine, collagen 
sponge 
favourable environment for host cell 
migration and provides source of 
cytokines and growth factors 
temporary skin replacement; 
designed as dressing; risk of 
rejection and disease  
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CEAs remain a common choice for the treatment of burn injuries to this day; however, 
they have numerous disadvantages including lengthy hospital stays with 2-3 weeks 
required for cultivation of cells (58). CEAs are also difficult to manipulate due to their 
fragility and inherently thin nature (58). Furthermore, the enzymatic treatment used to 
detach the CEAs from culture dishes is thought to lead to poor basement membrane 
formation (62) which in turn is responsible for blistering and variable graft take ranging 
from 0 % to more than 80 % (76, 77). CEAs can also take several years to develop 
normal histological appearance (78). CEAs were originally intended to replace 
autografts in the treatment of deep burns; however, use of CEAs alone have been 
shown to be unsuitable as they do not replace the damaged dermis and its 
components which are necessary for normal skin function and appearance (67, 79). 
 Acellular dermal substitutes 
Skin substitutes designed for dermal replacement aim to guide regeneration of skin 
tissue as the complexity of ECM makes it difficult to replicate. There are several dermal 
substitutes commercially available, the most popular of those is Integra Dermal 
Regeneration Template (IDRT; Integra Life Sciences Corporation, Plainsboro, NJ, 
USA), a collagen-based matrix developed in the early 1980s (80-84). It is a porous, 
acellular substitute fabricated by lyophilising a solution of bovine, collagen type I and 
chondroitin-6-sulphate to form the dermal layer. The temporary, epidermal layer 
consists of silicone and acts as a barrier to prevent fluid and heat loss as well as 
minimising bacterial infection (Figure 1.6). The collagen matrix serves as a 
biodegradable support and provides guidance for cell infiltration of the wound area. 
After the collagen matrix is vascularised the silicone layer is replaced by a thin, split-
thickness autograft to form the new, epidermal layer. Integra is also commercially 
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available as a single layer, silicone free substitute intended for the treatment of deep 
dermal skin injuries. 
 
Figure 1.6: Schematic of an IDRT graft. Adapted from (85). 
IDRT is used in the treatment of deep-partial to full-thickness burn injuries when a 
shortage of skin donor sites are available (86). The use of IDRT has been seen to 
improve epidermal graft take while also decreasing hypertrophic scarring and 
improving the cosmetic outcome of new skin (87-89). However, although IDRT is a 
commonly used substitute there are high costs involved and multiple surgeries 
required with high risks of infection, limited graft take, wound contraction and scarring 
(90, 91). 
MatriDerm (Skin and Health Care AG, Billerbeck, Germany) is another commercial 
substitute and it is the only skin substitute available containing elastin, the critical 
matrix protein in the elastic network of human dermis. MatriDerm is fabricated by 
lyophilisation of bovine collagen to form a non-cross-linked matrix which is then coated 
with 3 % α-elastin derived from bovine ligament nuchae. Studies of MatriDerm have 
returned mixed results with one study showing improved results of hand wounds 
Silicone layer 
Collagen-GAG matrix 
Epidermis 
Dermis 
Adipose Tissue 
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treated with MatriDerm and non-meshed skin grafts compared to conventionally 
grafted wounds (92-94). Other benefits also included reduced wound contraction and 
stimulation of dermal regeneration (95). However, a long-term clinical trial showed no 
difference in scar elasticity between MatriDerm and split-thickness grafts alone (96). 
 Cultured, dermal substitutes  
Further development of dermal substitutes have investigated cellular substitutes in 
which wound healing is stimulated by the seeding of fibroblasts into the scaffold to 
promote ECM synthesis (97). One such study demonstrated that a gelatin-based 
scaffold in a mouse model enhanced re-epithelialisation of full-thickness wounds 
grafted with fibroblast-seeded scaffolds compared to wounds grafted with acellular 
scaffolds (98). Another study with pigs showed that improved tissue regeneration, 
decreased wound contraction and less scarring was correlated with increasing 
fibroblast numbers (99). Clearly, the inclusion of fibroblasts has promising results in 
the improvement of wound healing. 
Cellular dermal substitutes are commercially available, for example TransCyte 
(Advanced BioHealing, Inc., La Jolla, CA, USA) contains allogeneic, neonatal 
fibroblasts cultured for 17 days in vitro on nylon fibres. The fibres are embedded in a 
silastic layer allowing cells to synthesise ECM and growth factors before being 
rendered nonviable by freezing (97, 100, 101). Accelerated wound healing and 
decreased inflammation has been observed with the use of TransCyte when 
compared to the use of split-thickness grafts in partial-thickness burns (102, 103). 
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 Cultured, bilayered skin substitutes 
Bilayered, cellular skin substitutes, also known as living skin substitutes, have been 
developed and have great potential to improve and simplify treatment with both the 
epidermal and dermal components being replaced in a one-step procedure (79, 97). 
Currently, the components used to construct bilayered constructs are simple. For 
example, Apligraf (Organogenesis, Canton, MA, USA) is composed of allogeneic, 
neonatal fibroblasts and keratinocytes cultured on a type I, bovine, collagen scaffold 
(104). Apligraf has extensive studies with treatment of venous and diabetic ulcers 
(105) and a study examining its use in burn wound treatment demonstrated that a 
combination of Apligraf with meshed, split-thickness grafts improved skin 
pigmentation, pliability and vascularisation compared to meshed grafts alone (106). 
 Issues with existing, commercial skin substitutes 
Current, skin substitutes provide alternative treatment options which can improve 
clinical outcomes. Epidermal replacements provide wound closure and promote 
wound healing while dermal replacements can reduce wound contraction and replace 
lost elements required for regeneration such as basal keratinocytes and stem cells 
located at the base of hair follicles. The dermal substitutes provide guidance for cell 
infiltration and wound remodelling and the new skin generated has a more natural 
appearance with reduced scarring than if a wound is left untreated. However, scar 
tissue is often functionally, mechanically and aesthetically abnormal as the internal 
architecture provided by substitutes does not adequately replicate the complex internal 
structure of normal skin tissue required to direct tissue growth (107). 
For example, many substitutes suffer from poor graft take resulting from insufficient, 
early-stage vascularisation. A blood supply is vital to maintain long-term survival and 
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integration of the graft, otherwise cells in the substitute die and the construct will slough 
away. A recent study demonstrated central blood vessels of an autograft were refilled 
between 48-60 hrs after grafting and this was attributed to early anastomoses forming 
between the graft and bed vessels in the surrounding undamaged skin (108). This 
indicates the incorporation of prefabricated vessels into a substitute or the use of 
materials with biosignals which accelerate angiogenesis could improve treatment by 
preventing delays in vascularisation and thereby decrease the chances of graft 
rejection. 
Absence of differentiated structures and the physical appearance in scar tissue are 
another two serious issues encountered with current substitutes. The absence of 
sweat glands results in skin unable to perform homeostatic functions such as 
thermoregulation, missing melanocytes leads to a lack of melanin deposition in 
keratinocytes and thereby increased ultraviolet (UV) sensitivity and variations in skin 
colour and the lack of Langerhans cells leads to compromised immune defence in 
skin. Current substitutes do not provide the necessary signals to trigger regeneration 
of all the components of skin. However, one study has shown the ability of a mixture 
of melanocytes, fibroblasts and keratinocytes to spontaneously sort on a skin 
substitute (109). This highlights the ability of skin substitutes to function as a delivery 
device for cell mixtures while providing a three-dimensional (3D) environment 
conducive to normal cell behaviour. The inclusion of chemotactic materials or signals 
in the scaffold could further assist regeneration. 
The lack of elasticity in scar tissue is yet another issue arising from the use of current 
substitutes. Inelastic skin restricts movement especially if the affected area is one such 
as knees, fingers or shoulders. It has been seen that some substitutes, such as 
MatriDerm, can sometimes regenerate skin with normal elasticity and flexibility. 
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However, variable and unreliable outcomes such as these are highly undesirable and 
further development of scaffolds is necessary. Attention should focus on improving the 
internal structure of substitutes and the effect on the deposition of new ECM which is 
central in defining the properties of new tissue. For example, the elastic network of 
normal, skin tissue relies heavily on the formation of mature, elastin fibres to provide 
strength and elasticity (110). Internal architecture and composition which closely 
mimics that of normal ECM would likely be beneficial to regeneration of normal tissue. 
1.5 Ultimate goal of skin tissue engineering 
Skin tissue engineering is a multi- and interdisciplinary field encompassing fields such 
as polymer chemistry, biochemistry and stem cell research. Skin tissue engineering 
aims to combine the knowledge of these fields to development a substitute which can 
be rapidly produced and regenerate skin to its normal mechanical, functional and 
aesthetic properties. This includes regeneration of: the ECM to provide support and 
guidance; the vascular network to improve graft take; skin appendages for functions 
such as thermoregulation and sensitivity; and the different cell types required for 
protection. 
There are essentially two approaches to this goal. The first is the development of a 
highly sophisticated, biodegradable scaffold capable of releasing a cocktail of 
signalling molecules in a temporally and spatially controlled manner to facilitate cell 
migration, adhesion and essentially skin regeneration. The second approach is to 
engineer a minimally designed, temporary scaffold which would act as a carrier for 
undifferentiated or stem cells that would interact to regenerate the skin (51). Both 
approaches require the creation of a 3D environment which can support cell 
interactions and promote wound regeneration. It is with this necessity at the forefront 
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of skin tissue engineering that there are a burgeoning number of investigations into a 
wide array of scaffold materials and techniques. 
1.6 Materials investigated for skin tissue engineering 
1.6.1 Natural materials  
Natural materials are biologically-derived components such as collagen, elastin, silk, 
chitosan and fibronectin. There is focus on the use of natural polymers to fabricate 
skin substitutes as they provide the advantages of constructing biocompatible and 
biodegradable scaffolds with non-toxic degradation products. Natural polymers are 
attractive due to their evolutionarily-developed peptides which provide cell signals to 
promote wound healing. The disadvantages of natural polymers are batch-to-batch 
variation, risk of immune rejection and risk of pathogen transfer. 
 Silks 
Silks have only recently begun to be researched as natural biomaterials for tissue 
engineering despite their clinical use as sutures for centuries. They are lightweight 
polymers with tensile strength similar to Kevlar 49 while being more elastic and 
requiring more energy to break than Kevlar 49 (111, 112). Silks are also thermally 
stable up to around 250 °C allowing a wide range of processing temperatures (113). 
The most commonly studied silks are cocoon silk from the silkworm Bombyx mori and 
dragline silk from the spider Nephila clavipes (114-118). 
Silks are composed of a filament core protein, called silk fibroin, with a glue-like coating 
consisting of a family of sericin proteins (111). Silks from B. mori and N. clavipes are 
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structurally characterised by block copolymers of hydrophobic blocks with highly 
preserved repetitive sequences of short side-chain amino acids and hydrophilic blocks 
composed of more complex sequences of larger side-chain and charged amino acids 
(119, 120). The hydrophobic blocks give rise to the tensile strength of silk fibroin by 
forming β-sheets or crystals via hydrophobic interactions or hydrogen bonding (121, 
122) and the elasticity and toughness of silk arises from the combination of these 
hydrophobic blocks with less ordered hydrophilic blocks (114, 117, 123). The repetitive 
hydrophobic regions are the basis for genetic engineering of host systems, such as 
Escherichia coli, yeast, mammalian cells and plants, to produce recombinant silk 
fibroin-like proteins which exhibit low water solubility due to hydrophobicity (118, 121, 
122, 124-133). 
Many studies have shown the ability of silkworm silk to support human fibroblast 
attachment and proliferation (134-137); however, it has been identified that sericin is 
a major cause of adverse immune responses (138). Removal of sericin and 
regeneration of silk fibroin has shown good biocompatibility (138-141), 
haemocompatibility (142) and oxygen and water permeability (143, 144). It has also 
been reported that the use of silk fibroin films and composites in wound dressings 
promote in vivo healing (145, 146). 
 Chitosan 
Chitosan is produced through the partial deacetylation of chitin, which is the second 
most abundant natural polymer obtained from the exoskeletons of crustaceans (147). 
It is a linear polysaccharide composed of glucosamine and N-acetyl glucosamine units 
linked by β (1-4) glycosidic bonds (148). The hydroxyl and amino groups can be 
modified to synthesise various derivatives of chitosan (149-151). The content of 
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glucosamine is called the degree of deacetylation which varies from 30-95% 
depending on the source and preparation procedure and this also determines the 
molecular weight (152, 153). 
Chitosan is insoluble in aqueous solutions above pH 7; however, the protonated free 
amino groups on glucosamine facilitate chitosan’s solubility in dilute acids (pH <6.0) 
(154). Conversely, the ionic groups make techniques such as electrospinning 
challenging as the cationic groups require a solvent that forms a salt with chitosan to 
destroy the interactions between neighbouring chitosan molecules (155-158). 
Chitosan’s cationic groups also facilitate pH-dependent electrostatic interactions with 
anionic glycosaminoglycans (GAG) and proteoglycans (159). 
Among the benefits of chitosan, its biocompatibility, biodegradability and bioactivity 
have made it a polymer of interest in skin tissue engineering (160, 161). Also of interest 
are chitosan’s properties to achieve haemostasis, accelerate tissue regeneration and 
stimulate collagen synthesis by fibroblasts (162-165). Chitosan’s properties have also 
been seen to persist or improve when used to make double-polymer scaffolds. For 
example, a chitosan-alginate polyelectrolyte complex membrane showed greater 
stability to pH changes than either material alone which provides more effect 
controlled-release membranes (166). This ability to retain properties after blending is 
useful in skin tissue engineering as it allows the combination of multiple materials to 
produce a scaffold with enhanced capabilities. 
 Collagen type I 
‘Collagen’ is a generic term for proteins forming a characteristic triple helix of three 
polypeptide chains and, based on structure and supramolecular organisation, can be 
grouped into fibril-forming, fibril-associated, network-forming, anchoring fibril, 
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transmembrane, basement membrane or other collagens with unique functions (167). 
Collagens also have functional properties providing cell signals for attachment and 
proliferation (168). All collagens have a characteristic supramolecular structure that is 
a right-handed triple helix (169, 170) and each of the α-chains form an extended left-
handed helix with a pitch of 18 amino acids per turn (171). Collagen can be 
homotrimers consisting of three identical chains or heterotrimers consisting of two or 
three different chains. The chains are staggered by one residue relative to each other 
and supercoiled around a central axis (172). Close packing of the α-chains is permitted 
around this axis by use of glycine at every third residue which is positioned in the 
centre of the triple helix while the more bulky side chains of other amino acids are 
located in the outer positions (167, 173). 
Networks of fibril-forming collagens provide a dynamic, 3D environment in tissues 
such as skin, bone and articular cartilage and include collagen types I, II, IV, V and XI 
(167). They are characterised by their ability to assemble into highly orientated 
supramolecular aggregates and, under SEM, have a banding pattern with periodicity 
of about 70 nm (174). Collagen type I is the most abundant and well-studied collagen 
providing tensile stiffness in fascia (Figure 1.7). It is a heterotrimeric collagen with two 
α1-chains encoded in the 17q21.31-q22 region in humans and one α2-chain encoded 
in the 7q22.1 region (167). A previous study has demonstrated the ability collagen type 
I to support the formation of neo-follicles when a collagen-GAG scaffold was cultured 
with murine dermal papilla cells (175) indicating collagen provided the required 
structure and signals for development of the neo-follicles. 
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Figure 1.7: Chemical structure of collagen type I, the major collagen type in skin. 
 Elastin 
Elastin is another natural polymer steadily garnering interest in skin tissue engineering. 
The monomer form of elastin is called tropoelastin which undergoes cross-linking to 
form the insoluble biopolymer, elastin (176). Tropoelastin is encoded by a single copy 
gene in humans located in the 7q12.2 region (177) and is characterised by alternating 
hydrophobic and hydrophilic domains (178). These alternating domains are involved 
in different functions of the protein with the hydrophobic domains implicated in 
monomer association and elastic function while hydrophilic domains are involved in 
polymerisation of the monomer through cross-linking (179). 
Elastin is found in elastic tissues such as large arteries, lung, tendons and skin (180) 
and is produced by several cell types including fibroblast, smooth muscle cells and 
endothelial cells (181). Elastogenesis primarily occurs during late fetal and early 
neonatal periods with little elastin turnover occurring in healthy adult tissue (182). 
Elastin is extremely durable with a half-life of approximately 70 years (183).Elastin is 
one of two distinct components responsible for the composition of elastic fibres, elastin 
is the core around which is wrapped a sheath of microfibrils 10-12 nm wide (184). 
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Elastin is well-known for imparting elasticity, flexibility and resilience to skin while also 
determining skin texture and quality (183). In damaged skin, elastin has been shown 
to be reduced or even absent which accounts for the reduced pliability of scar tissue 
(185). 
Elastin also has inherent cell signalling properties including chemotaxis, cell 
attachment, proliferation and differentiation (178, 186). These structural and functional 
properties make elastin an attractive polymer for use in skin tissue engineering with 
the expectation that inclusion of elastin in a skin substitute could increase a 
substitute’s elasticity while possibly improving cell-scaffold interactions. Interestingly, 
the presence of enzymatic elastin products have been seen to have stimulatory effects 
on elastin and collagen production (187). Dermal fibroblasts cultured with elastin 
products had significantly higher production of elastin and collagen fibres. This 
increase in elastic fibre deposition was also seen in cultures of skin explants and, 
furthermore, increased elastic fibre production by human, dermal fibroblasts (HDFs) 
was translated into athymic nude mice upon injection of HDFs (187). 
1.6.2 Synthetic polymers 
Synthetic polymers are manufactured polymers which are readily available. 
Biodegradable, biocompatible and/or bioresorbable synthetic polymers are of interest 
in skin tissue engineering as the polymer can be degraded and removed via the body’s 
natural pathways with no surgical intervention. The batch-to-batch consistency of 
synthetic polymers is also advantageous as mechanical properties, such as tensile 
strength, are predictable allowing for reliable treatment outcomes. However, synthetic 
polymers also lack the biological signals inherent in natural polymers. There are many 
synthetic polymers under investigation for use in skin tissue engineering such as 
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poly(lactic acid) (PLA) (188), poly(glycolic acid) (PGA) (189) and polycaprolactone 
(PCL) (190). In this study the only synthetic polymer used was PCL, which is discussed 
below. 
 Polycaprolactone (PCL) 
PCL is an aliphatic polyester biodegraded by hydrolysis and has been approved by 
the Food and Drug Administration (191, 192) (Figure 1.9). It was first synthesised in 
the 1930s and has regained attention in the tissue engineering field due to its 
biocompatibility, high tensile strength and controllable biodegradability (193, 194). 
Degradation of PCL can span months to years depending on polymer properties such 
as molecular weight, degree of crystallinity and degradation conditions (195-197). The 
degradation products of PCL are also non-toxic unlike other synthetic polymers such 
as PLA which can cause mild inflammation (173, 198). 
 
Figure 1.8: Chemical structure of PCL. 
There have been clinical trials of supercutaneously implanted PCL capsules that 
indicate PCL was well-tolerated over 40 weeks with other studies using PCL as a 
release vehicle for drugs (199-201). One study developed an ultrathin PCL film as a 
wound dressing and when tested in rat and pig models the PCL films had a lower level 
of fibrosis compared to control, non-dressed wounds. There was also no inflammation 
induced by PCL films with the wound dressing supporting normal wound healing in 
both partial- and full-thickness wounds (190). 
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 Poly(D,L-lactic-co-glycolic acid) (PLGA) 
PLGA is a family of FDA-approved biodegradable, biocompatible polymers and is 
popular due to its long clinical experience and possibilities for sustained drug delivery 
despite the degradation products being mildly inflammatory. It is a copolymer of PLA 
and PGA and contains equal ratios of the optically active D and L forms of PLA which 
has an asymmetric α-carbon, PDLA and PLLA respectively (202). Generally, PLA can 
be highly crystalline in the PLLA form or completely amorphous in its PDLA form 
whereas PGA is highly crystalline. 
PLGA is soluble in a wide range of common solvents such as acetone and ethyl 
acetate (203, 204). When in water PLGA undergoes degradation by hydrolysis at its 
ester linkages. Therefore, the rate of degradation can be decreased by including more 
of the comparatively less hydrophilic PLA to decrease water absorption and 
subsequently slow down degradation (202). Physical properties of PLGA have also 
been shown to depend on other factors such as storage temperature and molecular 
weight which affects mechanical strength (205). 
Since PLGA has poor surface chemistry it is widely incorporated with natural polymers 
to improve cellular interactions and proliferation. One such study has investigated a 
knitted PLGA mesh with web-like bovine collagen type I sponges in the interfibre 
spaces of the PLGA mesh (206). The blended scaffolds were shown to support HDF 
attachment and proliferation with more homogenous cell and ECM distribution than 
PLGA-only scaffolds. Further in vivo experiments of the scaffold as a living dermal 
substitute in a nude mouse model demonstrated tissue remodelling after 2 weeks and 
full re-epithelialisation within 4 weeks.  
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1.6.3 Composite scaffolds 
Natural and synthetic polymers each have their advantages and disadvantages and 
one approach to address these shortcomings is to produce scaffolds with a blend of 
polymers. Composite scaffolds aim to utilise the advantageous properties of both 
types of polymers during fabrication resulting in a scaffold with improved properties 
such as increased mechanical strength and enhanced cell signalling abilities. Many 
different combinations have been investigated with a heavy focus on collagen. 
1.7 Scaffold fabrication methods investigated for tissue 
engineering 
Scaffold structure is greatly influenced by the scaffold fabrication method employed 
and there are a diverse range of methods available. However, there are generally two 
types of scaffolds produced from current fabrication methods, either a fibrous or non-
fibrous scaffold. The resulting scaffolds are porous with interconnected pores and 
controlled pore size and shape. 
1.7.1 Production of non-fibrous scaffolds 
 3D printing 
3D printing, or bioprinting is a flexible, automated platform for free-form fabrication of 
complex living structures of which two, main, distinct technologies have emerged (207). 
The first of these relies on the use of inkjet printing of either individual or small clusters 
of cells (208-216). The technique is rapid, versatile and cheap; however, it is difficult 
to assure the high cell density required for fabrication of solid, organ structures. The 
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high speed encountered in this technique also causes considerable cellular damage, 
although recent developments have improved cell survival (207). 
The second approach utilises mechanical extruders to place multicellular aggregates 
of definite composition, also called bioink particles, into a supporting environment 
using computer-generated templates of the desired biological structure (217-221). The 
method forms structures by the post-printing fusion of bioink particles and the sorting 
of cells within the particles. This form of printing also allows cell-cell adhesion within 
particles providing cells with a more physiologically normal environment. However, the 
relatively high cost of the printers required for this method are a limiting factor in their 
use (207). 
A study which employed 3D printing demonstrated its effectiveness with the printing 
of collagen, keratinocytes and fibroblasts to represent the ECM, epidermis and dermis 
respectively (222). The printed tissue was shown to be morphologically and 
biologically representative of human skin with keratinocytes undergoing terminal 
differentiation and forming the stratum corneum, the uppermost layer of epidermis. 
However, over a 14-day culture period the thickness of the constructs decreased from 
500 μm to as thin as 150 μm. 
 Thermally induced phase separation (TIPS) 
TIPS has been extensively investigated and produces polymeric structures with 
controlled porosity and pore size (223). TIPS includes two types of separation, the first 
of those is liquid-liquid phase separation (224) in which the polymer solution is cooled 
to produce a polymer-rich phase and polymer-lean phase followed by solvent removal. 
One such example of this technique was the production of a porous, biocompatible 
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and biodegradable poly(lactic-co-glycolic acid) (PLGA) scaffolds by dissolving varying 
concentrations of PLGA in dioxane and water followed by heating, quenching, freezing 
and solvent evaporation (225). 
The second form of separation is solid-liquid phase separation (226), also called 
lyophilisation. This method is employed in the production of commercial substitutes 
such as IDRT and MatriDerm with the polymer solution frozen followed by removal of 
the solvent. Solvent freezing at higher temperatures generally produces larger pores 
as a low nucleation and crystal growth rate leads to the production of a small number 
of large solvent crystals (227). 
 Gel casting 
Hydrogels have become increasingly prevalent in the last decade (228), likely due to 
their biocompatibility and structural similarity to the macromolecular-based 
components in the body (229). They are often considered favourable for promoting 
cell migration, angiogenesis, high water content and rapid nutrient diffusion (230). 
According to Jhon and Andrade (1973) there are three different mechanisms of gelling 
which can be used to form hydrogels: firstly, ionic cross-linking with multivalent 
counterions is simple but those ions could be exchanged with others in the aqueous 
environment leading to uncontrolled deterioration of the hydrogels’ original properties 
(231); secondly, covalent cross-linking provides more precise control but the toxicity 
of cross-linking molecules and the non-degradable cross-links may not be desirable; 
and, thirdly, utilisation of the phase transition behaviour of certain polymers (232). 
Collagen hydrogels are well studied and show excellent biological functionality (233, 
234). For example, a type I collagen hydrogel was fabricated by freeze-drying 
neutralised collagen followed by immersion in ethanol, evaporation of ethanol, fixation 
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by UV irradiation and finally addition of cell suspension (235). However, contraction of 
collagen scaffolds is a major drawback. Volume loss of the gels can be caused by self-
compression, contraction, degradation or induced by fibroblasts (236-239). One study 
has attempted to address this by compressing collagen type I hydrogels prior to cell-
seeding (240). It was seen that plastic compression of 5 mL gels to a thickness of  
0.5 mm dramatically reduced contraction and degradation while HDFs were still able 
to evenly distribute throughout the compressed gel without affecting HDF viability or 
function. 
 Gas foaming 
Gas foaming involves dissolution of a blowing agent into a hydrogel. When the agent 
is released this generates a porous scaffold (241, 242). This technique has been used 
to generate a PCL-thermoplastic gelatin scaffold by gas foaming N2/CO2 through a 
melt mix of PCL and thermoplastic gelatin and then extracting thermoplastic gelatin by 
soaking the sample is dH2O (243). Synthetic- and natural-polymer based scaffolds 
have been produced using this technique (244-246). Previously, polymeric foaming 
employed organic solvents but supercritical fluids (SCFs) can be used as a good 
alternative as they eliminate the possibility of leaving unwanted contaminants (247). 
The advantage of SCFs is that they leave no unwanted contaminants such as residual 
solvents or salts (248). However, this technique often produces scaffolds too compact 
for cells (249) and requires specialised equipment which is not readily adapted to most 
laboratory settings. 
 35 
1.7.2 Production of fibrous scaffolds 
 Electrospinning 
Fibrous scaffolds can be produced by several techniques such as wet spinning (250), 
needled non-woven or electrospinning. The technique of electrospinning is gaining 
momentum in the skin tissue engineering field as it is simple and inexpensive (251). A 
large array of single-polymer and composite scaffolds have been electrospun in skin 
tissue engineering including synthetic polymers such as PCL (252), polyethylene oxide 
(PEO) (253), PLA (254) and PGA (255), and natural polymers, such as collagen (172), 
chitosan (256), silk (257), elastin (258) and hyaluronic acid (259). 
In electrospinning, fibres are formed by positively charging a polymer solution as it 
emerges from a needle and this jet is attracted to a negatively charged or grounded 
collector. The solvent evaporates as the jet travels towards the collector forming dry, 
positively-charged, ultrathin fibres which accumulate on the collector to create a non-
woven, fibrous mat. 
Electrospinning has many advantages including morphological similarity to native 
ECM by producing nano- to microscale fibres (260) which mimic the local cellular 
environment (Figure 1.10). These ultrathin fibres provide a large surface area which 
promotes cell adhesion (260-262). Electrospun scaffolds also provide the appropriate 
tensile strength required for skin while maintaining scaffold integrity. The internal 
structure of the scaffolds are highly interconnected which promote gas and fluid 
exchange and cell infiltration (260, 263). 
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Figure 1.9: Scanning electron microscope (SEM) images of native ECM (A) and an 
electrospun scaffold (B). 
For example a composite scaffold of poly((D,L-lactide)-co-glycolide) and collagen was 
electrospun resulting in a scaffold with porosities between 85-90 % and pore sizes 
ranging from 90-130 μm (264). Enhanced cell attachment, proliferation and ECM 
secretion were seen to depend on the amount of collagen; however, cell morphology 
and distribution was similar on all scaffolds containing collagen. Slight cell infiltration 
was observed on all scaffolds indicating the pore size and scaffold porosity, which 
were controlled by electrospinning, were the main determinants. 
1.8 Importance of scaffold structure on cell-scaffold interactions 
Scaffold structure is a strong determinant in the success of a substitute by influencing 
cell interactions. Macroscopically, a scaffold defines the boundaries for tissue growth 
with rough, disordered surfaces promoting cell differentiation and ECM synthesis while 
negatively impacting cell proliferation (265-269). On a microscopic level scaffolds 
provide a framework for cell attachment, migration and proliferation and ultimately 
tissue organisation (270) with large pore volumes required for accommodation of a 
sufficient cell mass for tissue repair (271). Particularly on a microscopic scale high 
A B 
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scaffold porosity and pore interconnectivity are critical to cell infiltration and 
vascularisation by promoting nutrient and waste exchange, metabolite dispersal and 
cell signalling. Hindrance of interconnectivity, and therefore inhibition of cell migration, 
can occur through scaffold degradation creating bottlenecks (272) or through lack of 
degradation with attached cells blocking pores (271). Pore size also plays an important 
role by affecting cell proximity during seeding and cell ingrowth with optimal pore sizes 
varying according to tissue requirements. 
1.9 Development of novel scaffolds in skin tissue engineering 
There is a plethora of research in skin tissue engineering with many different materials 
and fabrication methods being investigated using the two major skin cells, i.e. 
epidermal keratinocytes and dermal fibroblasts. There appears to be a focus on the 
development of composite scaffolds. This is likely due to their ability to produce 
scaffolds which encompass the advantageous properties of the individual polymers 
while overcoming the disadvantages. These combinations consist of all synthetic 
polymer scaffolds, all natural polymer scaffolds or, more commonly, a blend of 
synthetic and natural polymers in one scaffold. 
An example of a composite scaffold composed entirely of natural polymers is a cross-
linked, electrospun, collagen-elastin scaffold (273). It was composed of 20 % bovine, 
collagen type I and 80 % recombinant, human tropoelastin dissolved in HFP with 
microscale fibres and 64.5 ± 6.23 % porosity. The scaffold displayed accelerated HDF 
proliferation compared to pure collagen scaffolds in vitro. When tested as a 
subcutaneous implant in a mouse model the collagen-elastin scaffold was shown to 
perform similarly to IDRT with a moderate immune response, HDF infiltration, collagen 
deposition and angiogenesis observed over 6 weeks. 
 38 
On the other end of the spectrum, fully synthetic scaffolds have been fabricated via 
salt leaching (274). Relatively hydrophobic PLA and hydrophilic PEO were used to 
synthesise two tri-block co-polymers (275), presumably aiming to improve the cell-
interactive properties of PLA using PEO’s hydrophilicity. The porous scaffolds were 
shown to support human fibroblast and keratinocyte proliferation and differentiation 
over 6 weeks in vitro. Furthermore, the fibroblasts could colonise the scaffold and 
produce ECM while keratinocytes formed an epidermal barrier. 
Another approach to improving the cell-scaffold interactions of synthetic polymers is 
to fabricate the core of the scaffold with the synthetic polymer and then coat the fibres 
with natural polymers to provide a favourable surface for cell adherence. This method 
was used in the fabrication of a PLGA-collagen scaffold in which a PLGA knitted mesh 
was coated with bovine, collagen type I (206). The PLGA fibre widths were quite large 
(>100 μm) but the web-like collagen structures in the pores of the PLGA mesh were 
considered microsponges. The addition of collagen was shown to improve HDF 
attachment and proliferation in vitro with more homogenous cell and ECM distribution. 
However, when tested as a living, dermal substitute in a nude, mouse model there 
was no difference observed between the PLGA and PLGA-collagen scaffolds. 
Coating of synthetic fibres has also been performed using a modified version of 
electrospinning which produced fibres possessing a core-sheath structure. 
Transmission electron microscope imaging revealed electrospun PCL/silk emulsions 
formed core-sheath or multicore-sheath structures while maintaining nanoscale fibres 
(276). The incorporation of silk into the PCL scaffolds was shown to improve HDF 
attachment and proliferation with increasing silk concentrations improving cell-
interactions. These scaffolds were also tested with fluorescein isothiocyanate (FITC) 
and showed the composite scaffolds had significantly inhibited burst release of FITC 
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in the first two hours compared to PCL-only scaffolds and then continuous, gradual, 
long-term release of up to 80 hours. This delayed and prolonged release could be 
useful during treatment for delivery of drugs or biofactors which could accelerate 
wound healing. 
Blending of synthetic and natural polymers has also been performed by dissolution of 
all polymers in a single solvent to form one, homogenous solution. Electrospinning of 
such a solution has been performed using various ratios of bovine collagen and PCL 
(277). The study chose to use electrospinning as the fabrication method as a previous 
study had shown pure collagen, electrospun scaffolds significantly decreased wound 
contraction compared to lyophilised, collagen scaffolds when grafted onto full-
thickness wounds in athymic mice (278). The collagen-PCL, electrospun scaffolds 
were all shown to support cell interactions with decreasing PCL content, particularly 
PCL concentrations below 10 % (w/v), associated with increasing HDF density, better 
stratification of dermal and epidermal layers and higher HDF and normal, human, 
epidermal keratinocytes (NHEK) proliferations rates in vitro indicating PCL may be 
able to reduce wound contraction. Conversely, decreasing PCL content was seen to 
result in increased contraction of scaffolds when cultured with HDFs and NHEKs in 
vitro. Despite these varying results, cell infiltration was observed on all scaffolds by 
day 10. This indicates the internal structure of scaffolds produced by electrospinning 
was conducive to cell ingrowth. 
1.10 Project rationale and aims 
Commercial substitutes provide wound closure and promote repair; however, new skin 
tissue often lacks the elasticity, strength and complexity of normal skin with scarring 
and contraction often occurring. Current research in skin tissue engineering is 
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investigating a wide array of materials and fabrication techniques to improve available 
treatments. 
Elastin is a well-known, ECM protein which plays an important role in the elastic 
network of skin. This study explores the inclusion of elastin in two, novel scaffolds to 
determine elastin’s ability to improve current technology, particularly elasticity and 
performance in vivo. 
One of the novel scaffolds investigated is a modified version of the commonly used, 
dermal substitute IDRT in which 10 % (w/w) human, recombinant tropoelastin was 
incorporated during fabrication to form the final elastin-IDRT (EDRT). The presence of 
elastin in EDRT is expected to increase elasticity, improve cell-scaffold interactions 
and accelerate angiogenesis compared to IDRT. These capabilities are critical in a 
substitute to improve graft take rates and functionality of new skin, especially in full-
thickness, burn injuries in which the dermis and all regenerative elements have been 
lost. 
The other scaffold type examined is a novel, electrospun scaffold composed of a 
mixture of rat tail collagen type I, bovine ligament nuchae elastin and PCL. 
Electrospinning was chosen for its inherent ability to form scaffolds which closely 
mimic native ECM by producing highly porous scaffolds with high pore 
interconnectivity and ultrathin fibres which promote cell attachment, infiltration and 
fluid exchange. Electrospinning was also chosen as it has been shown to reduce 
wound contraction compared to lyophilisation. The three polymers were each chosen 
for advantageous properties they could contribute to the final scaffold. Elastin was 
chosen for favourable mechanical and cell-interactive abilities, collagen for its natural 
abundance in ECM and biosignals and PCL for its strength and ability to reduce wound 
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contraction. These electrospun, triple-polymer scaffolds are the first of their kind 
produced for use as a skin substitute. As such, early stage testing investigated 
mechanical and cell-interactive properties with the expectation of improved elasticity 
and favourable cell attachment and infiltration which, if translated to a clinical setting, 
could improve regeneration of skin structure, appendages and pliability. 
The overall aim of this study was the development of an electrospun scaffold 
composed of a novel combination of collagen, elastin and PCL and the 
characterisation of this electrospun scaffold and EDRT in vitro using fibroblasts and 
keratinocytes and in vivo using established mouse models. This was performed by: 
1. characterisation of morphological and mechanical properties of the scaffolds; 
2. in vitro characterisation of cell-scaffold interactions by culturing immortalised, 
human keratinocytes and HDFs on the scaffolds; and 
3. investigation of efficacy, ECM deposition, scaffold remodelling and ECM gene 
expression using established mouse models based on skin excision as burns 
wounds smaller than 20 % are debrided before treatment. 
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Materials and Methods 
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Chapter 2  Materials and Methods 
2.1 Materials 
Table 2.1: Table of reagents and consumables 
Item Supplier 
Acetic acid, glacial Sigma-Aldrich 
Acid Fuchsin Acros Organics 
Agarose (Molecular Biology Grade) Vivantis 
Ammonium iron (III) sulphate dodecahydrate Sigma-Aldrich 
AngioSense 750 EX Perkin Elmer 
Atrauman Hartmann 
Betadine solution Sanofi-Aventis Consumer Healthcare 
Bouin's Fluid Australian Biostain 
Bovine neck ligament elastin, soluble Sigma-Aldrich 
Bovine serum albumin, powder Sigma-Aldrich 
Carprofen Rimadyl 
CD146 antibody Abcam 
Celestine Blue Sigma-Aldrich 
CellTiter96 Aqueous Non-Radioactive Cell Proliferation 
Assay (MTS) Promega Corporation 
Chloroform Sigma-Aldrich 
Collagen antibody Abcam 
Cryomolds, Intermediate, Tissue-Tek Sakura Finetek 
DAB Substrate kit Vector Laboratories 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
DNA loading buffer blue, 5× Bioline 
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Item Supplier 
DNase/RNase free water, sterile Invitrogen 
dNTP mix Bioline 
Dodeca-molybdophosphoric acid (Phosphomolybdic 
acid) Ajax Finechem 
Dulbecco modified eagle's medium (DMEM) Sigma-Aldrich 
Elastin antibody Abcam 
EDRT Elastagen 
Eosin yellowish VWR 
Ethanol (for molecular biology), 100 % Sigma-Aldrich 
Ethanol, 100 % Point of Care Diagnostics 
Fetal bovine serum (FBS) Sigma-Aldrich 
Glutamine Sigma-Aldrich 
Glutaraldehyde, 25 %, EM grade ProSciTech 
Glutaraldehyde, 25 %, Grade 1 Sigma-Aldrich 
Glycerin Sigma-Aldrich 
Glycine Ajax Finechem 
Harris' Haematoxylin, Concord Modified Australian Biostain 
Hexamethyldisilazane (HMDS) Sigma-Aldrich 
HFP Sigma-Aldrich 
Hydrochloric acid (HCl) Sigma-Aldrich 
Hydrogen peroxide, 30 % (w/v) Sigma-Aldrich 
HyperLadder 100bp (IV) Bioline 
IDRT IDRT Life Sciences Corporation 
Isopropanol (for cell cryopreservation) VWR International 
Isopropanol (for mRNA extraction) Sigma-Aldrich 
IV3000 Smith & Nephew 
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Item Supplier 
L-Glutamine Sigma-Aldrich 
Light Green SF Yellowish Acros Organics 
MangoTaq colourless reaction buffer, 5× Bioline 
MangoTaq DNA polymerase Bioline 
MgCl2 solution Bioline 
Neutral-buffered formalin solution, 10 % (v/v) Sigma-Aldrich 
NucleoSpin RNA Clean-up Kit Macherey-Nagel 
Optimal Cutting Temperature (OCT) Compound Sakura Finetek 
OsO4, 4 % aqueous solution ProSciTech 
Paraformaldehyde, 16 % aqueous solution ProSciTech 
Penicillin-Streptomycin-Neomycin solution Sigma-Aldrich 
Phosphate buffered saline (PBS) Sigma-Aldrich 
Phosphotungstic acid hydrate Acros Organics 
PCL (Mn 80,000) Sigma-Aldrich 
Punch biopsy, 8 mm diameter Kai Medical 
Rat tail, Collagen Type I BD Biosciences 
Saline, sterile Astra Zeneca 
Slow Fade Gold antifade reagent with DAPI Invitrogen 
Sodium acetate Sigma-Aldrich 
Sodium cacodylate trihydrate Sigma-Aldrich 
Sodium Citrate Sigma-Aldrich 
Sulphuric acid Ajax Finechem 
SuperScript III First-Strand Synthesis SuperMix for qRT-
PCR kit Life Technologies 
SYBR Safe DNA gel stain Life Technologies 
TBE buffer, 10× Amresco 
Triton X-100 Sigma-Aldrich 
TRIzol reagent Sigma-Aldrich 
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Item Supplier 
Trypan Blue solution, 0.4 % Sigma-Aldrich 
Trypsin-EDTA solution, 0.25 % Sigma-Aldrich 
Universal SYBR Green Supermix kit BioRad 
VECTASTAIN Elite ABC Kit (Rabbit IgG) Vector Laboratories 
Visitrak Smith & Nephew 
Ilium Xylazil-100 (xylazine) Troy Laboratories 
Xylene Point of Care Diagnostics 
Xylidine Ponceau Acros Organics 
2.2 Methods 
2.2.1 Development and characterisation of novel, electrospun, triple 
polymer scaffolds 
Electrospun composite scaffolds were developed by varying four parameters; polymer 
composition, flow rate, air gap and applied electric potential. The effect of each 
parameter on electrospinning efficiency, scaffold removal, average pore diameter and 
average fibre width were examined. 
 Fabrication of triple polymer, electrospun scaffolds 
Rat tail, collagen type I solution was frozen overnight at -80 °C. Frozen collagen 
solutions were lyophilised at -45 °C at vacuum. Dry collagen was stored at 4 °C. 
Dried collagen, bovine neck ligament elastin and/or PCL were dissolved in HFP. 
Various polymer compositions (Table 2.1) were tested with total polymer concentration 
maintained at 15 % (w/v). Additional electrospinning parameters tested were flow rate 
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(1, 3 and 5 mL/hr), air gap (10, 15, 20 and 25 cm) and applied electric potential  
(15-40 kV) (Table 2.1). During electrospinning, 0.5 mL of polymer solution was loaded 
into a 1 mL syringe (Figure 1A) with a blunt, 18 gauge needle attached. Flow rates 
were regulated using a single-syringe infusion pump (SP100iZ, World Precision 
Instruments Inc., FL, USA), air gap was measured by distance between the needle 
point to the collector and applied electric potential was controlled by transferring a 
positive charge to the needle (ES30P, Gamma High Voltage Research Inc., FL, USA) 
and a negative charge to the bronze collector (ES30N, Gamma High Voltage 
Research Inc., FL, USA) (Figure 2.1). The final, non-woven, porous scaffold was 
peeled off the collector using fine-tipped forceps. 
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Table 2.2: Electrospinning conditions tested; collagen, elastin and PCL. 
Solution 
composition 
(% (w/v)) 
Flow rate 
(mL/h) 
Air gap 
(cm) 
Applied electric 
potential 
(kV) 
7.5 % collagen 
7.5 % PCL 
1 10 25 
1 20 30 
3 25 40 
3 % collagen 
12 % elastin 
1 10 20 
1 15 20 
1 20 20 
3 15 20 
3 20 20 
5 15 20 
1.5 % collagen 
12 % elastin 
1.5 % PCL 
1 10 20 
1 15 20 
1 15 25 
1 20 20 
3 15 25 
3 20 30 
2 % collagen 
12 % elastin 
1 % PCL 
1 15 20 
1 20 20 
1 25 20 
3 20 30 
3 25 30 
2.5 % collagen 
12 % elastin 
0.5 % PCL 
1 15 20 
1 20 25 
3 20 20 
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Figure 2.1: Schematic of electrospinning showing the three main stages; jet emergence (A), 
instability (B) and fibre collection (C). Adapted from (279).  
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2.2.1.1.1 Cross-linking of electrospun scaffolds 
The collagen and elastin polymers used are water soluble, so cross-linking was used 
to preserve scaffold structure. The triple polymer scaffolds were cross-linked using  
25 % (v/v) glutaraldehyde (1 mL) (Sigma-Aldrich) vapour cross-linking (273) for 24 hrs 
at room temperature (RT). After 24 hrs, cross-linking was stopped by immersing 
scaffolds in 0.2 M glycine overnight to quench any unreacted glutaraldehyde. Cross-
linked scaffolds were then washed in PBS to remove glycine, sterilised in 80 % (v/v) 
ethanol for 24 hrs and washed in 3 × sterile PBS. 
 Structural analysis of electrospun scaffolds using SEM analysis 
Non-cross-linked and cross-linked electrospun scaffolds were dehydrated by 
lyophilisation. Dry samples were mounted on aluminium sample stubs and sputter-
coated with platinum using an auto coater (JFC-1600 Auto Fine Coater, JEOL Ltd., 
Tokyo, Japan) prior to examination by SEM (JEOL JSM-6380, JEOL Ltd., Tokyo, 
Japan) at a voltage of 15 kV. 
Pore diameter and fibre width of scaffolds were quantified using SEM images. Pore 
diameter was defined as the longest axis of a pore (273) (Figure 2.2, blue lines) and 
fibre widths were measured at cross-sections of individuals fibres (Figure 2.2, yellow 
lines). Three images were taken per sample and 10 pore diameters and 30 fibre widths 
were randomly chosen from each image and measured using ImageJ (National 
Institute of Health) for a total measurement of 30 pore diameters and 90 fibre widths 
per sample. 
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Figure 2.2: SEM image of non-cross-linked (A) and cross-linked (B), electrospun, CEP scaffold 
demonstrating pore diameter (blue lines) and fibre width measurements (yellow lines). 
Four cross-linked, triple polymer, electrospun scaffolds and two, control, double-
polymer scaffolds (Table 2.2) were chosen for uniaxial tensile test based on pore 
diameter and fibre width results. Henceforth, all electrospun scaffolds referred to are 
cross-linked unless otherwise specified. 
Table 2.3: Electrospinning conditions of scaffolds chosen for uniaxial tensile tests; collagen-
PCL scaffold (CP), collagen-elastin scaffold (CE) and collagen-elastin-PCL scaffold (CEP). 
Scaffold 
Solution 
composition 
(% (w/v)) 
Flow rate 
(mL/h) 
Air gap 
(cm) 
Applied electric 
potential 
(kV) 
CP 
7.5 % collagen 
7.5 % PCL 
3 25 40 
CE 
3 % collagen 
12 % elastin 
3 15 20 
CEP 1 
1.5 % collagen 
12 % elastin 
1.5 % PCL 
3 15 25 
CEP 2 
2 % collagen 
12 % elastin 
1 % PCL 
1 20 20 
A B 
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CEP 3 
2.5 % collagen 
12 % elastin 
0.5 % PCL 
1 20 25 
CEP 4 
2.5 % collagen 
12 % elastin 
0.5 % PCL 
1 15 20 
 Uniaxial tensile tests of electrospun scaffolds 
Uniaxial tensile tests allow determination of the mechanical strain – stress relationship and 
modulus of scaffolds. The mechanical strain, 𝜀𝜀, can be defined and calculated as  
𝜀𝜀 = 𝐿𝐿 − 𝐿𝐿0
𝐿𝐿0
 
where 𝐿𝐿 is the deformed length and 𝐿𝐿0 is the original length of the specimen. While strain does 
not have unit, it may read as mm/mm or percent (%) for convention in biomedical engineering. 
Strips of cross-linked, electrospun scaffolds were used for tensile tests. The uniaxial 
elongation tensile tests were performed in an unconfined state using an Instron (Model 5543) 
with a 10 N biological load cell (Figure 2.3). All tests were run in PBS at 37 °C. Prior to 
mechanical testing, the samples were soaked for at least 2 hrs in PBS at 37 °C to yield isotonic 
hydrogels. The thickness (0.88 ± 0.01 mm), width (9.05 ± 0.05 mm) and height  
(16.28 ± 1.02 mm) prior to the tests. 
For the uniaxial tensile tests, the samples were clamped as seen in Figure 2.3 and subjected 
to a loading and unloading cycle at 37 °C [16] and the load (N) was applied at a cross speed 
of 0.5 mm/min. From the tensile tests, the ultimate strain to rupture was found to be 40 % for 
the scaffold samples. 
Note that the uniaxial tests of scaffolds exhibit a non-linear relationship between strain and 
stress (Figure 2.4). For this reason, the compressive and tensile Young’s modulus was 
obtained approximately from the tangent slope of the stress-strain curve between  
0.05 mm/mm and 0.10 mm/mm strain. For all the samples, the energy loss from the loading 
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to the unloading process was computed in the strain range of 0-0.15 mm/mm in the tensile 
tests. 
 
Figure 2.3: Image of a CEP, electrospun scaffold specimen which has undergone uniaxial 
tensile testing. 
Sample 
Clamps 
move 
apart 
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Figure 2.4: Representative schematic of a non-linear relationship between stress and strain. 
 Quantification of porosity 
Punch biopsies (8 mm in diameter) of CEPs were fixed in 10 % (v/v), neutral-buffered 
formalin for 24 hrs followed by dehydration in 70 % (v/v) ethanol for 24 hrs, 2 × 1 hr 
70 % (v/v) ethanol, 5 × 1 hr 100 % ethanol and 3 × 1 hr xylene incubations. Fixed and 
dehydrated CEPs were soaked in 3 changes of paraffin for 1 hr each and embedded 
in paraffin. Cross-sections (4 μm) were cut and mounted on SuperFrost Plus slides, 
followed by deparaffinisation in 3 × 2 mins xylene incubations, xylene removal in  
100 % ethanol (3 × 2 mins) and rehydration in tap water for 2 mins. Sections were 
incubated in Harris’ Haematoxylin for 5 mins, which stains cell nuclei purple, and 
excess haematoxylin was removed in tap water. Differentiation was performed using 
acid alcohol (0.3 % (v/v) HCl in 70 % (v/v) ethanol) followed by a 4 min tap water wash. 
Finally, a 30 sec incubation in alcoholic eosin stained soft tissue bright pink and excess 
solution was removed in tap water. Samples were dehydrated with 100 % ethanol  
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(3 × 1 min) followed by 2 xylene washes. Stained sections were imaged with a bright 
field microscope (EVOS FL Auto Cell Imaging System, Thermo Fisher Scientific, MA, 
USA) and colour images were converted to binary images using ImageJ in which fibres 
appeared black and interfibre spaces white (Figure 2.5). The porosity was calculated 
using ImageJ and defined as the percentage of interfibre space relative to the total 
scaffold area measured. 
 
Figure 2.5: Example of H&E image of CEP cross-section (A) converted to a binary image (B) 
using ImageJ for quantification of porosity. 
 Preparation of CEP 1 and CEP 2 for cell culture studies 
CEP samples were sterilised in 80 % (v/v) ethanol for 24 hrs and washed with sterile 
3 changes of PBS. Sterilised CEPs were partly dried by quickly touching wet scaffolds 
to sterilised filter paper and then placed in sterile container for immediate seeding of 
cells. 
 Culture of CEP 1 and CEP 2 with human keratinocytes 
HaCaT cells (gifted from the Weiss lab at The University of Sydney) are an 
immortalised keratinocyte cell line used as a substitute for NHEKs (280-282). Although 
A B 
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HaCaTs are cytogenetically abnormal, they are capable of differentiation under in vitro 
and in vivo conditions to form epidermal-like structures (283-285). 
2.2.1.6.1 Maintenance of HaCaTs 
HaCaTs were maintained in HaCaT media prepared with 10 % (v/v) FBS, 2 mM  
L-Glutamine, 100 U penicillin-0.1 mg streptomycin-0.2 mg neomycin/mL in DMEM. 
HaCaT cells were cultured and expanded in a static cell culture system at 37 °C and 
5 % CO2 (3111 Forma Series II Water-Jackets CO2 Incubator, Thermo Scientific, MA, 
USA). 
HaCaTs were detached from tissue culture flasks when approximately 90 % 
confluency was obtained for sub-culturing, cryopreservation or experiments. Media 
was removed from flasks and attached cells were rinsed with PBS. HaCaTs were 
detached by incubating with 5 mL of 0.25 % (w/v) trypsin-0.02 % (w/v) EDTA for  
5 mins at 37 °C. Enzymatic treatment was stopped by adding 5 mL pre-warmed 
HaCaT media to inhibit trypsin activity. The cell suspension was then centrifuged at 
1000 rpm/min for 10 mins to pellet live HaCaTs. After the supernatant was discarded, 
live HaCaTs were resuspended in pre-warmed HaCaT media, split 1:2 or 1:3 and 
transferred to new culture flasks. Cells were incubated at 37 °C and 5 % CO2 and 
media was replaced every 2-3 days. 
2.2.1.6.2 Cryogenic storage of HaCaTs 
After cell detachment, HaCaTs were resuspended in HaCaT media containing  
10 % (w/v) DMSO, a cryoprotectant. The HaCaT cell suspension, at a concentration 
of approximately 1 × 106 cells/mL in cryovials, were placed in a cryogenic cooling 
container (Mr Frosty, Thermo Fisher Scientific, MA, USA), containing isopropanol 
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(VWR) and frozen at -1 °C/min overnight to -80 °C and stored at -80 °C for up to  
1 month or transferred to liquid nitrogen for long-term storage. 
2.2.1.6.3 Retrieval of cryopreserved HaCaTs 
Cryopreserved HaCaTs were thawed at room temperature (RT) and immediately 
transferred to sterile, cell culture flasks containing pre-warmed HaCaT media. HaCaT 
cells were left to attach overnight and the media replaced with normal, HaCaT media 
within 24 hrs to remove residual DMSO. 
2.2.1.6.4 Quantification of viable HaCaTs by Trypan Blue staining 
Detached HaCaT suspensions (15 μL) were diluted with an equal volume of  
0.4 % (w/v) Trypan Blue solution and cell number was quantified using a 
haemocytometer (Hemocytometer, Weber Scientific, NJ, USA). Briefly, 10 μL of 
suspension was placed onto each side of the haemocytometer and only the live cells 
counted in the 4 corner squares and centre square of both chambers (ten squares 
total). Dead cells were distinguished by their blue appearance as live cells had an 
intact cell membrane which excluded the dye. 
Original cell density was calculated using the formula below, in which 2 is the dilution 
factor from addition of the Trypan Blue solution and 𝑥𝑥 is the dilution factor, if any, of 
the original cell suspension. The resulting cell number had the unit cells/mL. 
cell density = 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ×103×2×𝑥𝑥, 
2.2.1.6.5 Cell culture of HaCaTs on CEPs 
HaCaTs were droplet-seeded at a density of 5 × 105 cells/20 μL onto punch biopsies 
(8 mm in diameter) of CEP 1 and CEP 2, giving a final cell number of 1 × 106 cells/cm2 
on the scaffolds. HaCaTs were left to attach to the scaffolds for 30-60 mins. During 
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cell attachment, scaffolds remained in cell culture media. Pre-warmed HaCaT media 
was gradually added to the edge of the wells to minimise disturbance of attached cells. 
HaCaT media was added to a total of 600 μL and replaced with fresh media every  
2-3 days. Cell-seeded scaffolds were incubated at 37 °C and 5 % CO2 in a static cell 
culture system and samples were collected on days 1, 14 and 28 post-seeding for 
histological analysis. 
 Culture of CEP 1 and CEP 2 with HDFs 
HDFs were isolated from donated skin biopsies of patients at the Burns Unit in 
Concord Repatriation General Hospital with approval from the Hospital Human Ethics 
Committee (Ethics number: CH 62/6/2006-026). HDF media consisted of DMEM,  
100 U penicillin-0.1 mg streptomycin-0.2 mg neomycin/mL and 10 % (v/v) FBS. 
2.2.1.7.1 Maintenance, cryopreservation and retrieval of HDFs 
HDFs were maintained, cryopreserved and retrieved according to HaCaT protocols in 
sections 2.2.1.6.1-2.2.1.6.3 using HDF media. 
2.2.1.7.2  Cell culture of HDFs on CEPs 
Similar to HaCaT seeding, HDFs were droplet-seeded with 5 × 104 cells/20 μL onto 
punch biopsies (8 mm in diameter) of CEP 1 and CEP 2 for a final cell concentration 
of 1 × 105 cells/cm2 per scaffold. HDFs were left to attach for 30-60 mins and then  
600 μL of pre-warmed HDF media was added. Scaffolds were kept immersed in media 
using a 100 μL pipette tip and media was changed once a day. Cell-seeded scaffolds 
were incubated at 37 °C and 5 % CO2 in a static cell culture system and were collected 
on days 1, 14 and 28 post-seeding for histological analysis. 
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 Assessment of seeding efficiency and proliferation of HaCaTs using 
the MTS assay 
In this assay, there is a direct relationship between absorbance and the number of 
metabolically active cells as only viable cells convert 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, innersalt (MTS) to a 
soluble, coloured formazan product by dehydrogenase enzymes and an electron 
coupling reagent, phenazine methosulfate (PMS). Therefore, a standard curve was 
first produced to plot the relationship between absorbance. HaCaT concentrations of 
1.0, 2.5, 5.0, 7.5, 10.0, 25.0 and 50.0 × 103 cells/well were used. 
Cell-seeding efficiency was examined on day 1. All cell-seeded CEPs were moved 
from the culture plate to a new plate, washed and re-immersed in fresh media. HaCaTs 
attached to the original culture dish were washed with new media followed by 
incubation in 200 μL HaCaT media with 40 μL of MTS/PMS reagent. The incubation 
was performed for 1 hr at 37 °C and 5 % CO2 in the dark. The media was transferred 
to a 96 well plate and the absorbance read at 490 nm. Cell number was calculated 
from the absorbance using the standard curve. Cell-seeding efficiency of HaCaTs was 
calculated using the following formula and expressed as a percentage of the seeded 
number of cells. 
HaCaT-seeding efficiency = 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 𝑐𝑐𝑐𝑐𝑛𝑛𝑛𝑛𝑐𝑐𝑛𝑛500,000 ×100 
Quantification of HaCaT numbers was performed on days 7, 14, 21 and 28 post-
seeding and an unseeded scaffold was used as a control for possible protein 
interference. Cell-seeded scaffolds were transferred to new plates and washed with 
fresh media followed by incubation with 200 μL HaCaT media and 40 μL MTS/PMS 
reagent as described above and the absorbance was used to calculate the HaCaT 
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number. Detachment of HaCaTs from the scaffold was not required as all metabolically 
active scaffolds, whether located in the interior or on the exterior of the scaffold, 
converted MTS to the coloured, formazan product. 
 Assessment of seeding efficiency and proliferation of HDFs using the 
MTS assay 
A standard curve for HDFs was produced using HDF concentrations of 1.0, 2.5, 5.0, 
7.5, 10.0 and 25.0 × 103 cells/well. Cell-seeding efficiency was examined on day 1 as 
described above for examination of HaCaT-seeding efficiency in section 2.2.1.8. Cell-
seeding efficiency of HDFs was calculated using the following formula and expressed 
as a percentage of the seeded number of cells. 
HDF-seeding efficiency = 𝐻𝐻𝐻𝐻𝐻𝐻 𝑐𝑐𝑐𝑐𝑛𝑛𝑛𝑛𝑐𝑐𝑛𝑛50,000 ×100 
Quantification of HDF numbers was performed on days 7, 14, 21 and 28 post-seeding 
as described above for quantification of HaCaT proliferation in section 2.2.1.8. 
 Co-culture of HaCaTs and HDFs on CEP 1 and CEP 2 
In the study both HaCaTs and HDFs were cultured on the same side of the same 
scaffold (Figure 2.6). Cell-seeded scaffolds were incubated at 37 °C and 5 % CO2 in 
a static cell culture system. Samples were collected on days 1, 14 and 28 post-seeding 
for further analysis. 
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2.2.1.10.1 Air-liquid interface co-culture of HaCaTs and HDFs on CEP 1 and CEP 
2 
Punch biopsies of CEP 1 and CEP 2 (8 mm in diameter) were placed on top of sterile 
gauze and HDFs were seeded and cultured as described in section 2.2.1.7.2 over  
7 days (Figure 2.6, steps 1 and 2). After 7 days, HaCaTs were seeded onto the same 
surface as HDFs (Figure 2.6, step 3) as described in section 2.2.1.6.5. HaCaT media 
was added until it contacted the base of the scaffold while the surface of the scaffold 
was exposed to air (Figure 2.6, step 4). The seeded scaffolds were then incubated at 
37 °C and 5 % CO2 in a static culture system and monitored to ensure the media was 
in contact with the scaffold. Media was replaced every 2-3 days. 
 
Figure 2.6: Schematic of air-liquid interface cell-seeding and culture. 
Step 1 
Day 0 
HDF seeding 
Step 2 
Days 0 to 7 
HDF culture 
Step 3 
Day 7 
HaCaT seeding 
Step 4 
Days 7 to 35 
HaCaT and 
HDF culture 
Gauze 
Scaffold 
Seeding 
droplet 
HDF 
HaCaT 
Key 
 62 
 SEM of cell-seeded CEP 1 and CEP 2 
Cell-seeded scaffolds were collected for SEM analysis on days 1, 14 and 28. Samples 
were washed in sterile PBS twice, then fixed with 2.5 % (w/v) glutaraldehyde 
(ProSciTech) for 2 hrs and washed 3 × 2 mins in 0.1 M cacodylate buffer. Samples 
were then immersed in 2 % OsO4 in 0.1 M cacodylate buffer for a secondary fixation 
followed by washing twice with 0.1 M cacodylate buffer. Fixed samples were 
dehydrated with increasing concentrations of ethanol (2 mins each of 1 × 50 % (v/v), 
3 × 70 % (v/v), 3 × 90 (v/v) %, 2 × 100 % and 2 × 100 % (molecular sieve)) followed 
by chemically drying with HMDS. Scaffolds were mounted on aluminium sample stubs, 
sputter-coated with platinum and examined by SEM. 
 H&E analysis of cell-seeded CEP 1 and CEP 2 
Cell-seeded scaffolds were collected for H&E staining on days 1, 14 and 28. Samples 
were fixed in 10 % (v/v), neutral-buffered formalin for 24 hrs followed by dehydration 
in 70 % (v/v) ethanol for 24 hrs. Further dehydration was performed with two 1 hr 
incubations in 70 % (v/v) ethanol, five 1 hr incubations in 100 % ethanol and then  
3 × 1 hr incubations in xylene. Scaffolds were then soaked in 3 changes of paraffin for 
1 hr and 20 mins each, embedded in paraffin blocks and cross-sections (4 μm) were 
mounted on SuperFrost Plus slides. 
H&E staining was performed to visualise cell distribution in scaffolds. Cross-sections 
were deparaffinised in 3 changes of xylene for 2 mins each followed by 3 ×2 min  
100 % ethanol incubations to remove xylene. Sections were then rehydrated in tap 
water for 2 mins. Samples were incubated in Harris’ Haematoxylin for 5 mins, which 
stains nucleic material purple, and excess haematoxylin was removed by washing in 
tap water until clear. Differentiation was performed using acid alcohol (0.3 % (v/v) HCl 
 63 
in 70 % (v/v) ethanol) to ensure good chromatin detail followed by a 4 min wash in tap 
water. A 30 sec incubation in alcoholic eosin stained tissue bright pink and excess 
solution was removed with a 2 min wash in tap water. Samples were dehydrated in  
3 × 1 min 100 % ethanol incubations followed by 2 xylene washes. Sections were then 
coverslipped and imaged using a brightfield microscope (Olympus BX60, Olympus, 
PA, USA). 
 Fluorescence analysis of cell-seeded CEP 1 and CEP 2 
Cell-seeded CEP scaffolds were collected on days 1, 14 and 28. Cell-seeded scaffolds 
were rinsed with sterile PBS and fixed in 4 % (v/v) paraformaldehyde for 15 mins at 
RT. Samples were then immersed in 0.2 % (v/v) Triton-X for 15 mins to permeabilise 
the cell membrane and rinsed in sterile PBS 3 × 5 mins. Fixed, HDF-seeded scaffolds 
were then embedded in OCT compound and frozen in 100 % ethanol chilled with dry 
ice. Sections (10 μm) were cut by cryosectioning (Leica CM 3050 S, Leica, NSW, 
Australia) and stained with Slow Fade Gold antifade reagent containing DAPI 
overnight in the dark followed by imaging using a fluorescent microscope (EVOS, FL 
Auto Cell Imaging System, Thermo Fisher Scientific, MA, USA). 
2.2.2 Characterisation of novel EDRT 
Single-layer, silicone-free IDRT was used for all studies throughout this thesis. 
Elastin-modified IDRT, EDRT, was provided by Elastagen. 
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 Structural analysis of EDRT and IDRT using SEM analysis 
Sections of EDRT and IDRT (1 × 1 cm2) were cut using a scalpel blade followed by 
washing in PBS for 5 mins and then 3 × 5 mins washes of MilliQ water. Both EDRT 
and IDRT were lyophilised overnight at -45 °C at vacuum and mounted onto aluminium 
sample stubs. Samples were sputter-coated with platinum and examined by SEM as 
described in section 2.2.1.2. 
Pore diameters of EDRT and IDRT were quantified using SEM images. Pore diameter 
was defined as the longest axis of a pore (273) and measured using ImageJ as 
described in section 2.2.1.2.. Thirty pores were measured for EDRT and IDRT each. 
In addition, porosity was analysed by converting H&E images to binary images as 
described in section 2.2.1.4. 
 Uniaxial compression tests of EDRT and IDRT 
Uniaxial compression tests were utilised to assess the mechanical property of EDRT 
and IDRT. The compression tests were performed in an unconfined state using a 
Series 5540 Single Column System - 5543 (Instron, Melbourne, VIC, Australia) with a 
10 N biological load cell according to the testing procedure (286, 287). Prior to this 
mechanical testing, the samples were soaked for at least 2 hrs in PBS. The thickness 
(1.0 ± 0.1 mm) and dimensions (10.0 × 10.0 mm) of each sample were then measured 
using digital callipers. The compressive properties of the samples were tested in PBS 
at 37 °C. 
During the test, samples were placed between two plates (Figure 2.7) and subjected 
to a single loading and unloading cycle. The compressive load (N) (288) was applied 
at a cross speed of 0.5 mm/min and up to a 40 % final strain level. The compressive 
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Young’s modulus was obtained as the tangent slope of the stress-strain curve between 
5-10 % strain level. Also, energy loss, based on the compression cycle, was computed 
for all samples. 
 
Figure 2.7: Image of equipment used for compression tests. 
 Co-culture of HaCaTs and HDFs on EDRT and IDRT 
Sections of EDRT and IDRT (1 × 1 cm2) were cut using a scalpel blade and then 
sterilised in 80 % (v/v) ethanol for 24 hrs followed by 3 washes in sterile PBS under 
sterile conditions. Before cell-seeding, sterilised scaffold sections were partly dried by 
briefly touching wet scaffolds to sterilised filter paper to partly absorb PBS held in the 
scaffolds. Scaffolds were cultured with cells as described in section 2.2.1.6.5 for 
HaCaTs and section 2.2.1.7.2 for HDFs. 
Plates 
press 
together 
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 Assessment of HaCaT- and HDF-seeding efficiency and HaCaT 
proliferation on EDRT and IDRT using the MTS assay 
Cell-seeding efficiency was examined and calculated as previously described in 
section 2.2.1.8 for HaCaTs and section 2.2.1.9 for HDFs. HaCaT proliferation was 
assessed as described in section 2.2.1.8. 
 Assessment of HDF proliferation on EDRT and IDRT by 
haemocytometer  
The number of HDFs was quantified on days 7, 14, 21 and 28 post-seeding using a 
haemocytometer (Weber Scientific, NJ, USA). HDF-seeded scaffolds were transferred 
and washed with sterile PBS. Cells were detached from the scaffolds using 500 μL of 
0.25 % (w/v) trypsin-0.02 % (w/v) EDTA per well followed by incubation at 37 °C and 
5 % CO2 for 5 mins. The number of HDFs detached from EDRT or IDRT was counted 
using a haemocytometer as described in section 2.2.1.6.4. 
 Analysis of HaCaT-seeded and co-cultured EDRT and IDRT by SEM and 
H&E staining  
Samples of HaCaT-seeded and co-cultured scaffolds for SEM analysis were collected 
on days 1, 14 and 28 post-seeding and imaged as described in section 2.2.1.11. 
Samples for histological analysis were H&E stained as described in section 2.2.1.13. 
 Fluorescence analysis of cell-seeded EDRT and IDRT 
HDF-seeded scaffolds were collected on days 1, 14 and 28 or 7, 14 and 21 post-
seeding and imaged as described in section 2.2.1.13. 
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 Assessment of HDF-induced EDRT and IDRT contraction 
HDF-seeded EDRT and IDRT were photographed on day 0. Cell-seeded scaffolds 
were then photographed with two day intervals over 28 days. The size of scaffolds 
was then measured using ImageJ. Scaffold contraction was expressed as a 
percentage of the original size and calculated using the following formula. 
contraction (%) = 𝑐𝑐𝑐𝑐𝑛𝑛𝑛𝑛𝑐𝑐𝑐𝑐𝑐𝑐 𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐
𝑐𝑐𝑛𝑛𝑠𝑠𝑜𝑜𝑠𝑠𝑐𝑐𝐻𝐻𝑐𝑐 𝑠𝑠𝑠𝑠𝑠𝑠𝑐𝑐 
2.2.3 Animal studies of novel, skin substitutes 
 Source of mice and ethics approval 
Mice were purchased from the Australian Animal Centre (WA, Australia) under ethics 
number AWC No. 2013/019. 
 Number of mice and gender distribution 
There were four mice per group to ensure results were in triplicate and to account for 
possible variations in wound healing due to gender at least one male or female was 
included in each group. 
 Preparation of scaffolds for grafting in mice 
Punch biopsies (8 mm in diameter) of CEP 1, CEP 2, EDRT and IDRT were sterilised 
in 80 % (v/v) ethanol for 24 hrs and washed 3 times with sterile PBS in a sterile 
environment. Sterilised scaffolds in sterile PBS were stored and transported in 
specimen containers. 
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 Surgery  
Pathogen-free, female (22.0 ± 1.6 g) and male (26.0 ± 1.8 g), Balb/c mice, aged  
12 weeks were housed in cages under standard conditions (19-22 °C, 12 hr light and 
12 hr dark cycle) with free access to food and water. 
Before surgery, each mouse was individually anaesthetised by intra-peritoneal 
injection of a mixture of ketamine (75 mg/mL) and xylazine (10 mg/mL) at 0.01 mL/g 
of body weight. Anaesthesia was monitored throughout the procedure by testing the 
rear foot reflex and eyes were kept moist with sterile saline. 
 Subcutaneous implantation of CEP 1, CEP 2, EDRT and IDRT in mice  
A subcutaneous implant, mouse model was chosen as this type of model is effective 
for screening samples and has previously been used for examining host responses 
such as cell-scaffold interactions and inflammation (273). 
The dorsal area of the mice was shaved (WAHL Specialty Rodent Hair Clipper, Able 
Scientific, WA, Australia) and cleaned with Betadine solution (Sanofi-Aventis 
Consumer Healthcare, QLD, Australia) and sterile saline. Four, 1 cm long incisions 
were made on the dorsal area separated by normal skin (Figure 2.7). Subcutaneous 
pouches were created using surgical scissors into which either CEP 1, CEP 2, EDRT 
or IDRT were placed according to implant patterns (Figure 2.7). All scaffolds were 
sutured to the skin before closing incisions with sutures. Wounds were dressed with a 
non-sticky dressing, Atrauman, and a sticky dressing, IV3000, which were maintained 
for the first 7 days post-surgery. Carprofen (5 mg/kg) was injected at the time of 
anaesthesia and for the following two days post-surgery as analgesia. 
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After surgery, each mouse was caged individually post-surgery for the first two days 
and then two mice per cage thereafter with free access to food and water. Wound 
dressings were checked every day for the first 7 days. Mice were weighed on days  
1-7, 9, 11, 14 and 21 post-surgery and if a mouse lost more than 10 % of its original 
body weight the mouse was euthanised. Mice were also monitored for normal 
grooming and behaviour, if scruffy appearance or frightened behaviour was noticed 
the mouse was housed separately for the remainder of the study. Mice were sacrificed 
using CO2 on weeks 1, 2, 4, 12 and 24 post-surgery and skin biopsies were collected 
for histological, immunohistochemical (IHC) and gene expression analysis. 
 
Figure 2.8: Schematic of CEP 1, CEP 2, EDRT and IDRT subcutaneous implant pattern in 
mice. 
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 Histological analysis of implants using H&E and Masson’s Trichrome 
staining 
Skin biopsies of wounds implanted with either CEP 1, CEP 2, EDRT or IDRT were 
processed, sectioned (4 μm) and stained by H&E as described in section 2.2.1.12. 
Cross-sections were also stained by Masson’s Trichrome to visualise collagen fibres. 
Sections were deparaffinised in xylene 3 × 2 mins followed by xylene removal in  
100 % ethanol 3 × 2 mins and rehydration in tap water for 2 mins. Samples were then 
incubated in Bouin’s Fluid for 1 hr at 56 °C and excess solution was removed by rinsing 
with tap water until clear. The second fixation in Bouin’s Fluid allows for crisper, 
nuclear staining. Nuclei were then double stained with Celestine Blue (5 % (w/v) 
ammonium iron (III) sulphate dodecahydrate, 1 % (w/v) celestin blue B, 14 % (v/v) 
glycerin and 0.1 % (v/v) sulphuric acid) for 5 mins at RT followed by immediate staining 
with Harris’ Haematoxylin for 5 mins at RT. Excess solution was rinsed away until tap 
water was clear. Initial differentiation for clear chromatin detail was performed with a 
brief dip in acid alcohol (1 % (v/v) HCl in 70 % (v/v) ethanol) immediately followed by 
a 4 min wash in tap water. Muscle was stained red in Ponceau-Acid Fuchsin solution 
(0.05 % (w/v) acid fuchsin, 0.05 % (w/v) xylidine ponceau and 1 % (v/v) glacial acetic 
acid) for 10 mins and then rinsed until tap water ran clear. A second differentiation 
step to decolourise collagen fibres was performed with Phosphomolydic-
Phosphotungstic acid (2.5 % (w/v) phosphomolybdic acid and 2.5 % (w/v) 
phosphotungstic acid) for a minimum of 5 mins or until fibres were colourless. Once 
fibres were colourless, samples were directly immersed in Light Green solution  
(1 % (w/v) light green SF yellowish and 1 % (v/v) glacial acetic acid) for 10 mins 
followed by a 1 min wash in tap water. Stained samples were dehydrated with  
3 × 1 min 100 % ethanol incubations followed by two xylene washes and then air-
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dried. Dry slides were coverslipped and imaged with a brightfield microscope 
(Olympus BX60, Olympus, PA, USA). 
 IHC staining 
Sections were deparaffinised in xylene 3 × 2 mins and then xylene removed with  
3 × 2 min 100 % ethanol incubations. Rehydration was performed by immersing slides 
in tap water for 2 mins followed by boiling slides in fresh 0.01 M citrate buffer (pH 6.0) 
for 5 mins. The citrate buffer breaks protein cross-links unmasking antigens and 
epitopes to enhance staining intensity of antibodies. Slides were then washed in PBT 
buffer containing (0.015 % (w/v) bovine serum albumin, 0.01 % (v/v) Triton X-100 in 
PBS). Samples were incubated with 3 % hydrogen peroxide for 5 mins to block 
endogenous peroxidase activity and washed with PBT buffer for 2 mins. The sections 
were incubated with 5 % (v/v) goat serum (VECTASTAIN Elite ABC Kit) for 30 mins to 
prevent non-specific binding of the secondary antibody to the sample. Excess goat 
serum was removed with PBT buffer washes. Primary antibodies at the specified 
dilutions (Collagen type I 1/500, Elastin 1/300, CD146 1/500) were incubated with the 
sample overnight at 4 °C and unbound primary antibody was removed. The secondary 
rabbit antibody was incubated with the samples at a dilution of 1/200 for 1 hr at RT 
and the unbound secondary antibody was removed with PBT buffer. ABC reagent 
(made 30 mins prior to use) was added for 30 mins then removed by washing with 
PBT buffer. Visualisation of fibres with bound primary antibody was performed using 
diaminobenzidine chromogenic (DAB) substrate (DAB reagent from DAB Substrate 
kit; made 10 mins prior to use) with 60 secs exposure, then counterstaining with Harris’ 
Haematoxylin for 30 secs, followed by dehydration with 3 × 1 min 100 % ethanol 
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incubations and 2 xylene washes. All samples were imaged with a brightfield 
microscope (Olympus BX60, Olympus, PA, USA). 
 Gene expression analysis of implanted CEP 1, CEP 2, EDRT and IDRT 
skin biopsies 
2.2.3.8.1 Sample collection and processing to preserve mRNA 
Implanted CEP 1, CEP 2, EDRT and IDRT skin biopsies were collected weeks 1, 2, 4, 
12 and 24 post-surgery and placed in sterile, DNase/RNase free tubes. Samples were 
frozen in liquid nitrogen and at -80 °C until messenger RNA (mRNA) isolation. 
2.2.3.8.2 Isolation and clean-up of mRNA from skin biopsies 
mRNA isolation was performed using sterile equipment and consumables. Frozen skin 
biopsies were cut into small pieces and transferred to 5 mL tubes containing 1 mL cold 
TRIzol reagent. Skin was then disrupted by alternately homogenising (T10 basic S5 
Ultra-Turrax Disperser, IKA, Selangor, Malaysia) at setting 6 (approximately  
30,000 rpm) for 30 secs and placing on ice for 30 secs until skin biopsies were well 
homogenised with no skin pieces visible. The homogenate was transferred to a new 
1.5 mL microfuge tube, incubated at RT for 5 mins after which 200 μL of chloroform 
was used to extract the proteins from the aqueous phase into the organic phase. The 
mixture was centrifuged at 12,000 g for 15 mins at 4 °C to form 3 phases. The top 
layer contained the RNA and was carefully transferred to a new 1.5 mL, DNase/RNase 
free tube without disrupting the protein interphase and 500 μL of isopropanol (Sigma) 
was added to precipitate RNA. The mixture was repeatedly inverted and then 
incubated at RT for 10 mins on a plate shaker. Centrifugation at 12,000 g for 10 mins 
at 4 °C formed a pellet of RNA at the bottom of the tube. The supernatant was 
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discarded and the RNA pellet was washed by vortexing in 1 mL of 80 % (v/v) ethanol 
and centrifuging at 7,500 g for 5 mins at 4 °C. The supernatant was discarded and the 
wash repeated. The clean pellet was left to air dry for 3-5 mins before redissolving in 
100 μL of DNase/RNase free water. The sample was then cleaned using the 
NucleoSpin RNA Clean-up kit (Macherey-Nagel, Germany) following the 
manufacturer’s protocol then checked for concentration and purity or stored at -80 °C. 
2.2.3.8.3 Contamination check and determination of concentration of isolated 
mRNA  
Purity of the isolated mRNA was examined for contamination by protein or organic 
compounds using absorbance ratios. Nucleic acids (i.e. RNA and DNA) absorb at  
260 nm due to the aromatic base present in their structures. Since aromatic proteins 
(e.g. tryptophan, phenylalanine, tyrosine and histidine) absorb at 280 nm an 
absorbance ratio between 260nm/280nm (A260/A280) lower than 1.8 indicates protein 
contamination. Organic compounds have strong absorbance around 230 nm, 
therefore, an A260/A230 ratio lower than 1.8 indicates contamination by organic 
compounds. mRNA concentration was also determined; at an optical density of 1.0 
RNA has a concentration of 40 μg/mL. Using this, mRNA concentration was calculated 
using the formula 𝑛𝑛𝑚𝑚𝑚𝑚𝑚𝑚 (𝜇𝜇𝑜𝑜/𝑛𝑛𝐿𝐿) = 𝑂𝑂𝐻𝐻×40  on a UV/Visible Spectrophotometer 
(Biochrom WPA Lightwave II UV/Visible Spectrophotometer, Biochrom, Cambridge, 
UK) which calculates A260/A280, A260/A230 and mRNA concentration using the 
Nucleic Acids and RNA setting. 
2.2.3.8.4 mRNA degradation check of isolated mRNA 
RNA samples were checked for degradation using gel electrophoresis. Isolated mRNA 
samples were run on a 1 % (w/v) agarose gel containing 0.05 % (v/v) SYBR Safe in 
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1× TBE buffer (0.089 M tris base, 0.089 M borate and 0.002 M EDTA, pH 8.3). 2 μg 
of each mRNA sample mixed with 8 μg of 1× loading dye (5× DNA loading buffer blue 
diluted 1 in 5 with MilliQ) were run at 90 V for at least 30 mins or until the loading dye 
had reached the base of the gel. The gel was then imaged (ChemiDoc MP System, 
Bio-Rad, CA, USA) and Hyperladder IV was used for size reference. mRNA integrity 
for each sample was deemed acceptable if two clear bands were visible. 
2.2.3.8.5 Complementary DNA (cDNA) synthesis by reverse transcription of 
mRNA 
mRNA was converted into cDNA using the SuperScript III First-Strand Synthesis 
SuperMix for qRT-PCR (Invitrogen, VIC, Australia) following the provided protocol. No 
Template Controls were included to check for DNA contamination of samples. cDNA 
was diluted to a final concentration of 10 ng/µL and aliquoted into 20 µL for storage at 
-20 °C. 
2.2.3.8.6 Primer design for genes of interest; collagen type I and elastin 
The forward and reverse primers for the genes of interest, collagen type I and elastin, 
were designed with DNAMAN (Lynnon LLC. CA, USA). Primer parameters included 
product size between 100 to 300 base pairs (bp), primer length between 18 to 22 
bases, melting temperature between 58 and 60 °C and GC content between 45 and 
55 %. Resulting primers were excluded if primer sequence contained GGG or CCC 
sequences or if strong secondary or higher structures were predicted by Sigma Aldrich 
Design Tool Technical Data (https://www.sigmaaldrich.com/configurator/servlet/ 
DesignTool). Gene accession numbers, primer sequences, annealing temperatures 
used and amplicon size are listed in Table 2.3. Peptidylprolyl isomerase A (Ppia) was 
used as the house keeping gene (289). 
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Table 2.4: List of primers synthesised by Sigma Aldrich. 
Gene Accession number Primer sequence 
Annealing 
temperature 
(°C) 
Amplicon 
size (bp) 
Ppia BC083076.1 
F: CAGATGATAAGGTCATCACGA 
R: GAATGGCTTCTATATCCCCAA 
65 217 
Collagen 
Type I NM_007742.3 
F: CCAGTGGCGGTTATGACTT 
R: GCGGATGTTCTCAATCTGC 
60 164 
Elastin NM_007925.3 
F: GCTACTGCTTGGTGGAGAATG 
R: CTGCTGCTGTCTGATTTCCTT 
65 131 
2.2.3.8.7 Generation of double-stranded DNA (dsDNA) by endpoint polymerase 
chain reaction (PCR) for use in standard curve generation to calculate 
relative expression of genes 
Endpoint PCR was used to generate template DNA for production of a standard curve 
to allow for calculation of relative levels of gene expression in quantitative real time 
PCR (qPCR) (see below section 2.2.3.7.8). cDNA resulting from an mRNA sample of 
known, high concentration and low contamination was chosen and 20 ng of cDNA was 
mixed with the following components to final concentrations of 10 mM dNTP mix,  
0.2 U/μL MangoTaq DNA polymerase, 1× MangoTaq colourless reaction buffer,  
25 mM MgCl2 solution, 250 nM forward primers, 250 nM reverse primers and made 
up to 20 μL with DNase/RNase free water. Samples were run using a CFX Connect 
Real-Time PCR Detection System (Bio-Rad, CA, USA) at 94 °C for 2 mins 
(polymerase activation and denaturation) followed by 36 cycles of: 94 °C for 5 secs 
(denaturation); 60 °C for collagen or 65 °C for Ppia and elastin (annealing); and 72 °C 
for 30 secs (extension). Samples were held at 4 °C before being run on a 3 % (w/v) 
agarose gel in 1× TBE buffer containing 0.05 % (v/v) SYBR Safe DNA gel stain at  
90 V for 30 mins. 8 μL of dsDNA were run using the Hyperladder IV as a size reference. 
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Only pure dsDNA samples appearing at the correct size and as a single clear band, 
indicating no contamination, were used or stored at -20 °C. 
2.2.3.8.8 qPCR of collagen type I and elastin 
Quantification of mRNA levels was performed by qPCR using the CFX Connect Real-
Time PCR Detection System with the SsoAdvanced Universal SYBR Green Supermix 
Kit (Bio-Rad, CA, USA) according to the manufacturer’s protocol. Samples were run 
in triplicate and the reaction (20 µL) consisted of 1× SYBR Green Supermix, 500 nM 
each for forward and reverse primers and 20 ng of cDNA. No Template Controls and 
No Enzyme Controls were run concurrently with samples to check for contamination. 
The reaction conditions were as follows: 95 °C for 3 mins (polymerase activation and 
denaturation); 40 cycles of: 95 °C for 10 secs (denaturation); 60 °C for collagen or  
65 °C for Ppia and elastin for 15 secs (annealing); and 72 °C for 30 secs (extension). 
A melting curve analysis was performed at the end of the reaction to check for primer-
dimer formation and contamination (Figure 2.8A and B). The absolute mRNA copy 
number of the genes of interest was calculated using a standard curve (Figure 2.8C) 
generated from dsDNA produced in section 2.2.3.7.7. Normalisation between samples 
was performed using Ppia. 
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Figure 2.9: (A) Melt curve showing no primer dimer formation, (B) melt curve with primer dimer 
formation and (C) standard curve generated from dsDNA for quantifying relative expression. 
 One-step grafting of EDRT and IDRT in mice 
The dorsal area was shaved and cleaned with Betadine solution followed by sterile 
saline. Four, identical, 1 × 1 cm2, full-thickness, skin excision wounds were surgically 
created adjacent to each other but separated by intact skin (Figure 2.9). Each wound 
was grafted with either EDRT+autograft, IDRT+autograft, an autograft or kept as an 
open wound. All autografts were full-thickness autografts and were sourced from 
neighbouring skin excisions in a clockwise pattern. Wounds grafted with 
EDRT/IDRT+autograft, grafting was performed by first suturing either EDRT or IDRT 
to the wound followed by immediate suturing of the graft over the substitute. Wounds 
were dressed with Atrauman and IV3000 for 7 days. Carprofen (5 mg/kg) was 
administered at the time of anaesthesia and on the first two days post-surgery for 
A B 
C 
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analgesia. Wound contraction was monitored throughout the study with wound size 
measured on days 0, 3, 7, 14, 21 and 28 post-surgery using Visitrak (Smith & Nephew, 
NSW, Australia). 
 
Figure 2.10: Schematic of EDRT and IDRT one-step graft pattern in mice. 
Mice were housed, monitored and given access to food and water as described in 
section 2.2.3.5. Mice were sacrificed using CO2 on days 7, 14, 21 and 28 post-surgery 
and skin samples were collected for histological and IHC analysis.  
 Quantification of angiogenesis in one-step grafted EDRT and IDRT 
Angiogenesis of wounds was examined at weeks 2 and 4 post-surgery by using the 
fluorescent probe, AngioSense 750 EX, with signal detection performed with the IVIS 
Lumina XR live imager (Thermal Fisher, Australia). AngioSense 750 EX is a near-
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infrared labelled fluorescent macromolecule that works in vivo localising in blood 
vessels for 72 hrs. It allows imaging of vasculature leakage, such as areas undergoing 
angiogenesis, by pooling of the fluorescent probe in these areas resulting in a stronger 
signal. Each mouse was injected with 10 μL of the fluorescent probe diluted in sterile 
PBS to a concentration of 2 nmol/100 μL via a tail-vein injection. After 24 hrs the mouse 
was scanned using the IVIS live imager and the signal generated was captured for 
analysis of fluorescent radiant efficiency. The radiant efficiency was used to determine 
density of neo-vascularisation and angiogenesis. 
 Two-step grafting of EDRT and IDRT in mice 
The first step of the procedure was to shave the dorsal area and clean with Betadine 
solution followed by sterile saline. Two, identical, 1 × 1 cm2, full-thickness, skin 
excision wounds were surgically created adjacent to each other but separated by intact 
skin (Figure 2.10, step 1). Each wound was grafted with either EDRT or IDRT. All 
wounds were then individually covered with a silicone layer and dressed with 
Atrauman and IV3000 for 7 days. Carprofen (5 mg/kg) was administered at the time 
of anaesthesia and on the first two days post-surgery for analgesia. The second step 
of the procedure was 14 days later during which the silicone layer was removed and 
a full-thickness skin graft was cut from the dorsal area and grafted on the surface of 
an EDRT- or IDRT-regenerated wound bed (Figure 2.10, step 2). Autograft sites and 
grafted wounds were dressed with Atrauman and IV3000 for 7 days. 
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Figure 2.11: Schematic of EDRT and IDRT two-step graft pattern in mice. 
Mice were housed, monitored and given access to food and water as described in 
section 2.2.3.5. All mice were weighed on days 1-7, 9, 11 and 14 post-surgery and 
then after autografting on day 14 mice were weighed on days 15-21, 23, 25, 28 and 
35 post-surgery. 
2.2.4 Expression and statistical analysis of data 
All data are expressed as mean ± standard error. Statistical significance was 
determined by analysis of variance with Bonferroni post-hoc analysis, independent  
t-tests or multiple linear regression analysis with least significant difference post-hoc 
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analysis. Statistical significance was accepted at p<0.05 and significance is indicated 
in figures by * p<0.05, ** p<0.01 and *** p<0.001. 
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Chapter 3 
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Chapter 3  Development and characterisation of novel, 
electrospun, triple polymer scaffolds 
3.1 Introduction 
Electrospinning was first described over a century ago by Cooley and Morton in 1902 
(290, 291) and regained attention in the 1990s due to a surging interest in the field of 
nanotechnology (292). The simplicity and low cost involved in the setup as well as the 
reproducibility and versatility of electrospinning make it an attractive form of scaffold 
fabrication (293). Particularly for skin tissue engineering, the nanoscale fibres are 
advantageous for several reasons: the high surface area is ideal for cell attachment 
and drug loading; the highly porous structure of the scaffold facilitates nutrient and 
waste exchange; the scaffolds have improved mechanical performance compared to 
traditional methods which is beneficial for the stresses placed on skin; and the fibrous 
scaffold structure closely resembles the structure of native ECM (293-295) (Figure 
1.9). 
3.1.1 Electrospinning setup and theory 
The concept of electrospinning is similar to that of traditional spinning of fibres except 
an electric force is used to form the fibres rather than a mechanical force. The basic 
apparatus required is a voltage box, syringe pump, syringe/spinneret and collector 
(Figure 2.1). Electrospinning begins by dissolving polymers in a volatile, organic 
solvent and this polymer solution is loaded into a spinneret. A hemispherical drop of 
solution is held at the tip by surface tension and a high voltage power supply is used 
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to electrically charge the polymeric solution. The charge accumulates on the surface 
of the drop and as the charge increases the electric field causes the droplet to distort 
into a conical shape, commonly called the Taylor cone, and further increasing the 
charge causes the cone to diminish (253, 296) (Figure 2.1). At a critical voltage the 
repulsive charges within the solution overcome the surface tension of the solution and 
a jet is ejected from the tip of the cone (297). 
A high viscosity solution is required to form a continuous jet as macromolecular 
entanglements prevent the solution from undergoing Rayleigh instabilities and 
breaking up into droplets, which would result in electrospraying rather than 
electrospinning (293, 296). Electric forces accelerate the jet away from the tip and the 
longitudinal stress caused by this stabilises the jet initially keeping it straight. At some 
point along its path the jet undergoes stress relaxation and as the jet approaches the 
oppositely charged or grounded collector the surface charge density on the jet 
increases (253, 298). When the charge is sufficiently high this, in conjunction with the 
stress relaxation, causes the jet to rapidly whip and small perturbations grow leading 
to large looping motions resulting in thinning of the jet (253, 293, 297). This is often 
called bending instability and causes accelerated solidification of the fluid jet to form 
dry fibres (297). As the solvent evaporates a continuous, nanoscale fibre is formed 
which accumulates on the collector forming a non-woven, fibrous, highly porous mat. 
Electrospinning efficiency and physical properties of scaffolds such as fibre 
morphology and width, pore diameter, porosity, elasticity and strength are affected by 
electrospinning parameters and post-electrospinning modifications (Table 3.1). For 
example, increasing the polymer concentration can increase fibre diameter of 
electrospun gelatin (299), while surface morphology of polystyrene fibres can change 
from being smooth to pitted by increasing humidity to higher than 30 % (300). There 
 85 
are also many different electrospinning setups such as the single syringe and flat 
collector setup used in this study which results in randomly aligned fibres or multiple 
spinnerets which can be used to obtain a combination of single-polymer fibres in the 
scaffold (301-303). If fibre alignment is desired a rotating drum/disc or parallel 
electrodes can be used (304-307) as seen with PLLA fibres collected on either a plate 
to give randomly oriented fibres (Figure 3.1A) or aligned PCL fibres collected on a 
rotating disc (Figure 3.1B). Another conformation is core-shell electrospinning which 
uses a coaxial, dual-capillary spinneret to encapsulate one component, which can be 
drugs or enzymes, inside another component (308, 309). 
 
Figure 3.1: Representative image of electrospun fibres randomly oriented from collection on a 
plate (A) and aligned fibres collected on a rotating disc (B). 
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Table 3.1: Electrospinning parameters. Adapted from (310, 311). 
Polymer 
parameters 
Solution parameters Process parameters 
• Molecular weight 
• Molecular weight 
distribution 
• Glass-transition 
temperature 
• Solubility 
• Viscosity 
• Viscoelasticity 
• Concentration 
• Surface tension 
• Electrical 
conductivity 
• Substrate properties 
• Solution flow rate 
• Distance between the 
needle tip and collector 
• Collector composition and 
geometry 
• Vapour pressure of the 
solvent 
• Ambient parameters 
o Temperature 
o Humidity 
o Air velocity 
3.1.2 Electrospinning of polymers 
Nearly 100 different polymers have been electrospun to date (294) including both 
synthetic and natural polymers as listed in section 1.7.2.1. Synthetic polymers are 
ideal for electrospinning as they are cost effective and have well-defined, predictable 
properties which translate into uniform behaviour during electrospinning (262). For 
tissue engineering, synthetic polymers permit fabrication of reproducible scaffolds, 
often have superior mechanical properties compared to natural polymers and are 
stable in aqueous environments without the need for cross-linking (262, 312). 
However, synthetic polymers can have poor cell-interactive properties, toxic 
degradation products and may be rejected after grafting (313). 
Synthetic polymers can be functionalised by chemically modifying the polymer or by 
addition of signalling peptides or natural polymers to the electrospinning solution (314). 
Inclusion of biologically derived materials, i.e. natural polymers, provides biosignals 
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improving cell interactions such as attachment, migration, proliferation and 
differentiation (298, 315). For example, PCL was conjugated with heparin to 
electrospin nonwoven tubular scaffolds for use as a vascular substitute. These PCL-
heparin fibres had improved hydrophilicity which could reduce inflammation and 
thrombus risk in vivo (316). However, there are difficulties involved in using these 
materials due to inter- and intramolecular interactions arising from chemical 
composition, 3D structures and polyelectric character of proteins (262). Many natural 
polymers also require post-electrospinning modifications in the form of cross-linking to 
maintain protein structure in aqueous environments (251). 
3.1.3 Cellular Interactions with electrospun scaffolds 
Electrospun scaffolds closely mimic ECM structure and as such are of great interest 
in tissue engineering. The scaffolds are highly porous and interconnected which 
facilitate exchange of cellular nutrients and metabolic waste (293) and also provide a 
more homogenous environment for cellular interaction compared to other fabrication 
techniques such as lyophilisation (278). Previous studies have shown a 
heterogeneous scaffold environment can have negative impacts on cell adhesion, 
morphology and ECM distribution (317, 318) which can lead to inferior biomechanical 
properties of deposited tissue (319). 
The continuous, nanoscale fibres formed by electrospinning provide a large surface 
area which promotes cell adhesion (260-262). Electrospun fibres also promote cell 
proliferation compared to smooth films of the same materials (278). Cell orientation 
and morphology are also affected by electrospun fibres with cells aligning along fibres, 
which is especially evident when a scaffold has aligned fibres (254, 320). There have 
been a wide range of cells shown to have favourable interactions with electrospun 
 88 
scaffolds including fibroblasts, keratinocytes, endothelial cells, smooth muscle cells, 
adipocytes and neural cells (278, 320-322). 
3.1.4 Aim 
This chapter aimed to utilise 2 natural polymers, collagen and elastin, and a synthetic 
polymer, PCL, to produce a scaffold which exhibited the advantageous properties of 
each polymer, namely, the promotion of cell interactions by collagen, imparting of 
elasticity by elastin and increased scaffold strength from PCL. The fabrication method 
of electrospinning was chosen as resulting scaffolds have a large surface area 
promoting cell adhesion and are highly porous which facilitates nutrient and waste 
exchange as well as cell infiltration. The triple-polymer scaffolds were characterised 
for morphological, mechanical and cell-interactive properties using HDFs and human 
epidermal keratinocytes. 
3.2 Methods 
Please refer to section 2.2.1 for all protocols used in this study. 
3.3 Results and Discussion 
The combination of collagen, elastin and PCL was tested in this study to determine if 
advantageous properties from all three polymers would be present in a single, 
composite, scaffold and glutaraldehyde, vapour cross-linking was used to stabilise the 
natural polymers and prevent immediate dissolution of the scaffold in an aqueous 
environment. 
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3.3.1 Effect of electrospinning parameters on electrospinning efficiency 
 Effect of polymer composition on electrospinning efficiency 
A scaffold was produced using a polymer composition of 3C12E at a flow rate of  
1 mL/h, an air gap of 15 cm and an applied electric potential of 20 kV. The scaffold 
showed a smooth surface before removal with minimal radiating fibres extending from 
the collector (Figure 3.2A). After removal, the scaffold had minimal wrinkling of the 
surface resulting from peeling the scaffold off the collector (Figure 3.2B). Fibre loss 
occurred when the scaffold was peeled from the collector which was evident by the 
white coat covering the surface of the brass collector (Figure 3.2C). 
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Figure 3.2: Electrospinning of various polymer solutions at a flow rate of 1 mL/h, air gap of  
15 cm and applied electric potential of 20 kV. Images of the electrospun scaffolds produced 
using the 3C12E solution (A-C), 2.5C12E0.5P solution (D-F) and 2C12E1P solution (G-J) after 
electrospinning (left column), after removal from the collector (middle column) and fibre loss 
on the collector (right column). 
A triple polymer scaffold was produced using 12 % (w/v) elastin, decreased collagen 
content of 2.5 % (w/v) and an addition of 0.5 % (w/v) PCL (2.5C12E0.5P). The resulting 
scaffold was soft and smooth after fabrication (Figure 3.2D) with easy removal. The 
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final, detached scaffold demonstrated more wrinkles on the surface of the scaffold and 
increased fibre loss was noticed compared to the 3C12E scaffold (Figure 3.2E). The 
increased fibre loss could be attributed to inclusion of PCL which may have decreased 
elasticity and flexibility of the fibres leading to fibres snapping and remaining on the 
collector. The final scaffold would still be considered suitable for cross-linking and 
further testing due to the even, low levels of fibre loss from removal (Figure 3.2F) and 
a resulting intact scaffold with uniform thickness. 
Further reduction of the collagen content to 2 % (w/v) with an increase in PCL content 
to 1 % (w/v) (2C12E1P) resulted in poorer scaffold formation and droplet deformation 
(Figure 3.2G, orange arrows). Droplet deformation occurs when drops of solution are 
formed from the Taylor cone rather than a stable jet. This results in droplets contacting 
the surface of the scaffold, dissolving dry fibres and forming crater-like deformations 
on the scaffold surface. Under such situations, the electrospinning conditions are 
considered closer to electrospraying (323), hence the formation of droplets rather than 
jet. An unstable jet could be adjusted by changing the solution composition to increase 
the solution’s viscosity or by decreasing the applied electric potential to reduce the 
repulsive charge within the solution (296, 324-326). Droplet deformations also led to 
a poor scaffold with points of droplet deformation seen to be origins of fibre loss on 
the collector leading to increased fibre loss (Figure 3.2J). The resulting 2C12E1P 
scaffold was intact with similar amounts of wrinkling to that observed in the 
2.5C12E0.5P (Figure 3.2H). However, due to fibre loss and droplet deformation this 
scaffold was not considered for further tests. 
Surprisingly, a further decrease in collagen to 1.5 % (w/v) with increase of PCL to  
1.5 % (w/v) (1.5C12E1.5P) improved scaffold fabrication (data not shown). No droplet 
 92 
deformation and minimal fibre loss was observed compared to fabrication of 
2.5C12E0.5P scaffolds. 
This visual analysis of the effects of polymer composition on scaffold formation 
indicated that adding PCL to a CE solution had a variable effect on efficiency of 
scaffold formation and removal capability. Scaffold fabrication was possible with the 
CEP solutions and further optimisation could be performed with variations in flow rate 
and air gap. 
 Effect of flow rate on electrospinning efficiency 
Electrospinning of the 1.5C12E1.5P solution at 1 mL/h, 15 cm and 20 kV, as previously 
discussed in section 3.3.1.1, resulted in a defect-free scaffold with minimal wrinkling 
and low, even fibre loss during removal. Electrospinning at an increased flow rate of  
3 mL/h was abandoned due to solution dripping from the tip of the needle and therefore 
absence of a stable jet. An increase of the positive charge to the solution could 
overcome this issue as jet formation occurs when the repulsive force within the 
solution overcomes surface tension (292). 
Decreased electrospinning efficiency was also observed with increasing flow rate 
during optimisation of electrospinning of the 3C12E solution. Electrospinning of the 
3C12E solution at 1 mL/h, 15 cm and 20 kV resulted in a smooth scaffold with minimal 
wrinkling and fibre loss during removal (Figure 3.3A-C). Electrospinning at a flow rate 
of 3 mL/h resulted in a scaffold which appeared fluffier but the surface near the edge 
of the scaffold was thick and uneven with radiating fibres (Figure 3.3D). The final 
scaffold was quite wrinkled (Figure 3.3E) and had uneven fibre loss during removal 
from the collector (Figure 3.3F). The scaffold produced at 5 mL/h was poorer still with 
the entire surface of the scaffold appearing lumpy (Figure 3.3G) and, although the 
 93 
scaffold was removed intact (Figure 3.3H), fibre loss during removal was uneven 
(Figure 3.3J). The lumpy surface could be a result of unstable Taylor cone formation 
and, therefore, a non-uniform flow rate. This unstable jet would result in varying 
amounts of fibre formation rather than a single, continuous jet and lead to uneven 
deposition on the collector. 
 
Figure 3.3: Electrospinning at various flow rates using the 3C12E solution, an air gap of 15 cm 
and an applied electric potential of 20 kV. Images of the electrospun scaffolds produced using 
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1 mL/h (A-C), 3 mL/h (D-F) and 5 mL/h (G-J) after electrospinning (left column), after removal 
from the collector (middle column) and fibre loss on the collector (right column). 
Conversely, electrospinning of 1.5C12E1.5P at 15 cm and 25 kV experienced 
improved electrospinning when flow rate was increased from 1 to 3 mL/h. When 
electrospun at 1 mL/h the scaffold exhibited droplet deformation but an increase to  
3 mL/h resulted in a smooth scaffold with some fibre loss during removal. This 
improvement could be attributed to the formation of a continuous jet at a flow rate of  
3 mL/h. As previously discussed, droplet deformation occurs when conditions are 
more akin to electrospraying. When the jet is stretched too thin, surface tension 
overcomes the repulsive charge within the solution and the jet breaks up forming 
droplets. Therefore, an increase in the flow rate had more macromolecular 
entanglements and a thicker, stable jet leading to the formation of fibres (296). 
Increasing flow rate can improve scaffold formation by providing a sufficient amount 
of solution to eliminate droplet deformation, but in opposition higher flow rates can also 
provide excess solution resulting in solution dripping from the needle tip. The various 
outcomes are partially due to interaction with other electrospinning parameters. 
Primarily a high solution viscosity is needed for jet formation (296) and larger applied 
electric potentials with increasing flow rate are also necessary to provide the repulsive 
charge to form a stable Taylor cone and permit jet initiation (297). 
 Effect of air gap on electrospinning efficiency 
Beginning with an air gap of 10 cm, the 1.512E1.5P solution was electrospun using a 
flow rate of 1 mL/h and an applied electric potential of 20 kV. The resulting scaffold 
was smooth with slight wrinkling and minimal fibre loss during removal. Fabrication 
with a larger air gap of 15 cm resulted in similar results to electrospinning at 10 cm, 
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but an air gap of 20 cm resulted in droplet deformation of the scaffold. Electrospinning 
with a 25 cm air gap was abandoned as solution was dripping from the needle tip. 
Electrospinning efficiency clearly decreased with increasing air gap at these 
parameters and this could result from the applied electric potential being insufficient 
at larger air gaps to support stable jet formation between the needle tip and collector. 
A previous study has observed that a larger applied electric potential increased the 
length of jet stability (323). Therefore, fabrication could be improved by increasing the 
applied electric potential while maintaining a constant polymer composition, flow rate 
and air gap. In addition, it was previously seen that insufficient repulsive charge at a 
high flow rate can also lead to solution dripping highlighting the interrelatedness 
between electrospinning parameters. 
Conversely, increasing the air gap from 15 cm to 20 cm and 25 cm when 
electrospinning the 2C12E1P solution at 1 mL/h and 20 kV led to improved fabrication. 
The scaffold produced at 10 cm had uneven fibre loss originating from droplet 
deformation (Figure 3.4C). Electrospinning at 20 cm resulted in decreased, more even 
fibre loss during removal (Figure 3.4F) producing a scaffold with a more uniform 
environment and thickness. The scaffold fabricated at 25 cm was a further 
improvement from 20 cm. Fabrication at 25 cm resulted in good scaffold removal with 
almost little fibre loss observed on the collector (Figure 3.4J). Increasing the air gap 
most likely improved electrospinning by providing more time for solvent evaporation 
and collection of dry fibres. At the shorter air gaps of 15 and 20 cm insufficient solvent 
evaporation could have resulted in the deposition of droplets on the collector leading 
to fused fibres. 
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Figure 3.4: Electrospinning at various air gaps using the 2C12E1P solution, a flow rate of  
1 mL/h and an applied electric potential of 20 kV. Images of the electrospun scaffolds 
produced using an air gap of 15 cm (A-C), 20 cm (D-F) and 25 cm (G-J) after electrospinning 
(left column), after removal from the collector (middle column) and fibre loss on the collector 
(right column). 
Altering the air gap can either increase or decrease electrospinning efficiency, similar 
to the effects of flow rate. A larger air gap allows sufficient time for solvent evaporation 
and dry fibre formation but if the air gap is too large failed jet initiation can occur if the 
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applied electric potential is too weak. This can be addressed by increasing the applied 
electric potential; however, this can also lead to ionisation of the air resulting in 
decreased fibre deposition on the collector. Yet again the interplay of electrospinning 
parameters is evident. 
 Effect of applied electric potential on electrospinning efficiency 
Scaffold production of the 1.5C12E1.5P solution was performed using a flow rate of  
3 mL/h and an air gap of 15 cm. The initial applied electric potential of 20 kV was 
abandoned due to solution dripping from the tip. This was addressed by increasing the 
positive charge to the solution to 25 kV which increased the repulsive force within the 
solution and permitted jet formation. The resulting scaffold had some radiating fibres 
observed and removal from the collector had a low level of even fibre loss. 
In comparison, electrospinning of the 1.5C12E1.5P solution at 1 mL/h, 15 cm and an 
initial applied electric potential of 20 kV experienced decreased electrospinning 
efficiency when the positive charge was increased to 25 kV. At the higher charge, 
droplet deformation was observed on the scaffold which in turn lead to poor scaffold 
removal. The inverse relationship between applied electric potential and flow rate is 
contrary to previous work (323) in which a positive correlation was observed between 
flow rate and applied electric potential. The differential effect of applied electric 
potential highlights the different electrospinning behaviours of polymer solutions due 
to variations in properties such as solution composition, viscosity, conductivity and 
surface tension. 
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 Interactions of electrospinning parameters electrospinning efficiency 
It is evident that electrospinning efficiency is dependent on numerous parameters and 
that parameters not only directly affect efficiency but also indirectly through 
interactions with other parameters. Formation of a scaffold with a smooth surface, 
even thickness and main fibre deposition on the surface has been seen to require not 
only fine-tuning of individual parameters, such as solution composition and air gap, 
but also changes of parameters in concert such as a decrease in flow rate for solutions 
with lower viscosity or larger applied electric potentials for larger air gaps. The four 
parameters examined in this study are only a small portion. There are many 
parameters such as solution viscosity, humidity and temperature which also affect 
scaffold formation and need to be examined (295, 298, 323, 327). 
3.3.2 Effect of inclusion of elastin on fibre morphology of non-cross-
linked and cross-linked scaffolds 
Surface morphology of scaffolds was examined using SEM analysis and images 
showed a surface with ribbon-like fibres and no beads. Cross-sections of non-cross-
linked, elastin-containing fibres were seen to be rectangular (Figure 3.5A and E) 
compared to CP fibres which appeared circular (Figure 3.5C). The rectangular 
morphology of elastin-containing fibres could be due to formation a thin polymer skin 
on the liquid jet during jet travel between the needle-tip and collector. This polymer 
skin collapses from atmospheric pressure when the solvent inside the polymer skin 
evaporates changing a circular cross section to elliptical and then a rectangular with 
the fibre taking on the appearance of a flat ribbon (328, 329). The ribbon-like 
morphology did not appear in CP fibres which could be explained by slower solvent 
evaporation preventing formation of a polymer skin. 
 99 
 
Figure 3.5: SEM images of the surface of electrospun scaffolds showing cross-sections of 
fibres (yellow lines) before cross-linking (left column) and after cross-linking (right column). A 
respresentative CEP scaffold (A and B), CP scaffold (C and D) and CE scaffold (E and F). 
Magnification is 5000× and scale bars are 5 μm. 
After crosslinking, no difference in fibre morphology was noticed with all fibres 
displaying a circular cross-section (Figure 3.5B, D and F). Additionally, elastin-
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containing scaffolds displayed interconnected fibres which were not observed in CP 
scaffolds (Figure 3.5B and F). The change in fibre morphology of the CE and CEP 
scaffolds could be attributed to the higher content of natural polymer (elastin and 
collagen containing scaffolds) which would provide more sites for cross-linking leading 
to more interconnected fibres in scaffolds. Such interconnected networks of fibres are 
believed to facilitate cell infiltration by providing bridges for cell migration. In contrast, 
a CP scaffold was reported to delay cell migration and infiltration which could be 
attributed to the distinct fibres (330). 
3.3.3 Effect of electrospinning parameters on pore diameter and fibre 
width of non-cross-linked, CEP scaffolds 
Surface morphology of scaffolds was examined using SEM analysis and the pore 
diameters and fibre widths were quantified using ImageJ. Pore diameters were defined 
as the longest axis of the pore (Figure 2.2, blue lines) and fibre widths were measured 
at the cross-sections of individual fibres (Figure 2.2, yellow lines). 
 Effect of simultaneous increase in collagen content and decrease in 
PCL content on pore diameter and fibre width of non-cross-linked, CEP 
scaffolds 
Stepwise increase of collagen content by 0.5 % (w/v) with corresponding decreases 
in PCL content resulted in estimated marginal means of pore diameter of  
4.56 ± 0.26 μm for the 1.5C12E1.5P solution, 5.86 ± 0.35 μm for the 2C2E1P solution 
and 6.48 ± 0.41 μm for the 2.5C12E0.5P solution (Figure 3.6A). The mean pore 
diameters of the 2C12E1P and 2.5C12E0.5P solutions were shown to be significantly 
higher than the 1.5C12E1.5P solution (p<0.01 and p<0.001 respectively) indicating 
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the increase in collagen content and decrease in PCL content led to steady increases 
in pore diameter. 
A similar trend was observed with fibre width increasing as collagen content increased 
and PCL content decreased (Figure 3.6B). The 1.5C12E1.5P solution had the lowest 
estimated marginal mean of 1.43 ± 0.03 μm, which increased to 1.6 ± 0.04 μm for the 
2C12E1P solution and the 2.5C12E0.5P solution had the largest mean of  
1.61 ± 0.05 μm. The 1.5C12E1.5P solution was shown to have significantly thinner 
fibre widths than both the 2C12E1P and 2.5C12E0.5P solutions (p<0.01). Previous 
electrospinning of pure, bovine, collagen type I has also demonstrated a positive, 
linear relationship between fibre width and collagen concentration (258). 
Larger pores are favourable in a skin substitute as they will facilitate exchange of 
nutrients, waste and metabolites. In conjunction with the higher pore interconnectivity 
observed of CEP scaffolds compared to CP scaffolds, the large pores will also promote 
cell ingrowth of the scaffolds. The increasing fibre width observed, although shown to 
be significantly different between scaffolds, is not likely to have a noticeable effect on 
cell attachment. The CEP scaffolds had microscale fibres which have been shown to 
promote cell interactions (260). The concurrent increase in both pore diameter and 
fibre width is also expected as previous studies of statistical modelling and 
experimental data have shown this relationship (331-337). 
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Figure 3.6: Graphical representation of estimated marginal means of pore diameter (A) and 
fibre width (B) plotted against simultaneous increases in collagen and decreases in PCL 
content for all, non-cross-linked, CEP scaffolds tested (**p<0.01 and ***p<0.001). 
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 Effect of flow rate on pore diameter and fibre width of non-cross-linked, 
CEP scaffolds 
Pore diameter and fibre width were found to increase with increasing flow rate. At the 
lower flow rate tested, 1 mL/h, the estimated marginal mean of pore diameters was 
4.62 ± 0.31 μm which increased to 6.65 ± 0.33 μm at 3 mL/h (Figure 3.7A). This 
increase in pore diameter was found to be significant (p<0.001). The change in fibre 
width was also significant with an increase from 1.28 ± 0.04 μm at 1 mL/h to  
1.81 ± 0.04 μm at 3 mL/h (p<0.001) (Figure 3.7B). The effect of increasing flow rate 
leading to increased fibre width has been observed in previous studies (332, 338). As 
discussed above, the larger pores and microscale fibres will have advantageous 
effects on cell interactions such as attachment, infiltration (260) and growth by 
improving exchange of fluids. 
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Figure 3.7: Graphical representation of estimated marginal means of pore diameter (A) and 
fibre width (B) plotted against flow rate for all, non-cross-linked, CEP scaffolds tested 
(***p<0.001). 
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 Effect of air gap on pore diameter and fibre width of non-cross-linked, 
CEP scaffolds 
Increasing the air gap resulted in decreasing estimated marginal mean of pore 
diameter of 5.96 ± 0.64 μm at 10 cm, 5.78 ± 0.30 μm at 15 cm, 5.51 ± 0.23 μm at  
20 cm and 5.28 ± 0.45 μm at 25 cm. These differences were shown to be insignificant 
(Figure 3.8A). Decreased pore diameter was expected since the jet had a longer path 
to travel undergoing more instabilities and elongation leading to fibre thinning. The 
positive relationship between pore diameter and fibre with would then dictate smaller 
pores would result as air gap increased. 
However, fibre width was shown to increase from 1.41 ± 0.08 μm at 10 cm to  
1.66 ± 0.03 μm and then to 1.71 ± 0.03 μm at 20 cm before decreasing back to  
1.41 ± 0.06 μm at 25 cm (Figure 3.8B). Significance was observed between 10 and  
15 cm (p<0.01), 10 and 20 cm, 15 and 25 cm as well as 20 and 25 cm (p<0.001). The 
cause of this surprising result is unclear, especially since a positive relationship 
appeared between pore diameter and fibre width with collagen/PCL content and flow 
rate. 
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Figure 3.8: Graphical representation of estimated marginal means of pore diameter (A) and 
fibre width (B) plotted against air gap for all, non-cross-linked, CEP scaffolds tested (** p<0.01 
and ***p<0.001). 
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 Effect of applied electric potential on pore diameter and fibre width of 
non-cross-linked, CEP scaffolds 
The applied electric potential had a variable effect on both pore diameter and fibre 
width. Estimated marginal mean of the pore diameter decreased from 5.22 ± 0.28 μm 
at a potential of 20 kV to 4.05 ± 0.41 µm at 25 kV; however, increasing the potential to 
30 kV resulted in a larger pore diameter of 7.63 ± 0.47 μm (Figure 3.9A). Conversely, 
fibre width mean increased from 1.37 ± 0.03 μm at 20 kV to 1.71 ± 0.05 μm at 25 kV 
and then decreased to 1.57 ± 0.06 kV at a potential of 30 kV (Figure 3.9B). As seen 
with air gap, there was no relationship observed between pore diameter and fibre width. 
The two electrospinning parameters of increasing collagen content/decreasing PCL 
content as well as increasing flow rate were shown to form larger pores while 
maintaining microscale fibres. Air gap and applied electric potential were seen to have 
varying effects on both pore diameter and fibre width. This lack of relationship 
observed between pore diameter and fibre width was unexpected as previous studies 
have shown a positive relationship between the two and further investigation of these 
two parameters would be useful to elucidate if any relationship exists with pore 
diameter and fibre width (331-337). Despite this, increasing natural polymer content 
while decreasing synthetic polymer content can be used to improve scaffold structure 
by not only increasing pore diameter but by also improving fibre and pore 
interconnectivity to facilitate cell infiltration and fluid exchange. 
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Figure 3.9: Graphical representation of estimated marginal means of pore diameter (A) and 
fibre width (B) plotted against applied electric potential for all, non-cross-linked, CEP scaffolds 
tested (** p<0.01 and ***p<0.001). 
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3.3.4 Effect of cross-linking on pore diameter and fibre width of CEP 
scaffolds 
Six scaffolds were chosen for cross-linking based on favourable morphological 
properties of large pores and microscale fibres. Four CEP scaffolds were chosen, one 
CP and one CE scaffold. Scaffold designations and electrospinning parameters are 
listed in Table 2.2. 
Despite the intermittent trends observed between morphological properties and 
individual electrospinning parameters the effect of cross-linking on scaffolds was 
variable with no significance observed (Figure 3.10). 
 Mechanical properties CEP scaffolds 
Tensile tests were used to examine physical properties of electrospun scaffolds. The 
CP scaffold was shown to have a significantly higher tensile modulus of  
1411.8 ± 25.0 kPa compared to 108.0 kPa in CE, 108.0 ± 18.2 kPa in CEP 1,  
53.0 ± 4.9 kPa in CEP 2, 66.0 ± 8.7 kPa in CEP 3 and 153.7 ± 9.0 kPa in CEP 4 
(p<0.001; Figure 3.11A). The lower tensile moduli observed in scaffolds fabricated with 
elastin confirms the presence of elastin increases elasticity (339, 340). Energy loss, 
an indicator of good shape retention at low values, was also calculated and no trend 
was observed with 36.7 ± 1.5 % in CP, 82.0 % in CE, 73.0 ± 0.0 % in CEP 1,  
24.0 ± 1.2 % in CEP 2, 18.7 ± 0.3 % in CEP 3 and 69.0 ± 0.0 % in CEP 4 (Figure 
3.11B). 
CEP 1 and CEP 2 were chosen for further characterisation based on improved 
elasticity and favourable morphological properties. 
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Figure 3.10: Changes in average pore diameter (A) and fibre width (B) of cross-linked, 
electrospun scaffolds before and after cross-linking. 
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Figure 3.11: Graphical representation of the tensile moduli (A) and energy loss (B) of 
electrospun scaffolds (*** p<0.001). 
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3.3.5 Pore diameter, fibre width and porosity of CEP 1 and CEP 2 
CEP 1 and CEP 2 were chosen for further cell characterisation due to the favourable 
morphological and mechanical properties demonstrated by both scaffolds. CEP 1 had 
an average pore diameter of 5.30 ± 0.38 μm which was significantly smaller than the 
average pore diameter of CEP 2 at 7.83 ± 0.42 μm (p<0.001; Figure 3.12). The pores 
of CEP 1 and CEP 2 should be sufficiently large to allow cell infiltration as a previous 
study using electrospun, CP scaffolds demonstrated HDF infiltration with pore 
diameters approximately 5 μm in diameter (277). In contrast, average fibre width of 
CEP 1 was significantly larger than CEP 2 at 1.69 ± 0.08 μm and 1.41 ± 0.07 μm 
respectively (p<0.01; Figure 3.13) which may affect cell-seeding efficiency as thinner 
fibres results in less surface area for cell attachment. Differences between CEP 1 and 
CEP 2 could not be predicted or explained due to the numerous differences in 
electrospinning parameters during fabrication; however, it was surprising pore 
diameter and fibre width did not positively correlate since previous statistical modelling 
and experimental data supported this relationship (331-337). CEP 3 was not chosen 
due to poor removal from the scaffold with uneven fibre (Figure 3.14) loss which would 
affect scaffold uniformity and integrity and CEP 4 was not chosen due to high amounts 
of fibre loss during removal (Figure 3.2D-F). 
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Figure 3.12: Average pore diameters of CEP 1 and CEP 2 (*** p<0.001). 
 
Figure 3.13: Average fibre widths of CEP 1 and CEP 2 (** p<0.01). 
0.00
3.00
6.00
9.00
CEP 1 CEP 2
Po
re
 d
ia
m
et
er
 (μ
m
)
***
0.00
1.00
2.00
3.00
CEP 1 CEP 2
Fi
br
e 
w
id
th
 (μ
m
)
**
 114 
 
Figure 3.14: Electrospinning of 2.5C12E0.5P solution at a flow rate of 1mL/h, an air gap of  
20 cm and an applied electric potential of 25 kV after electrospinning (left image), after removal 
from the collector (middle image) and fibre loss on the collector (right image). 
Sections of cross-linked CEP 1 and CEP 2 were stained using H&E to visualise the 
fibres. Images of the stained cross-sections were converted to binary images and both 
scaffolds were seen to have fibrous structures (Figure 3.15). Based on the significant 
differences in pore diameter and fibre width between CEP 1 and CEP 2, it was 
surprising that porosity measurements showed no significant difference between the 
scaffolds with 74.0 % for CEP 1 and 70.4 % for CEP 2 (Figure 3.16). This lack of 
significance could simply be due to variation within and between scaffolds produced 
as Figures 3.11 and 3.12 show a range of pore diameters and fibres widths for both 
scaffolds. 
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Figure 3.15: H&E images (A and B) of CEP 1 (left column) and CEP 2 (right column) converted 
to binary images (C and D) for quantification of porosity. Magnification is 20× and scale bars 
are 200 μm. 
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Figure 3.16: Porosity of CEP 1 and CEP 2 calculated from binary images. 
3.3.6 HaCaT behaviour on CEP 1 and CEP 2 
HaCaTs were seeded onto CEP 1 and CEP 2 to investigate keratinocyte interaction 
with scaffolds examining cell attachment, migration and proliferation. The morphology 
of HaCaTs on the surface of electrospun scaffolds was examined on days 1 and 14. 
SEM images showed flattened and attached HaCaTs on both scaffolds (Figure 3.17A 
and B, yellow arrows), indicating differences in pore diameter and fibre width had no 
effect on morphology of HaCaTs attached to the scaffolds. Migration of HaCaTs was 
observed on CEP 1 (Figure 3.17A, orange arrows) and the beginnings of a 
subconfluent cell layer forming on CEP 2 (Figure 3.17B, outlined in green). Cell layers 
were observed on both scaffolds on day 14 suggesting favourable biocompatibility of 
the electrospun scaffolds (Figure 3.14C and D). H&E staining confirmed the presence 
of a confluent cell layer on day 28 (Figure 3.18C and D) while also revealing HaCaTs 
66.0
69.0
72.0
75.0
CEP 1 CEP 2
Po
ro
si
ty
 (%
)
 117 
formed a subconfluent layer on day 1 (Figure 3.18A and B). Cells remained on the 
surface of the scaffolds with no cell infiltration over 28 days. 
 
Figure 3.17: SEM images of flattened and attached HaCaTs (yellow arrows), migrating 
HaCaTs (orange arrows) and a subconfluent cell layer (outlined in green) on the top surface 
of HaCaT-seeded CEP 1 (left column) and CEP 2 (right column) at day 1 (A and B) and day 
14 (C and D) post-seeding. Magnification is 1000× and scale bars are 10 μm. 
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Figure 3.18: H&E images of HaCaT-seeded CEP 1 (left column) and CEP 2 (right column) at 
day 1 (A and B) and day 28 (C and D) post-seeding. Magnification is 20× and scale bars are 
200 μm. 
HaCaTs attached and remained on the surface of electrospun scaffolds. These are 
desirable behaviours since keratinocytes are responsible for regenerating the 
epidermal layer of skin. The formation of subconfluent layers of cells on day 1 would 
facilitate keratinocyte growth on the scaffolds through the expression of autocrine 
factors such as TGF-α, amphiregulin and epiregulin (341). Accelerated cell growth of 
keratinocytes could lead to more rapid development of an epithelial layer that would 
accelerate wound healing by promoting re-epithelialisation. DAPI staining of nucleic 
material and fluorescence analysis displayed an intact layer of HaCaTs on the surface 
of the scaffolds (Figure 3.19). Detachment of HaCaT cells were noticed on CEP 2 at 
CEP 1 CEP 2 
D
ay
 1
 
D
ay
 2
8 
A B 
C D 
 119 
day 28 which may have been caused by physical effects during tissue processing 
(Figure 3.19F). 
 
Figure 3.19: DAPI images of HaCaT-seeded CEP 1 (left column) and CEP 2 (right column) at 
day 1 (A and B), day 14 (C and D) and day 28 (E and F) post-seeding. Magnification is 10× 
and scale bars are 400 μm. 
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In an attempt to circumvent the cell layer separation issue arising from processing for 
paraffin embedding an alternative method of cryosectioning of the seeded samples 
was tested. The samples were fixed in 4 % (v/v) paraformaldehyde for 15 mins at RT, 
then embedded in OCT compound and finally frozen in 100 % ethanol chilled with dry 
ice. Section were cut by cryosectioning with thicknesses varying from 5 μm to 10 μm; 
however, all samples showed visible separation of the cell layers from the scaffold 
during sectioning and this technique was abandoned for analysis of in vitro cell 
localisation. 
Cell numbers of HaCaTs on CEP 1 and CEP 2 were measured using a 
haemocytometer on day 1 which revealed both electrospun scaffolds had good cell-
attachment with 98.2 ± 0.4 % on CEP 1 and 96.4 ± 0.6 % on CEP 2 (Figure 3.20). 
Furthermore, CEP 1 demonstrated a significantly higher cell attachment compared to 
CEP 2 (p<0.05) which could be due to the smaller pores of CEP 1 (5.30 ± 2.09 μm) 
compared to CEP 2 (7.83 ± 0.42 μm) (P<0.001). The higher cell attachment may also 
be explained by the significantly larger fibres of CEP 1 (1.69± 0.08 μm) compared to 
CEP 2 (1.41 ± 0.07 μm) (p<0.01) and the smaller average pore diameter of CEP 1 
may have facilitated cells bridging the pores. The microscale pores of the scaffolds 
may have aided HaCaT migration and confluency as a previous study has shown that 
intercellular adhesion between keratinocytes is sufficiently strong to pull neighbouring 
cells along over non-adhesive substrates (342). 
 121 
 
Figure 3.20: HaCaT-seeding efficiency on CEP 1 and CEP 2 (* p<0.05). 
HaCaT proliferation on both CEP 1 and CEP 2 scaffolds was also assessed (Figure 
3.21). CEP 1 was shown to have significantly higher HaCaT numbers compared to 
CEP 2 over 28 days (Figure 3.21). However, despite the higher number of HaCaTs on 
CEP 1, CEP 2 displayed a consistent cell proliferation over 28 days with  
10,955 ± 1,665 cells on day 7, 18,708 ± 7,888 cells on day 14, 47,896 ± 7,420 cells 
on day 21 and extensive cell proliferation of 221,608 ± 29,729 cells. Comparatively, 
CEP 1 showed a slight drop in cell number from 43,501 ± 10,259 cells on day 7 to 
20,248 ± 9,334 cells on day 14, but thereafter cell number increased to  
72,332 ± 6,491 cells on day 21 and finally 240,229 ± 21,635 cells on day 28. 
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Figure 3.21: HaCaT proliferation over 28 days on CEP 1 and CEP 2 (* p<0.05, ** p<0.01,  
*** p<0.001). 
3.3.7 HDF behaviour on CEP 1 and CEP 2 
HDF infiltration and proliferation on CEP 1 and CEP 2 were investigated on days 1 
and 14 post-seeding. SEM analysis showed HDF migration on days 1 and 14 on the 
surface of CEP 1 and CEP 2 (Figure 3.22, yellow arrows). These HDF interactions 
with electrospun scaffolds indicate favourable scaffold environments. Additionally, 
H&E images showed initial HDF infiltration on day 14 (Figure 3.23A and B, black 
arrows) and both H&E and DAPI images showed complete infiltration of both scaffolds 
by day 28 (Figure 3.23C and D and Figure 3.24C and D respectively). This is in line 
with previous studies which have shown cell infiltration into scaffolds with 5 μm pores 
(277) despite the previously established pore range of 20-120 μm required for cell 
infiltration (343). No confluent cell layers of HDFs were observed on the surface of the 
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scaffold compared to HaCaT cells, suggesting both electrospun, CEP scaffolds had 
favourable internal structure to support HDF infiltration. This indicates both scaffolds 
could be used to produce a living, skin substitute since scaffolds supported HDF 
infiltration and HaCaT localisation and confluency on the scaffold surface. 
 
Figure 3.22: SEM images of migrating HDFs (yellow arrows) on the top surface of HDF-seeded 
CEP 1 (left column) and CEP 2 (right column) at day 1 (A and B) and day 14 (C and D) post-
seeding. Magnification is 1000× and scale bars are 10 μm. 
CEP 1 CEP 2 
D
ay
 1
4 
D
ay
 1
 
B A 
D C 
 124 
 
Figure 3.23: H&E images of infiltrating HDFs (black arrows) on HDF-seeded CEP 1 (left 
column) and CEP 2 (right column) at day 14 (A and B) and day 28 (C and D) post-seeding. 
Magnification is 20× and scale bars are 200 μm. 
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Figure 3.24: DAPI images of HDF-seeded CEP 1 (left column) and CEP 2 (right column) at 
day 1 (A and B) and day 28 (C and D) post-seeding. Magnification is 10× and scale bars are 
400 μm. 
Previous work with an electrospun, CP scaffold showed no cell infiltration with pore 
diameters in the range of 1.0-13.6 μm (330). The pore diameters of the present CEP 
scaffolds are similar to those of the CP scaffold. Therefore, the HDF infiltration 
observed on CEP scaffolds could be attributed to the elastin in the scaffolds. It has 
been seen the repeating, Val-Gly-Val-Ala-Pro-Gly peptide in elastin is chemotactic for 
fibroblasts and as such the inclusion of elastin during fabrication of the scaffolds 
resulted in fibres with biosignals for the migration of fibroblasts (344). This could be 
confirmed by observing HDF infiltration in different CEP scaffolds with varying 
amounts of elastin. A previous study has also shown a pure elastin scaffold supported 
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cell infiltration with subsequent incorporation of collagen leading to enhanced 
infiltration (273). 
HDF infiltration was also seen to modify the structure of CEP 1 and CEP 2 with fibre 
distribution appearing altered on day 28 compared to the original structure of the 
scaffolds on day 1 (Figure 3.24). Electrospun scaffolds seeded with HDFs lost their 
original shape with non-uniform thickness and varying fibre distribution. The change 
of scaffold structure was more apparent in images of CEP 1 which did not appear as 
a strip of scaffold on day 28 and CEP 2 had large pores and uneven thickness. These 
results could indicate scaffold breakdown and further investigation for the presence of 
enzymes, such as MMPs, would elucidate the cause of scaffold degradation. 
Assessment of HDF numbers on day 1 revealed CEP 1 and CEP 2 had similar cell 
seeding efficiency of 92.8 ± 1.5 % and 92.4 ± 1.4 %, respectively (Figure 3.25). Cell 
proliferation rate showed cell numbers on day 7 were also similar between both 
scaffolds with 20,976 ± 6,101 cells on CEP 1 and 11,968 ± 6,901 cells on CEP 2 
(Figure 3.26). On day 14, CEP 1 had significantly higher cell numbers with  
54,389 ± 5,549 cells compared to 26,715 ± 711 cells on CEP 2 (p<0.001). It was also 
found that CEP 1 had significantly higher numbers of HDFs on day 21 of  
27,781 ± 16.043 cells compared to 153,984 ± 34,064 cells on CEP 2. This result, 
combined with previous data showing CEP 1 had higher HaCaT proliferation on the 
surface, suggested that CEP 1 is more suitable as a skin substitute. A drop in HDF 
numbers was observed on day 28 to 141,921 ± 32,720 cells on CEP 1 and  
142,247 ± 41,657 cells on CEP 2. 
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Figure 3.25: HDF-seeding efficiency on CEP 1 and CEP 2. 
 
Figure 3.26: HDF proliferation over 28 days on CEP 1 and CEP 2 (* p<0.05, ** p<0.01). 
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The increase in cell number from days 7 to 21 support the findings from the histological 
analysis that the electrospun scaffolds provide a favourable environment for HDFs. 
Additionally, the significantly higher number of HDFs on CEP 1 at days 14 and 21 
suggest that the higher collagen content and/or lower PCL content are conducive to 
HDF-scaffold interactions. The unexpected drop in HDFs from day 21 to 28 on both 
scaffolds could result from limited mass transport and nutrition supply to the internal 
area of the scaffold which causes cell death. The reduction of cell number may also 
be explained by the structural change of the scaffold as noticed in the DAPI images 
(Figure 3.24) which leads to closure of pores and a sealed structure inside the 
scaffolds and subsequent cell death. 
3.3.8 Co-culture of HaCaTs and HDFs on CEP 1 and CEP 2 
HDFs were seeded onto CEP 1 or CEP 2 for one week before seeding of HaCaTs. 
Co-culture of skin cells was analysed for cell-scaffold interactions on days 1, 14 and 
28 post-seeding. SEM analysis revealed a confluent layer on day 1 (Figure 3.27A and 
B); however, the two cell types were indistinguishable. The confluent cell layer was 
maintained on days 14 and 28 with the surface appearing rough (Figure 3.27C-F). 
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Figure 3.27: SEM images of the top surface of HaCaT- and HDF-seeded CEP 1 (left column) 
and CEP 2 (right column) at day 1 (A and B), day 14 (C and D) and day 28 (E and F) post-
seeding. Magnification is 1000× and scale bars are 10 μm. 
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Fluorescence analysis showed multilayers and aggregation of cells detached from 
CEP 1 and CEP 2 on day 1 (Figure 3.28A and B). This cell detachment is likely due to 
sample processing since a cell layer was observed attached to the scaffold in the SEM 
images. Partial separation of the HaCaT layer from CEP 2 was also previously noticed 
in DAPI images (Figure 3.19F). Cell layers were absent on days 14 and 28 in DAPI 
images (Figure 3.28C-F). Fluorescence analysis also revealed minimal cell infiltration 
over the 28 days which was unexpected since HDF infiltration was previously 
observed in the HDF-only study, although there appears to be some nuclei fragments 
in the day 28 CEP 2 sample (Figure 3.28F). Moreover, accelerated scaffold expansion 
and breakdown was observed compared to HDF-seeded scaffolds. This breakdown 
of the scaffolds in vitro could be due to the inhibition of ECM deposition as basic 
fibroblast growth factor, secreted by keratinocytes, could inhibit TGF-β1 which 
stimulates production of elastin and collagen type I (345, 346). Rapid scaffold 
degradation is undesirable as it may not provide sufficient mechanical support for cell 
infiltration and tissue regeneration in wound healing. Further modifications such as the 
use of a coaxial electrospinning setup with PCL in one solution and a CE blend in 
another could allow for more durable scaffolds that still provide sufficient biosignals. 
The natural polymer fibres would promote cell attachment and migration and as the 
natural fibres are degraded or subjected to contraction, the PCL-only fibres would 
provide an alternate, more resilient, fibrous network for cell attachment while scaffold 
remodelling occurred.  
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Figure 3.28: DAPI images of HaCaT- and HDF-seeded CEP 1 (left column) and CEP 2 (right 
column) at day 1 (A and B), day 14 (C and D) and day 28 (E and F) post-seeding. Magnification 
is 10× and scale bars are 400 μm. 
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3.4 Summary 
Electrospun, CEP scaffolds were successfully produced with modification of pore 
diameter, porosity and fibre width. Alteration in flow rate, air gap and applied electric 
potential were studied aiming to improve scaffold fabrication. It was found increasing 
natural polymer content and higher flow rates increased pore diameters which could 
result in facilitated cell infiltration and remodelling. Tensile testing of the scaffolds 
revealed the inclusion of elastin produced more elastic scaffolds. CEP 1 and CEP 2 
were chosen based on advantageous morphological and enhanced mechanical 
properties. Investigations with skin cell cultures revealed both scaffolds supported 
formation of a confluent layer of HaCaT cells and full infiltration of HDFs over 28 days; 
however, co-cultures were inconclusive due to processing issues. Both CEP 1 and 
CEP 2 displayed promising cell-scaffold interactions supporting normal cell behaviour; 
however, CEP 1 had higher HaCaT proliferation at all time points and higher 
proliferation of HDFs at some time points. There was also no observable scaffold 
degradation observed by day 28 in either scaffold indicating there was no scaffold 
remodelling biodegradation occurring in vitro. This could be attributed to increased 
protein stability of the scaffold from cross-linking. The two scaffolds are good 
candidates for further testing using animal models to examine biocompatibility. 
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Chapter 4  Morphological characterisation and cell-
interactive properties of novel elastin-Integra 
Dermal Regeneration Template 
4.1 Introduction 
Burn injuries are some of the most traumatic and debilitating injuries, but with improved 
intensive care and advances in surgical techniques patients can survive burns 
affecting over 90 % TBSA (183). The gold-standard treatment for burn injuries are 
autologous skin grafts harvested from healthy, undamaged sites. However, patients 
with severe burn injuries affecting over 50 % TBSA lack donor sites. Skin substitutes 
have been developed to address this shortage, but patients can still suffer from a loss 
in skin functionality, especially elasticity and flexibility. 
4.1.1 IDRT 
IDRT is an acellular, bilaminar, dermal substitute first introduced in 1977 (347). The 
substitute is a lyophilised scaffold cross-linked with glutaraldehyde (82) consisting of 
a matrix of bovine, collagen type I and a shark GAG, chondroitin 6-sulphate, in a ratio 
of 92:8 with a temporary, artificial, epidermal layer of silicone bonded to the collagen 
matrix (348). Once the matrix is vascularised the silicone layer can be removed and 
covered with a thin split-thickness autograft to form the epidermal layer (349). In 2010 
a single-layer IDRT was released consisting of only the collagen-GAG matrix. Single-
layer IDRT was designed for use in conjunction with IDRT to fill deeper wounds, but 
has since been used in one-step grafting procedures (349, 350). 
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IDRT was intended for use on burn survivors of partial- to full-thickness, extensive, 
life-threatening injuries who had insufficient skin donor sites for autografting (348). The 
immediate issues of massive infection and severe fluid loss were taken into 
consideration during its design while also addressing the long-term issues of 
disfiguring scars and crippling contractures (84). In the years since, IDRT has been 
used not only for burn survivors but in a wide array of circumstances in which skin 
substitutes are needed such as deglovement injuries (351), scar contracture release 
procedures (352), excision of giant nevi (353) and skin avulsion injuries (350). IDRT 
allows for wound bed regeneration and its effectiveness has been shown by its higher 
elasticity compared to split-thickness skin grafts in vivo (354). It has also been shown 
to result in a thicker dermis compared to MatriDerm, a non-cross-linked matrix of 
collagens type I, II and V coated with α-elastin hydrolysate from bovine ligamentum 
nuchae, in animal models (355). 
However, newly produced skin is not always morphologically or functionally normal 
(73, 101) with new skin having reduced elastic function in comparison to normal skin 
in the long-term (356). A study revealed IDRT induced more foreign body reaction than 
Alloderm (LifeCell, Branchburg, NJ, USA) due to macrophages clearing the cross-
linked IDRT in a mouse model (357). Another study compared IDRT to an artificial, 
dermal substitute called Hyalomatrix (Anika, Therapeutics Bedford, MA, USA), which 
has a dermal layer of hyaluronic acid derivative and an epidermal layer of 
semipermeable silicone. It was found that Hyalomatrix had better cell regulation and 
stimulatory activity resulting in better deposition of ECM (354). Clearly, there are still 
aspects of IDRT that can be improved, especially in regards to cell-scaffold 
interactions. The presence of elastin in the scaffold could achieve this by not only 
 136 
increasing elasticity of the substitute but also by improving fibroblast infiltration and 
thereby wound healing. 
4.1.2 Recombinant, human tropoelastin 
Elastin is a major component of elastic fibres and is formed through the cross-linking 
of its precursor tropoelastin, a 60-70 kDa protein depending on splice variants (176). 
Tropoelastin is encoded by separate exons and characterised by alternating 
hydrophobic and hydrophilic domains (178). The hydrophobic domains are involved in 
monomer association in solution and also elastic function of elastin while the 
hydrophilic domains are implicated in polymerisation of the monomer through cross-
linking (179). 
Elastin is a durable protein with a half-life of approximately 70 years (181) and is mainly 
formed during late fetal and early neonatal periods (183). It is synthesised from several 
cell types including fibroblasts (181). Elastin is a key structural and mechanical 
component in the elastic-fibre network which gives skin its resilience, texture and 
quality while also possessing cell signalling properties which promote cell responses 
such as cell attachment, proliferation and differentiation (358-362). Previous studies 
have shown scaffolds electrospun from tropoelastin have similar stiffness to native 
elastin and that these electrospun scaffolds support fibroblast infiltration, fibroblast 
persistence and scaffold remodelling in vitro (338). Further studies have shown that 
these electrospun scaffolds also enhanced fibroblast proliferation and migration in vitro 
compared to IDRT and in vivo the electrospun, tropoelastin scaffolds also supported 
fibroblast infiltration, collagen deposition and angiogenesis (273). 
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4.1.3 Aims 
The well-established use of IDRT in a clinical setting has elucidated properties that 
can be improved. It is with this knowledge the elastin-modified version of IDRT, called 
EDRT, has been developed by incorporating 10 % (w/w) recombinant, human 
tropoelastin, purified from Escherichia coli as previously described (363, 364), during 
fabrication. The aim of this chapter was to characterise the morphological, mechanical 
and cell-interactive changes from the presence of elastin in the substitute. 
4.2 Methods 
Please refer to section 2.2.2 for all protocols used in this study. 
4.3 Results and Discussion 
4.3.1 Pore diameter and porosity of EDRT and IDRT 
EDRT and IDRT displayed soft, hydrogel characteristics (Figure 4.1). SEM analysis of 
EDRT and IDRT revealed both scaffolds had a network of fibrous material resembling 
a sponge (Figures 4.2). The pores of both scaffolds were irregular in both shape and 
size as well as being interconnected. Quantification of the range of pore diameters 
revealed IDRT had average pore diameters of 272.5 ± 65.0 μm. Comparatively, 
inclusion of 10 % tropoelastin during fabrication significantly increased average pore 
size to 375.0 ± 48.4 μm in EDRT (p<0.05; Figure 4.3). 
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Figure 4.1: Photographs of EDRT (A) and IDRT (B) sections. 
 
Figure 4.2: SEM images of the surface of acellular EDRT (A) and IDRT (B) showing pore 
diameter (blue lines). Magnification is 100× and scale bars are 100 μm. 
A B 
A B 
 139 
 
Figure 4.3: Average pore diameters of EDRT and IDRT (* p<0.05). 
Porosity was visualised by converting H&E stained cross-sections of EDRT and IDRT 
to binary images (Figures 4.4). The porosity of EDRT was shown to be significantly 
higher at 88.3 ± 2.4 % compared to IDRT at 83.8 ± 2.7 % (p<0.01; Figure 4.5) which 
is in accordance with the significantly larger macropores observed in EDRT. The larger 
pores and subsequently higher porosity observed in EDRT could be attributed to the 
suspected increased elasticity, imparted by the presence of elastin, resulting in a more 
flexible fibrous network. Mechanical tests will be conducted to examine scaffold 
elasticity and rigidity. H&E analysis confirmed SEM results that elastin had no effect 
on IDRT structure with both scaffolds displaying a sponge-like appearance (Figure 
4.2). 
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Figure 4.4: H&E images (A and B) of EDRT (left column) and IDRT (right column) converted 
to binary images (right column) for quantification of porosity. 
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Figure 4.5: Porosity of EDRT and IDRT calculated from binary images (** p<0.01). 
4.3.2 Mechanical properties of EDRT and IDRT 
Mechanical properties of the scaffolds were investigated using compression tests. 
IDRT had a compressive Young’s modulus of 3.1 ± 0.9 kPa which was significantly 
higher than EDRT’s at 1.1 ± 0.3 kPa (p<0.001) (Figure 4.7). revealing that the addition 
of 10 % (w/w) tropoelastin increased rigidity of IDRT. This is in line with a previous 
study which found an electrospun, CE scaffold was stiffer than an elastin-only scaffold 
(365). From a mechanical perspective, a lower stiffness indicates that EDRT deforms 
more than IDRT under the same loading. From a materials perspective, it suggested 
that the EDRT scaffolds has a lower degree of cross-linking and a higher swelling ratio, 
which would translate into less resistance to compression and the reduced hysteresis 
(Figure 4.6). 
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Figure 4.6: Compressive stress-strain curve of EDRT and IDRT scaffolds (366). 
 
Figure 4.7: Graphical representation of the compressive Young’s modulus, calculated in the 
linear region of 0.05-0.1 mm/mm from Figure 4.6 of EDRT and IDRT scaffolds (*** p<0.001) 
(366). 
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Figure 4.8: Graphical representation of the energy loss in 0.25 mm/mm strain level from Figure 
4.6 of EDRT and IDRT scaffolds (** p<0.01) (366). 
The ultimate compressive strain results revealed that EDRT had significantly higher 
elasticity of 0.37 ± 0.02 % compared to IDRT 0.26 ± 0.02 % (p<0.01; Figure 4.9) which 
again translates into a better skin substitute as increased flexibility and elasticity of the 
scaffold allows higher deformability. The confirmation of increased elasticity of EDRT 
could account for the larger pores observed in EDRT providing more flexibility and 
deformability to relieve stress within the network. 
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Figure 4.9: Graphical representation of the ultimate compressive strain of EDRT and IDRT 
scaffolds (** p<0.01) (366). 
4.3.3 HaCaT behaviour on EDRT and IDRT 
Cell-seeding efficiency was examined at 24 hrs. The results showed both scaffolds 
had a high level of HaCaT attachment with seeding efficiency over 92 %, but IDRT 
was shown to have a slightly higher efficiency with 96.9 ± 0.2 % compared to EDRT, 
92.6 ± 0.6 % (p<0.001; Figure 4.10) which could be due to the smaller average pore 
size of IDRT resulting in more cells being captured in the scaffold. 
HaCaT proliferation was assessed over 28 days and cell numbers gradually increased 
on scaffolds with 131,773 ± 4,531 cells on EDRT on day 7 to 148,488 ± 16,729 cells 
on day 14 followed by a large increase to 486,940 ± 36,047 cells on day 21 and 
584,483 ± 17,277 cells on day 28 (Figure 4.11). Likewise, on IDRT had  
136,200 ± 9,029 cells on day 7 with an increase to 153,129 ± 6,702 cells on day 14 
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and larges increase on day 21 to 407,590 ± 15,529 cells and 560,837 ± 56,292 cells 
on day 28 (Figure 4.11). There were no significant differences observed in cell 
numbers between EDRT and IDRT at all-time points or between time points. 
 
Figure 4.10: Cell-seeding efficiency of HaCaTs on EDRT and IDRT (*** p<0.001). 
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Figure 4.11: HaCaT proliferation over 28 days on EDRT and IDRT. 
HaCaTs were seeded onto the top surface of EDRT and IDRT to examine cell-scaffold 
interactions including cell attachment, proliferation and migration. SEM analysis 
revealed HaCaTs attached to the surface of both scaffolds within 24 hrs and began to 
form bridges between cells covering the interfibre spaces (Figure 4.12, orange 
arrows). These bridges suggested that EDRT and IDRT have favourable surfaces 
which can support HaCaT attachment and migration to form a confluent layer (342). 
Formation of a subconfluent cell layer likely occurred through cell migration rather than 
cell proliferation as the culture period was too short for exponential cell proliferation to 
have begun (367). By day 14 post-seeding, HaCaTs had formed confluent layers on 
the scaffold surfaces with no cellular bridges or scaffold pores evident. EDRT also had 
the characteristic rough surface of keratinocytes. This rough surface was likely due to 
the ongoing development of an epithelial layer of HaCaTs forming a differentiated 
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epithelium. This behaviour has been previously observed on collagen gels in vitro 
(282). 
 
Figure 4.12: SEM images of cellular bridges (orange arrows) on the top surface of HaCaT-
seeded EDRT (left column) and IDRT (right column) at day 1 (A and B) and day 14 (C and D) 
post-seeding. Magnification is 1000× and scale bars are 10 μm. 
In H&E-stained cross-sections, cells appeared as purple spots (Figure 4.13, orange 
arrows). A partial layer of HaCaTs was observed on the surface of EDRT on day 1 
post-seeding (Figure 4.13A); however, on day 14 no cell layer was found (Figure 4.13B 
and C) and there was also no cell layer observed on IDRT at all-time points (Figure 
4.13B, D and F). 
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Figure 4.13: H&E staining of cells stained purple (orange arrows) and tissue deposition 
remnants (green arrows) on HaCaT-seeded EDRT (left column) and IDRT (right column) at 
day 1 (A and B), day 14 (C and D) and day 28 (E and F) post-seeding. Magnification is 20× 
and scale bars are 200 μm. 
This lack of cell layer is suspected to result from separation of the cells from the 
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SEM images (Figure 4.12). This cell layer separation was previously observed in CEP 
scaffolds (Figure 3.27A and B) and in these H&E images there appear to be remnants 
of tissue deposition (Figure 4.13, green arrows). However, separation cannot be 
confirmed for EDRT and IDRT as there were images showing this occurrence. 
In both H&E and DAPI imaging HaCaTs were observed inside the scaffolds and DAPI 
staining revealed HaCaTs were more concentrated at the surface of EDRT in 
comparison to an even distribution of HaCaTs throughout IDRT (Figure 4.14). This 
could be attributed to migration of HaCaTs toward the surface of EDRT as elastin 
peptides, possibly generated from cellular elastin breakdown, can have chemotactic 
effects on keratinocytes (360). 
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Figure 4.14: DAPI images of HaCaTs (orange arrows) on HaCaT-seeded EDRT (left column) 
and IDRT (right column) at day 1 (A and B), day 14 (C and D) and day 28 (E and F) post-
seeding. Magnification is 10× and scale bars are 400 μm. 
With increased pore size, EDRT was expected to show higher dispersal of HaCaTs 
but surprisingly, EDRT appeared to have better localisation of HaCaTs at the scaffold 
surface. These results indicate the presence of elastin may have been responsible for 
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promoting HaCaT attachment, migration and/or cellular interactions thereby enabling 
the formation of an epithelial layer. The proliferation study showed no difference in cell 
numbers further indicating that the locations of the HaCaTs were critical to the 
formation of the epithelial layer as similar cell numbers alone on IDRT was insufficient. 
The accelerated development of an epithelial layer on EDRT is an encouraging result 
as this could translate into faster re-epithelialisation and wound healing in vivo. 
4.3.4 HDF behaviour on EDRT and IDRT 
Seeding of HDFs on EDRT had 120 ± 7.99 % efficiency in comparison to IDRT which 
had a cell-seeding efficiency recorded at 92.78 ± 6.79 % (Figure 4.15); however, there 
was no significant difference observed in the data. HDF proliferation was monitored 
over 28 days with cell numbers consistently increasing on EDRT over 28 days from 
229,645 ± 27,351 cells on day 7, 325,026 ± 32,765 cells on day 14 to  
342,962 ± 18,022 cells on day 21 and 491,480 ± 35,294 cells on day 28 (Figure 4.16). 
In contrast, IDRT showed a reduction of cell numbers from days 7 to 21 with a drop in 
cell number from 293,000 ± 46,500 cells on day 7 to 254,666 ± 41,353 cells on day 14 
and then to 233,639 ± 394 cells on day 21. However, an increase in cell number was 
observed from day 21 to 300,859 ± 26,521 cells on day 28 (Figure 4.16). EDRT was 
also observed to have significantly higher numbers of HDFs than IDRT on days 21 
and 28. 
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Figure 4.15: HDF-seeding efficiency on EDRT and IDRT. 
 
Figure 4.16: HDF proliferation over 28 days on EDRT and IDRT (* p,0.05, ** p,0.01) 
(366). 
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The improved proliferation of HDFs on EDRT could be attributed to the inclusion of 
tropoelastin during fabrication, which can promote cell interactions as shown in a 
previous study (368). Other studies have shown that a larger surface area to volume 
ratio, as seen in EDRT, can also be conducive to promoting cell proliferation (257). 
Significantly increased cell numbers on EDRT are likely to yield faster ECM production 
and remodelling in vivo thereby accelerating wound healing and take of skin grafts in 
burn survivors. 
HDF interactions with EDRT and IDRT were also investigated by droplet-seeding 
HDFs onto the scaffolds and examining seeded-scaffolds. Using DAPI staining, HDFs 
were seen to infiltrate both scaffolds on day 7 (Figure 4.17A and B). Cells migrated 
through EDRT to approximately 250 μm on day 7 (Figure 4.17A). In contrast, most of 
the HDFs remained on the seeded surface of IDRT on day 7 (Figure 4.1B). On days 
14 and 21 post-seeding, cells had distributed through the entire EDRT scaffold (Figure 
4.17C and E) but on IDRT remained near the surface with a few cells migrating  
200 μm into the scaffold (Figure 4.17D and F). This enhanced infiltration in EDRT 
could be attributed to the presence of elastin in the scaffold providing biosignals and 
altering structure. It has been observed that interconnecting pores and open interfibre 
spaces are key to controlling cell migration in addition to influencing tissue ingrowth, 
nutrient supply to cells, metabolic dispersal, local pH stability and cell signalling (369). 
Therefore, the significantly enlarged pore size and higher porosity observed in EDRT 
could have promoted cell infiltration and migration. Although, previous studies have 
shown the optimal pore size for HDF attachment and migration was smaller than  
160 μm in PLA and PLGA scaffolds (274), these results show that enhanced cell 
infiltration was attainable on EDRT with pore diameters of 375.0 ± 48.4 μm. 
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Figure 4.17: DAPI images of HDFs (orange arrows) on HDF-seeded EDRT (left column) and 
IDRT (right column) at day 7 (A and B), day 14 (C and D) and day 21 (E and F) post-seeding. 
Magnification 10× and scale bars are 50 and 100 μm (366). 
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 HDF-induced contraction of EDRT and IDRT 
HDF infiltration and proliferation on scaffolds can cause scaffold contraction. Therefore, 
scaffold area of EDRT and IDRT was measured over 12 weeks. No contraction was 
observed over the short-term 28 day period (Figure 4.18) or long-term 12 week period 
(Figure 4.19) for both scaffolds. Surprisingly, EDRT and IDRT swelled in cell culture 
media and expanded up to 15 % of its original size for EDRT and 8 % of its original 
size for IDRT. This lack of HDF-induced contraction could be due to a lack of 
fibroblasts differentiating into contractile myofibroblasts in vitro. These processes 
usually follow inflammatory events (370) which are absent in vitro. 
 
Figure 4.18: Scaffold contraction of EDRT and IDRT during HDF culture over 28 days (366). 
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Figure 4.19: Scaffold contraction of EDRT and IDRT during HDF culture over 12 weeks. 
4.3.5 Co-culture of HaCaTs and HDFs on EDRT and IDRT 
HaCaTs were seeded onto the same side of scaffolds as HDFs one week after seeding 
of HDFs. SEM analysis of scaffolds at day 1 showed formation of a cell layer with 
migrating cells observed on EDRT (Figure 4.20A, orange arrows); however, HDFs 
could not be distinguished from HaCaTs. On day 14, a flat cell layer was observed 
with a rough appearance (Figure 4.20C and D), which as described in the HaCaT 
culture, and is likely due to a developing epithelial layer (282). The small gaps in the 
cell layer on day 14 (Figure 4.20C and D, yellow arrows) confirms the presence of 
epithelial bridges as cells are subjected to high tension and when cell division occurs 
this can result in holes forming (342). By day 28 the surfaces of the cell layers were 
clearly rough, more so on EDRT than IDRT (Figure 4.20E and F), which is consistent 
with the more advanced epithelial layer development previously observed on EDRT in 
the HaCaT culture (Figure 4.12). 
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H&E analysis of cross-sections confirmed a confluent layer of cells on both scaffolds 
at day 1 (Figure 4.21A and B, orange arrows); however, on days 14 and 28 scaffolds 
appeared to have had some cells removed from the surface as deposited tissue was 
observed (Figure 4.21, green arrows) on sections of the scaffold surface with some 
cells present. DAPI staining confirmed the presence of cells at the surface of the 
scaffold and more clearly highlighted some cell infiltration on all scaffolds at all-time 
points (Figure 4.22). The cell infiltration is unlikely to result from active cell migration 
into the scaffold as the depth of infiltration and number of cells appears consistent 
throughout the 28 days indicating it was more likely the cells fell through the pores 
during seeding.  
Epithelial development appeared more advanced in the co-culture compared to the 
HaCaT culture with a rougher surface observed. This improvement is in accordance 
with previous studies which have shown both cell types are necessary for the 
development of normal epidermal morphogenesis (371, 372). Further analysis of cell 
distribution via cell specific stains could not be conducted due to separation of the cell 
layer from the scaffolds during sample preparation or from loss of cell attachment to 
the scaffold surfaces. 
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Figure 4.20: SEM images of migrating cells (orange arrows) and gaps in the cell layer (yellow 
arrows) on the top surface of HaCaT- and HDF-seeded EDRT (left column) and IDRT (right 
column) at day 1 (A and B), day 14 (C and D) and day 28 (E and F) post-seeding. Magnification 
is 1000× and scale bars are 10 μm. 
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Figure 4.21: H&E images of confluent cell layers (orange arrows) and deposited tissue (green 
arrow) on HaCaT- and HDF-seeded EDRT (left column) and IDRT (right column) at day 1 (A 
and B), day 14 (C and D) and day 28 (E and F) post-seeding. Magnification is 20× and scale 
bars are 200 μm. 
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Figure 4.22: DAPI images of cells (orange arrows) on HaCaT- and HDF-seeded EDRT (left 
column) and IDRT (right column) at day 1 (A and B), day 14 (C and C) and day 28 (E and F) 
post-seeding. Magnification is 10× and scale bars are 400 μm. 
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4.4 Summary  
The inclusion of tropoelastin in the commercial dermal substitute, IDRT, to form EDRT 
had no effects on integrity of the scaffolds while significantly enlarging average pore 
diameter, increasing porosity and increasing deformability. EDRT also displayed more 
advanced epithelial development, accelerated HDF infiltration and improved HDF 
proliferation in vitro; however, similar to the electrospun CEP scaffolds there was no 
significant degradation of IDRT or EDRT observed during the study period. Overall, 
EDRT has great potential as a novel dermal substitute to improve elasticity and 
accelerate healing of severe burn injuries. 
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Chapter 5  Animal studies of novel, skin substitutes 
5.1 Introduction 
Safety and efficacy of a skin substitute is of the utmost importance. The effects and 
outcomes of a substitute on the wound, and the body, must be predictable. Without 
such predictability, a substitute cannot be responsibly used in treatment. As such, a 
crucial step in the development of skin substitutes is the investigation of their 
performance in a controllable environment. Unfortunately, there are no in vitro systems 
which accurately replicate the human system. Therefore, mammalian animal models 
representative of the human system are utilised to investigate potential, skin 
substitutes and examine host response to substitute properties such as the materials 
used for fabrication. Common models employed in skin tissue engineering are mouse, 
rat and pig models. 
Mouse models are frequently utilised to study skin substitutes as they are economical, 
handling of mice requires little training and mice are relatively easy to house and 
maintain. The structure and the function of mouse skin are similar to humans with an 
outermost epidermis and inner dermis which is attached to adipose tissue (Figure 5.1). 
However, there are several points of difference such as: the epidermis of mice is much 
thinner than humans with fewer cell layers; the dermis is also thinner and lacks rete 
ridges; mice have more densely packed hair follicles; and immune systems in mice 
contain different cells such as Mast and γδ T cells (373) (Figure 5.1). In addition to 
this, wound healing in mice occurs primarily by contraction as the skin is loosely 
connected to the subcutaneous connective tissue whereas humans heal by  
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re-epithelialisation due to firmly-attached skin (Table 5.1). These differences can result 
in responses which vary from humans but for use in characterisation of substitutes, 
and first in vivo assessment of biosafety and efficacy, mouse models are ideal. 
 
Figure 5.1: Schematic of mouse skin (A) and human skin (B) illustrating differences in structure 
and immune cell types (373). 
  
A   Mouse skin B   Human skin 
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Table 5.1: Comparison between human, mouse and pig skin anatomy and physiology. 
Adapted from (374). 
Criteria Human Mouse Pig 
Skin attachment Firmly attached Loosely attached Firmly attached 
Hair coat Sparse Dense (except some breeds) Sparse 
Epidermis Thick Thin Thick 
Dermis Thick Thin Thick 
Panniculus 
carnosus Absent Present Absent 
Healing 
mechanism Re-epithelialisation Contraction Re-epithelialisation 
Pig model studies commonly follow on from mouse model studies as a tool to further, 
and more accurately, characterise potential skin substitutes. The structure of pig skin 
has similar thickness of the epidermal and dermal layers to human skin; however, the 
adipose tissue layer is generally thicker than in humans (374). Further similarities arise 
in the wound healing mechanisms with wound healing in pigs proceeding via  
re-epithelisation as pig skin is also firmly attached to the subcutaneous layer as seen 
in humans (Table 5.1). Despite the similarities between human skin and pig skin, pig 
models are used at a later stage of characterisation due to the expense incurred.  
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5.1.1 Established mouse models 
Different mouse models have been established to examine potential, skin substitutes. 
One study used a subcutaneous implant model in Balb/c mice to investigate host 
response to an electrospun, CE scaffold (273). Scaffolds were implanted through  
1 cm incisions in the dorsal area of male and female mice and skin biopsies were 
collected 6 weeks post-implantation for histological analysis. This model allowed 
visualisation of responses such as mild inflammation, cell infiltration, ECM protein 
deposition and angiogenesis. 
A substrain of Balb/c mice, called Balb/c nude, have been used in another study to 
examine a living, skin substitute (375). This strain of mouse is immunodeficient and 
was specifically chosen as human cells were used in the construction of the living 
substitute using acellular, dermal matrix of porcine origin. Hair follicle stem cells or 
immortalised bulge stem cells formed the epidermal layer and dermal papilla cells or 
dermal fibroblasts formed the dermal layer. Full-thickness, skin wounds were excised 
on the dorsal area of each mouse and substitutes grafted using an auto-adhesive, 
polyurethane, transparent bandage. This model revealed the development of 
embryonic, hair bud-like structures from human, dermal papilla cell-containing 
constructs in vivo without immune rejection. Other studies have also used skin 
excision procedures in athymic mice: one to evaluate mechanical properties, such as 
tensile strength and elasticity, by uniaxial tensile testing of substitutes after grafting 
(376); and another to examine wound contraction of scaffolds produced using different 
techniques by photographing and tracing wounds which were quantified using 
computer planimetry (278). 
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Another model of full-thickness, skin excision grafting has been examined in Balb/c 
and C57BL/6 mice in which wounds are splinted to prevent wound healing by 
contraction (377). This results in a healing process more like humans in which new 
tissue is generated through granulation and re-epithelialisation as skin is tethered to 
subcutaneous tissue (378-381). Wound closure can be photographed, as in non-
splinted wounds, with variations in contraction arising from skin contraction, animal 
posture and motion and wound dressing minimised (377) and after transplantation of 
living, skin substitutes cells can also be tracked via markers such as fluorescent 
protein gene (378, 382) or fluorescent dye (383). 
The use of mouse models is common and the choice of model depends on the 
characterisation required: subcutaneous models are ideal for examining host 
responses such as inflammation, immune response and cell-scaffold interactions to 
new substitutes; non-splinted grafting is sufficient for analysis of cytokines and gene 
or protein expression; and splinted grafting is useful for examination of wound closure 
in an environment more like human wound healing. 
5.1.2 Aims 
The previous studies investigated the morphological, mechanical and cell-interactive 
properties of two electrospun, CEP scaffolds in Chapter 3 and lyophilised EDRT in 
Chapter 4. The aim of this study was the characterisation of these novel, scaffolds 
using two established models: firstly, a subcutaneous implant, mouse model was 
chosen for examining the biosafety and efficacy of the electrospun and lyophilised 
scaffolds in wound healing by examining ECM deposition, scaffold remodelling and 
collagen and elastin gene expression; and secondly a full-thickness skin excision 
model was used to assess contraction and angiogenesis in EDRT. 
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5.2 Methods 
Please refer to section 2.2.3 for all protocols used in this study. 
5.3 Results and Discussion 
5.3.1 Host response to CEP 1 and CEP 2 in an established, subcutaneous 
implant model in mice 
Electrospun scaffolds were examined in vivo using an implantation model with skin 
biopsies collected weeks 1, 2, 4, 12 and 24 post-surgery. H&E staining of cross-
sections visualised cell infiltration of scaffolds by staining nucleic acids purple and 
scaffolds pink or light purple. Cells completely infiltrated both CEP 1 and CEP 2 at 
week 1 post-surgery (Figure 5.2A and B, purple spots) and vascularisation was 
observed in CEP 1 at 2 weeks with blood cells staining bright pink (Figure 5.2C, black 
arrows). By week 4, CEP 1 was fragmented (Figure 5.2E, green arrows), 
comparatively CEP 2 retained scaffold structure with no fragmentation (Figure 5.2F). 
No further degradation of CEP 1 fragments was seen at weeks 12 and 24 post-surgery 
(Figure 5.2G and J). 
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Figure 5.2: H&E images of pink blood vessels (black arrows), scaffold fragments (green 
arrows), inflammation (circled in green) and scaffold remodelling (circled in black) on 
implanted CEP 1 (left column) and CEP 2 (right column) at week 1 (A and B), week 2 (C and 
D), week 4 (E and F), week 12 (G and H) and week 24 (J and K) post-surgery. Magnification 
is 20× and scale bars are 100 μm. 
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The rapid vascularisation of CEP 1 seen at 2 weeks post-surgery is an encouraging 
result for the treatment of full-thickness burn wounds which characteristically lack 
sufficient blood vessels; however, CEP 1 also underwent rapid scaffold fragmentation 
with no remodelling observed. Comparatively, no vascularisation of CEP 2 was 
observed over the 24 week period and scaffold remodelling was evident at 12 weeks 
(Figure 5.2H, circled in black) with tissue deposition observed at the edges and small 
pockets of tissue stained pink throughout the scaffold. Scaffold remodelling became 
more evident at 24 weeks with remodelling observed in the middle of the scaffold 
(Figure 5.2K, circled in black). Limited scaffold degradation was likely due to the high 
presence of elastin preventing replacement by tissue due to elastin’s long half-life of 
approximately 70 years (183). No inflammation was observed in both scaffolds at week 
1 (Figure 5.2A and B), but there appeared to be minimal inflammation at week 2 in 
CEP 2, indicated by dense purple staining of cells (Figure 5.2D, circled in black). 
Masson’s Trichrome staining of the skin biopsies stained all collagens turquoise, 
nucleic acids purple and muscle and blood cells bright pink. Presence of scaffold 
collagen could be seen at weeks 1 and 2 post-surgery with a turquoise hue to the 
scaffolds (Figure 5.3 A-D). At week 2 post-surgery collagen degradation appeared to 
have occurred with the turquoise stain slightly fainter (Figure 5.3C and D). The inferred 
degradation of scaffold rat tail collagen could account for the minimal inflammation 
previously observed in H&E stained sections (Figure 5.2D). By weeks 4 and 12 the 
turquoise hue was less pronounced indicating a further decrease in scaffold collagen 
likely due to continued degradation (Figure 5.3 E-H). By week 24 the purple staining 
of the scaffold fibres indicated there was no collagen present in scaffolds which could 
be due to the scaffold structure of CEP 1 and CEP 2 providing sufficient structural 
support for cells to the extent that tissue deposition by infiltrated cells was unnecessary 
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(Figure 5.3J and K). However, the persistence of the scaffold indicates the scaffold 
was not degraded due to the high elastin content. Collagen deposition was observed 
from week 4 onwards in tissue encapsulating both scaffolds (Figure 5.3E and F) and, 
more importantly, in newly deposited tissue from scaffold remodelling of CEP 2 at 
weeks 12 and 24 stained a faint turquoise (Figure 5.3H and K, circled in black).  
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Figure 5.3: Masson Trichrome images of scaffold remodelling (circled in black) on implanted 
CEP 1 (left column) and CEP 2 (right column) at week 1 (A and B), week 2 (C and D), week 4 
(E and F), week 12 (G and H) and week 24 (J and K) post-surgery. Magnification is 20× and 
scale bars are 100 μm. 
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IHC staining for elastin was performed to visualise elastin as a brown stain and thereby 
examine the presence of elastin. The bovine elastin used to produce the electrospun 
scaffolds was observed at almost all-time points in CEP 1 except at week 4 (Figure 
5.4 left column). The lack of elastin at week 4 is likely due to rapid fragmentation and 
clearance of the CEP 1 fragments since elastin has a half-life of approximately  
70 years (384). This also indicates CEP 1 had varying rates of scaffold degradation in 
vivo since scaffold elastin was observed in skin biopsies collected at weeks 12 and 
24. The rapid and variable degradation rate of CEP 1 is extremely undesirable in the 
treatment of burn injuries since persistence of the scaffold would be unpredictable and 
provide insufficient time for wound repair. Comparatively, elastin was observed at all-
time points in CEP 2 indicating the structure of CEP 2 is more stable allowing for 
scaffold degradation and remodelling to transpire concurrently. 
There were very small amounts of elastin observed in newly deposited tissue at week 
4 from encapsulation but this was unsurprising as a previous study found regeneration 
of fibres of elastin was not observed until up to several years after treatment (385). 
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Figure 5.4: IHC elastin images of implanted CEP 1 (left column) and CEP 2 (right column) at 
week 1 (A and B), week 2 (C and D), week 4 (E and F), week 12 (G and H) and week 24 (J 
and K) post-surgery. Magnification is 20× and scale bars are 100 μm. 
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Further analysis of the impact of CEP 1 and CEP 2 after implantation was conducted 
by examining gene expression of collagen and elastin. Of the different collagens found 
in skin, collagen type I was investigated as it is the major isotype of skin dermis (386) 
and the gene encoding the α1 chain, COL1A1, was chosen for qPCR analysis. 
Collagen type I expression had no significant differences between CEP 1 and CEP 2 
at all-time points and expression was consistent over the 24 week period in both 
scaffolds (Figure 5.5). There was also no difference in elastin expression between the 
two scaffolds at all-time points but there was a significantly higher level of expression 
at week 4 compared to week 1 in both scaffolds (p<0.05) and higher non-significant 
elastin expression at 12 and 24 weeks (Figure 5.6). The increased elastin expression 
at week 4 could be attributed to the presence of elastin degradation products 
stimulating elastin expression as scaffold breakdown was observed from 2 weeks 
onwards in CEP 1 and 4 weeks onwards in CEP 2 (Figure 5.4). This is in accordance 
with a previous studies which observed increased elastin synthesis by pulmonary 
fibroblasts with damaged ECM (387) and also that the presence of enzymatic elastin 
products can have stimulatory effects on elastin production (187). 
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Figure 5.5: Gene expression analysis of COL1A1 by qPCR in skin biopsies of CEP 1 and CEP 
2 at weeks 1, 2, 4, 12 and 24 post-implantation (n=2-4). 
 
Figure 5.6: Gene expression analysis of elastin by qPCR in skin biopsies of CEP 1 and CEP 
2 at weeks 1, 2, 4, 12 and 24 post-implantation (* p<0.05) (n=2-4). 
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5.3.2 Host response to EDRT and IDRT in an established, subcutaneous 
implant model in mice 
Cell interactions on lyophilised scaffolds were examined using the subcutaneous 
model previously described for the electrospun scaffolds. Skin biopsies were collected 
weeks 1, 2, 4, 12 and 24 post-surgery with H&E staining performed to visualise cell 
distribution throughout the scaffolds. Purple-stained cells could be seen distributed 
throughout both EDRT and IDRT at week 1 with new tissue deposition evident by pink 
webs of fine fibres in between thicker scaffold fibres (Figure 5.7A and B). By week 2 
more cells were located in both scaffolds with increased amounts of tissue deposition 
(Figure 5.7C and D). From week 4 onwards, tissue deposition progressively increased 
with similar amounts of tissue deposition in both scaffolds at 24 weeks with dense 
webs of fine, pink fibres observed (Figure 5.7E-K). 
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Figure 5.7: H&E images of implanted EDRT (left column) and IDRT (right column) at week 1 
(A and B), week 2 (C and D), week 4 (E and F), week 12 (G and H) and week 24 (J and K) 
post-surgery. Magnification is 20× and scale bars are 100 μm. 
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Masson’s Trichrome staining confirmed the presence of scaffold collagen in both 
EDRT and IDRT with thick scaffold fibres staining turquoise and no collagen 
degradation observed at all times points (Figure 5.8). Newly deposited tissue in weeks 
1 and 2 post-surgery did not appear to contain collagen with fine fibres staining purple 
(Figure 5.8A-D), but at week 4 fine fibres had a turquoise tinge indicating the 
deposition of collagen by cells as part of the new ECM (Figure 5.8 E and F). It is likely 
collagen deposition had begun to occur earlier, since cells begin to remodel wounds 
after a few days (388), but the amount of collagen was too small to be viewed by 
microscopy. New tissue was clearly staining turquoise at weeks 12 and 24 showing 
increased collagen content at later time points (Figure 5.8G-K). Some vascularisation 
of EDRT was observed at week 2 and in IDRT at week 4 with blood cells staining 
bright pink. Angiogenesis in EDRT and IDRT was further examined in vivo using a 
one-step grafting model as described later in section 5.3.3.1. Gene expression 
analysis of COL1A1 confirmed the consistent expression of collagen over the 24 week 
period with no significant differences observed between EDRT and IDRT or between 
weeks (Figure 5.9). 
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Figure 5.8: Masson Trichrome images of implanted EDRT (left column) and IDRT (right 
column) at week 1 (A and B), week 2 (C and D), week 4 (E and F), week 12 (G and H) and 
week 24 (J and K) post-surgery. Magnification is 20× and scale bars are 100 μm. 
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Figure 5.9: Gene expression analysis of COL1A1 by qPCR in skin biopsies of EDRT and IDRT 
at weeks 1, 2, 4, 12 and 24 post-implantation. 
In addition to collagen, the ECM protein elastin was investigated using IHC with elastin 
appearing brown. As expected fibres of EDRT stained brown at all-time points 
confirming the presence of elastin in the EDRT scaffold whereas IDRT stained a faint 
purple from haematoxylin counterstaining due to absence of elastin. Elastin deposition 
was not observed in either scaffold at week 1 nor in EDRT at week 2 (Figure 5.10A-
C). IDRT displayed a few pockets of elastin deposition week 2 post-surgery (Figure 
5.10D) and by week 4 new tissue deposited in both scaffolds had a slight brown tinge, 
which was evident by colour comparison of new, fine fibres to thicker IDRT fibres 
(Figure 5.10E and F). By week 12 the faint brown hue of the fine fibres in EDRT and 
IDRT was more evident and became stronger at week 24 (Figure G-K). The increasing 
brown hue of the new tissue from weeks 4 to 24 is likely due to continual deposition 
and thereby accumulation of elastin. 
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Figure 5.10: IHC elastin images of implanted EDRT (left column) and IDRT (right column) at 
week 1 (A and B), week 2 (C and D), week 4 (E and F), week 12 (G and H) and week 24 (J 
and K) post-surgery. Magnification is 20× and scale bars are 100 μm. 
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The presence of elastin in IDRT at 2 weeks, and absence in EDRT, is surprising. 
Previous studies have shown the presence of elastin degradation products can 
promote the expression of elastin probably as a natural response to detecting damage 
to the ECM and facilitating repair (387). The apparent lack of newly synthesised elastin 
in EDRT at 2 weeks could simply be due to the thick, brown fibres of EDRT 
overwhelming faint, brown staining of new tissue since elastin gene expression 
analysis showed elastin expression was consistent over the 24 week period with no 
significant differences observed between EDRT and IDRT or between weeks (Figure 
5.11). In contrast, despite the lack of significance there did appear to be a sustained 
increase in elastin expression from 4 weeks onwards in EDRT and 2 weeks onwards 
in IDRT, as seen in the IHC staining. These concurring results strongly indicate elastin 
expression was possibly affected by other factors, such as tumour necrosis factor-α, 
interlukin1β or insulin-like growth factor-1 (389), more than the presence of elastin 
degradation products. 
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Figure 5.11: Gene expression analysis of elastin by qPCR in skin biopsies of EDRT and IDRT 
at weeks 1, 2, 4, 12 and 24 post-implantation. 
5.3.3 Wound contraction and angiogenesis of EDRT- or IDRT-grafted, full-
thickness, skin excision wounds in established grafting models in 
mice 
 Two-step grafting of mice 
A two-step grafting procedure is a commonly used clinical practice for grafting of the 
bilaminar IDRT which requires a second procedure for the epidermal graft. This two-
step grafting procedure was performed on mice to examine wound healing and 
contraction. 
The procedure was mimicked by creating full-thickness, skin excisions on the dorsal 
area of mice. The wounds were grafted with EDRT or IDRT and covered with a silicone 
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layer (Figure 5.12) then dressed for 1 week. Despite daily monitoring, mice removed 
dressings and silicone layers resulting in severe drying grafts (Figure 5.13). Skin 
irritation during wound healing is encountered in clinic as well; however, it is possible 
to reason with or prevent patients from removing dressings and grafts. To overcome 
this issue in mice a one-step grafting of EDRT and single-layer IDRT was performed 
as described in the following section 5.3.3.2. 
 
Figure 5.12: Image of EDRT and IDRT grafting on mice for two-step grafting procedure. Image 
of EDRT graft covered by a silicone layer (A) and image of IDRT (I) and EDRT (E) grafts on 
dorsal area covered by silicone (B). 
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Figure 5.13: Image of EDRT graft (A) and IDRT (B) after mice removed dressings and silicone 
overnight. 
 One-step grafting of mice 
One-step grafting of skin substitutes is currently performed in clinic with products such 
as MatriDerm. This procedure is similar to the two-step grafting procedure described 
above. The wound is still debrided and then grafted with the dermal substitute; 
however, the split-thickness autograft, which forms the epidermal layer, is grafted 
immediately after the dermal substitute during the same procedure. Mimicry of the 
one-step grafting procedure was performed in mice by creating full-thickness, skin 
excisions on the dorsal area which were grafted with EDRT or single-layer IDRT 
followed by immediate grafting of an autograft. The wounds were dressed for 1 week 
and contraction monitored over 4 weeks with angiogenesis examined at 2 and 4 weeks 
post-surgery. 
Examination of skin biopsies 4 weeks post-surgery showed cells infiltrated both EDRT 
and single-layer IDRT (Figure 5.14B and D respectively, black arrows) and with newly 
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deposited ECM evident by pink staining of fine fibres (Figure 5.14B and D). These 
results agree with those observed in the subcutaneous implant model in which cell 
infiltration and ECM deposition were also observed. Additionally, survival of autografts 
was observed at 4 weeks with skin grafts showing normal skin histology rather than 
dried scar tissue (Figure 5.14A and B). Mild inflammation in EDRT and single-layer 
IDRT was also seen with small, purple spots indicating the presence of immune cells 
in the skin graft (Figure 5.14 A and B). 
 
Figure 5.14: H&E image of one-step EDRT graft (left column) and IDRT graft (right column) at 
week 4 post-surgery. Magnification is 4× (A and B) and 20× (C and D) (366). 
Examination of wound contraction in one-step grafted wounds on day 3 showed that 
contraction of untreated, open wounds was 13.4 %, autografted wounds was 10.3 %, 
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EDRT grafted wounds was 11.8 % and IDRT grafted wounds was 16.8 % (Figure 
5.15). By day 7 open wounds had higher contraction of 59.9 % compared to 35.7 % in 
autografted wounds, 23.8 % in EDRT grafted wounds and 27.7 % IDRT grafted 
wounds respectively. The prevention of contraction by autografts, EDRT and IDRT at 
day 7 post-surgery compared to open wounds was maintained over the 28 day period 
with 100 % contraction of open wounds at day 28 post-surgery and 38.1 %, 37.6 % 
and 38.9 % of autografts, EDRT and IDRT grafted wounds respectively. There was no 
significance observed in the data. 
The similar wound contraction observed between wounds treated with EDRT and 
IDRT was unexpected due to the increased deformability observed in EDRT during 
mechanical tests. However, a previous study has shown an elastin-coated, collagen 
matrix also had similar wound contraction to a collagen-matrix while both matrices 
reduced wound contraction compared to an untreated, open wound (385). 
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Figure 5.15: Wound contraction of full-thickness, skin excisions wounds kept as an open 
wound or grafted with either an autograft, EDRT+autograft or IDRT+autograft in one-step 
grafting procedures over a 28 day period (366). 
Although the presence of elastin in EDRT did not reduce wound contraction, 
angiogenesis of EDRT grafted wounds was significantly improved compared to open 
and autografted wounds. Vascularisation was assessed using a fluorescent probe in 
vivo and radiant efficiency of the wounds was quantified (Figure 5.16). At 2 weeks 
post-surgery EDRT had significantly higher radiant efficiency of (236.15 ± 6.10) × 107, 
and therefore more vascularisation, compared to all other wounds with radiant 
efficiency of (21.43 ± 4.58) × 107 for open wounds, (26.23 ± 7.98) × 107 in autografts 
and (78.90 ± 7.99) × 107 for IDRT grafted wounds (p<0.01 compared to open and 
autografted wound and p<0.001 for IDRT grafted wounds; Figure 5.17). At 4 weeks, 
post-surgery vascularisation was similar between EDRT and IDRT grafted wounds, 
with (154.26 ± 5.55) × 107 and (149.15 ± 6.45) × 107 respectively, and wounds treated 
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with either EDRT or IDRT had significantly higher radiant efficiency compared to open, 
(19.43 ± 5.71) × 107, or autografted, (16.13 ± 5.27) × 107, wounds (p<0.001) (Figure 
5.17). 
 
Figure 5.16: Representative images of four, full-thickness, skin excision wounds kept as an 
open wound (O) or grafted with an autograft (A), EDRT+autograft (E) or IDRT+autograft (I) in 
one-step grafting procedures for quantification of vascularisation at week 2 and week 4 post-
surgery (366). 
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Figure 5.17: Quantification of vascularisation using fluorescent radiant efficiency of angiogenic 
probes in open wounds or wounds grafted with an autograft, EDRT+autograft or 
IDRT+autograft in one-step grafting procedures (** p<0.01, *** p<0.001) (366). 
The significantly higher vascularisation of EDRT at 2 weeks confirmed the accelerated 
angiogenesis observed in Masson’s Trichrome staining (Figure 5.8). This is in 
accordance with a previous study in which elastin stimulated vascularisation (385) 
possibly due to the presence of elastin and it’s degradation products indicating a 
damaged environment (390). Staining of endothelial cells using marker CD146 
confirmed vascularisation with small bundles of cells staining brown indicating the 
formation of new blood vessels in both EDRT and IDRT at 2 weeks (Figure 5.18, red 
arrows). The similar levels of vascularisation between EDRT and IDRT at 4 weeks 
could be due to binding or clearance of elastin degradation products in EDRT resulting 
in reduced signalling and therefore reduced vascularisation. The acceleration of 
angiogenesis in vivo by EDRT at 2 weeks could provide more nutrients and faster 
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exchange of waste products thereby facilitating wound regeneration. The vascular-
inductive effect of EDRT could also be beneficial to the graft survival and wound 
healing of full-thickness burn wounds which can suffer from an insufficient vascular 
network. 
 
Figure 5.18: IHC CD146 images of brown stained endothelial cells (red arrows) in one-step 
grafted EDRT (A) and IDRT (B) at week 2 post-surgery (366). 
5.4 Summary  
Histological analysis of implanted electrospun scaffolds showed CEP 2 had minimal 
inflammation with cell infiltration observed in the first week post-surgery. Scaffold 
remodelling and collagen deposition of CEP 2 were also seen from 4 weeks onward 
even though no scaffold remodelling was observed in vitro. However, in vitro 
experiments were performed for a shorter time of 4 weeks and the in vivo studies did 
not demonstrate scaffold remodelling at this time. In comparison, the performance of 
CEP 1 was far from ideal with rapid scaffold fragmentation and no remodelling 
observed. The reason for rapid fragmentation of CEP 1 was unclear and surprising 
since CEP 1 was previously shown to have higher energy loss compared to CEP 2 
indicating a higher degree of cross-linking which should translate into a more stable 
A B 
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scaffold. Despite the differences in scaffold degradation rates between the two 
scaffolds, both upregulated elastin gene expression from 4 weeks onwards as well as 
having no negative impact on collagen gene expression. Of the two scaffolds, in vivo 
studies showed CEP 2 is promising as a skin substitute and further investigation 
regarding scaffold improvement and effects of ECM protein gene expression and 
synthesis is warranted. 
Investigation of EDRT using a subcutaneous implant model showed new tissue 
deposition observed from 1 week post-surgery. Gene expression analysis of the ECM 
proteins collagen and elastin revealed consistent collagen expression was sustained 
over 24 weeks and elastin expression increased from 4 weeks onwards. Deposition of 
the collagen and elastin proteins could also be visualised in new tissue via staining at 
4 weeks post-surgery with increasing protein accumulation observed at weeks 12 and 
24. The presence of elastin in EDRT was also seen to significantly increase 
vascularisation at 2 weeks compared to IDRT with accelerated angiogenesis 
maintained at 4 weeks compared to open and autografted wounds. The modification 
of IDRT during fabrication to include 10 % (w/w) elastin yielded encouraging results, 
especially increasing early-stage angiogenesis which in turn could facilitate wound 
healing. 
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Chapter 6 
General Discussion 
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Chapter 6  General Discussion 
Over 11 million burn injuries require medical attention each year with partial- to full-
thickness injuries often resulting in new tissue which lacks normal appearance and 
function. These undesirable results arise from skin substitutes which are unable to 
support skin regeneration. A serious, and unfortunately common, issue is inelastic skin 
due to missing or incorrectly deposited components of the ECM, particularly the 
protein elastin which plays a major role in the elastic network of skin. Elastin is often 
absent or fragmented in scar tissue and the inclusion of elastin during fabrication of 
two, novel scaffolds was examined in this thesis with the aim to improve elasticity and 
cell-scaffold interactions. 
In this study the production of a novel, electrospun, CEP scaffold and the 
characterisation of this electrospun scaffold and EDRT, the elastin-modified version of 
the commercially-available IDRT, was performed. Characterisation of the scaffolds 
was accomplished by examining morphological, mechanical, cell-scaffold interactive 
properties in vitro and host response in animal models. 
6.1 Electrospun, CEP scaffolds 
The materials and fabrication method utilised in the construction of a skin substitute 
have a significant impact on its performance and success. For this reason, 
electrospinning was chosen as the fabrication method as the resulting nano- to 
microscale fibres and final scaffold structure closely mimic native ECM (260) providing 
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a large surface area, which is favourable for cell attachment, and a highly porous 
scaffold to facilitate cell infiltration (260-262) while also reducing wound contraction 
compared to the more common fabrication method of lyophilisation (278). The three 
polymers used were chosen for their favourable results in tissue engineering: collagen 
is well-known for its biosignals and abundance in the ECM; elastin for its role imparting 
elasticity; and PCL for its strength and use in long-term implants with no negative side 
effects (199, 201). 
Porous mats consisting of microfibres were successfully formed by electrospinning a 
combination of collagen, elastin and PCL and the four electrospinning parameters of 
polymer composition, flow rate, air gap and applied electric potential were investigated 
for their effects on electrospinning efficiency and morphological properties. The 
inclusion of 12 % (w/v) elastin during fabrication had the most notable effect with 
improved electrospinning efficiency of CEP scaffolds. CEP scaffolds remained intact 
and undamaged after cross-linking and tensile moduli of elastin-containing scaffolds 
was shown to be significantly lower than CP scaffolds indicating higher elasticity due 
to the presence of elastin. Elasticity is a favourable trait in skin substitutes as scaffolds 
will be better equipped to cope with shear stress. 
Solution composition was also varied by increasing collagen content and 
simultaneously decreasing PCL content stepwise by 0.5 % (w/v) which had variable 
effects on electrospinning efficiency but did result in successively larger pores and 
wider fibres. Flow rate, air gap and applied electric potential also had variable effects 
on electrospinning efficiency. When one parameter was altered, with all others held 
constant, an improving or declining trend in electrospinning efficiency was observed 
resulting in the identification of a ‘sweet spot’ for fabrication. However, to acquire 
optimal conditions for scaffold fabrication alteration of one parameter would usually 
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require compensation by alteration of another parameter. Despite variances in 
electrospinning efficiency some trends were observed with morphological properties: 
increasing flow rate was seen to increase both pore diameter and fibre width and larger 
air gaps resulted in smaller pores and generally larger fibres. 
Two cross-linked, electrospun, CEP scaffolds were chosen for their advantageous 
morphological and mechanical properties, specifically large pores, wide fibres and 
increased elasticity. CEP 1 was composed of the 1.5C12E1.5P solution and 
electrospun at 3 mL/h, 15 cm and 25 kV and CEP 2 was fabricated by electrospinning 
the 2C12E1P solution at 1 mL/h, 20 cm and 20 kV. Both scaffolds supported normal 
behaviour of HaCaTs in vitro with formation of a confluent, cell layer on day 1 and cell 
proliferation observed over 28 days. Normal HDF behaviour was also demonstrated 
with cell infiltration seen on days 14 and 28 with cell proliferation supported until day 
21. Proliferation of both skin cell types was significantly higher on CEP 1 at various 
time points. HaCaTs also showed higher proliferation on CEP scaffolds due to their 
nature as a cell line compared to the short-lived primary HDFs which had slower 
proliferation. Therefore in vitro studies indicated CEP 1 as a more favourable skin 
substitute. 
In contrast, in vivo, implant studies demonstrated more promising results with CEP 2. 
Both electrospun scaffolds supported cell infiltration from week 1 onwards with minimal 
inflammation observed at 2 weeks. CEP 1 underwent scaffold fragmentation from  
2 weeks with no remodelling observed. Comparatively, remodelling of CEP 2 was 
observed at week 12 which became more pronounced at week 24. The new tissue 
deposited during remodelling in CEP 2 was shown to contain collagen but no newly 
synthesised elastin was observed. Despite the lack of observable elastin protein in the 
IHC elastin stain, gene expression analysis of elastin showed non-significant, 
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increasing expression from weeks 1-4 and sustained higher expression of elastin at 
weeks 12 and 24. This discrepancy between elastin gene expression and IHC staining 
of elastin protein is surprising and is likely due to the prominent brown staining of 
scaffold elastin overwhelming any newly synthesised elastin which would have stained 
a much fainter brown colour. 
6.2 EDRT 
EDRT is a modified version of the commercial, dermal, collagen-based substitute 
IDRT. Although IDRT is a popular dermal substitute wound contraction and scarring 
are still commonly encountered. EDRT was produced by lyophilisation using the same 
method as IDRT; however, in EDRT 10 % (w/w) of the collagen is replaced with 
recombinant, human tropoelastin for a final scaffold composition of 8 % shark 
chondroitin-6-sulphate, 10 % recombinant human tropoelastin and 82 % bovine, 
collagen type I. The inclusion of tropoelastin during fabrication, and thereby the 
presence of elastin after cross-linking, resulted in a scaffold with larger pores and 
higher porosity than its collagen counterpart, IDRT. The larger pores are thought to 
result from the increased elasticity of the scaffold, a desirable trait in a skin substitute. 
However, EDRT also demonstrated increased rigidity. 
Cell studies revealed EDRT supported constant HaCaT and HDF proliferation over a 
28 day period in vitro with no HDF-induced contraction observed. HaCaTs displayed 
normal behaviour forming and maintaining a confluent, cell layer with a rough surface 
characteristic of keratinocytes. Normal HDF behaviour was also seen with complete 
infiltration of EDRT compared to only partial infiltration of IDRT. The improved 
infiltration on EDRT can likely be attributed to its larger pores and the presence and 
function of elastin. However, despite cell infiltration no scaffold remodelling was 
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observed which could be due to the long half-life of elastin. As explained with the 
electrospun, CEP scaffold studies HaCaTs displayed higher proliferation as these cells 
originate from a cell line, whereas, HDFs are primary cells with a finites lifespan and 
variability. 
Mouse model studies also displayed no scaffold remodelling over 24 weeks; however, 
new tissue deposition was visible from week 1 with no inflammation observed in both 
scaffolds. Collagen and elastin proteins were detected from 4 weeks onwards. 
Enhanced performance of EDRT was observed with accelerated angiogenesis  
2 weeks post-grafting compared to IDRT. 
6.3 Conclusions and future work 
Electrospinning of the novel combination of collagen, elastin and PCL clearly 
demonstrated the ability of this fabrication method to produce structurally, biomimetic 
scaffolds capable of supporting remodelling in vivo. The synchronous temporal and 
spatial scaffold degradation and tissue deposition of CEP 2 in conjunction with the 
improved elasticity observed in vitro could decrease wound contraction. Additionally, 
scarring and contraction could also be further reduced because of the minimal and 
delayed inflammatory response caused by implantation of CEP 2. This short period of 
inflammation would indicate the wound does not have prolonged activity of TGF-β1 
and TGF-β2 which leads to hypertrophic scarring and wound contraction (29). 
Investigations of TGF-β levels are warranted to elucidate this further. Following studies 
should examine the performance of CEP 2 as a living, skin substitute since translation 
of the formation of a keratinocyte layer in vitro to an in vivo setting could result in a 
substitute capable of supporting not only dermal, wound remodelling but  
re-epithelialisation as well. However, the lack of angiogenesis in implanted CEP 2 
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could result in metabolically inactive or even necrotic cells as the thickness of 
electrospun scaffolds could place keratinocytes further than 200 μm from a blood 
supply (271). 
Comparatively, EDRT clearly demonstrated its capacity to act as a dermal substitute 
with its vascular inductive properties and deposition of new tissue inside pores despite 
a lack of scaffold degradation. Translation of this rapid angiogenesis would be 
particularly useful in full-thickness, burn injuries in which graft rejection or loss can 
occur due to insufficient vascularisation and therefore deficient nutrient supply and 
waste exchange. EDRT would be especially useful to replace single-layer IDRT which 
was specifically designed for use to help fill deep, burn injuries. 
CEP 2 and EDRT are both promising, potential, skin substitutes and while further 
investigation would more clearly elucidate the properties of both scaffolds future work 
should consider producing a substitute which combines both scaffolds. A bilayered 
scaffold could result in a skin substitute capable of treating full-thickness burn injuries 
with a single substitute that would improve elasticity, accelerate angiogenesis, support 
dermal remodelling and serve as a template for re-epithelialisation. 
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